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EDITORIAL
THE

CHANGING REALM OF
IN MEDICINE

WOMEN

By Aaron M . Glickman & Carla Garcia
ne of the reasons that this particular volume was
assembled was the need to recognize the changes
that North American women have gone through in
all aspects of contemporary We. This is clear here at the
UWO Faculty of Medicine simply by the quantity and
breadth of the material submitted for the topic of
Women's Health for the UWO Medical Journal. Although
many of these changes have brought women gr eater
benefits, it has also brought greater risks particularly with
regards to their health.
The topic of ' women's health' has meant a wide
variety of things to a wide variety of people over the
centuries. Until relatively recently, women's health meant
obstetrics and gynecology, putting women in the
unenviable position of being viewed medically only in the
context of their reproductive role.1 As a result, solutions to
women's health needs had been limited to improving
maternal and child health, while ignoring the wide
spectrum of other health concerns that enter a woman's
life. However, it soon became apparent that 'women's
health' not only encompassed much more than
reproduction, but also influenced a larger spectrum of the
population than the previously targeted reproductive
female. Indeed, the pendulum has swung recently so far to
the other side that some women's groups are complaining
that 'women's health' has become an umbrella term for
everything from pediatric health to geriatric health to
global health trends.2 This incredibly broad spectrum of
influence can be at least partially explained b y the
extremely important roles women continue to play in
nearly all societies as primary caregivers in the home. The
care of society's dependants-<:hildren, the elderly, the
infirm-<:ontinues to fall upon the shoulders of women/
and health organizations such as the WHO, have come to
realize that women-and their health-thus have a very
direct effect on these segments of the population's health
careI.
However, this significant role as caregivers comes in
addition to increasing work hours outside the home, and,
in North America, increasing age of this population of
caregivers .4 Thus, it is not surprising that women are
experiencing an increase in chronic diseases, eating
disorders, depression, stress-related illnesses, physical and
substance abuse, etc.1' 4.s This situation is compounded by
the fact that neither the medical profession nor society nor
women themselves appear well informed on certain
aspects of their health. For example, both lung cancer and
smoking continue to rise alarmingly in women, despite
efforts at education and prevention,6 and only recently has

O
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the medical community come to accept that female
pulmonary physiology may indeed vary significantly
from the 'standardized male' values that all patients are
traditionally measured against. 7 In fact, that same medical
tendency to treat women based on data collected from
males has developed into a significant obstacle on many
fronts, and recent studies have found a wide variety of
gender specific differences that are currently not being
accounted for properly in the treatment of women. 8
Perhaps the most worrisome combination of
ignorance on the part of women, their healthcare workers,
and society at large is observed in the management and
outcome of ischemic heart disease in women vs. men. The
misinformation exists at every level. Clinical trial s
evaluating drug therapy for IHD do not adequatel y
represent women (even those that claim to have genderrelated policies).9 Physicians tend to diagnose women with
IHD later than men, and tend to refer them for bypass
surgery at a much more advanced disease state than their
male patients, 10•11 which may help to explain the fact that
women's outcomes and prognosis are significantly poorer
than men ' s for this disease. Women are similar! ~
misinformed about their relative risk for heart disease, 2
and in fact, many were under the impression that their
gender reduced the risk of cardiac disease to the point of
inconsequence, and took few if any preventativ e
measuresY Fortunately, previous misapprehensions are
being corrected, and there have been great strides in the
education of both women and their health care providers
in both the treatment and prevention of IHD. Two papers
in this issue deal with post-menopausal hormone
replacement therapy, and its emerginr role as a
cardioprotective agent in high risk women. 14•1
This naturally leads to the inevitable question-how
well are we as students being educated in women 's
health? As several of the papers in this issue reveal, there
are certainly significant gaps in our current curriculum.
For example, Briar Sexton's paper 16 discovered a startling
lack of formal training for one of the most important
clinical skills in women ' s health-the breast exam.
Baugniet et a/. found that their workshops on
menstruation filled a significant knowledge gap in both
young girls and medical students.17 Tess Pitre comments
in her article on the consequences of lack of physician
knowledge with respect to breastfeeding and neonatal
nutrition. 18 Jim Grochowski' s paper emphasizes the
important role that emergency room physicians play in
the management of spousal abuse (which remains one of
the greatest threats to women's health), and yet there was
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Editor t a
little forma l training on this subject in the old
curriculum-a situation which has fortunately been
corrected in the new system at Westem.19
However, despite these still-lingering problems, great
strides have been made in other areas of women's health.
Three articles in this issue deal with the progress that has
been made in the.Jrevention, diagnosis, and treatment of
breast cancer.20.21 In particular, Mason. Ross' article on
breast reconstruction is an excellent example of medicine
ass is ting women in their p h ys ical and psychological
recovery following mastectomy. 22 Rupinder Singh Sahsi
has found a wealth of useful, accurate information for
wo men and heal th care profess ionals alike on the
intemet. 23 The increasing presence of women in medicine
hav e also lead to significant changes in both how the
profession views itself and its female patients-an issue
w h ich is addressed in Rodin & Saibil' s paper in this
issue.24 And, the profile of Dr. Nisker reveals a physician
educator who has made a great effort to educate medical
students and facul ty at UWO about one of the mos t
tenuous realms of women's health-the ethical issues
surrounding current advances in fertility treatments. 25
Thus, th e scope of th is issue remains necessaril y
broad, in an effort to reflect some of the span of topics that
fall into the domain of women's health. While a complete,
thorough review of this area of medicine would be nearimpossible, it is our hope to present a collection of articles
reflecting some of its recent triumphs and more pressing
concerns.
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PROFILES
EDITOR: HELEN LEWANDOWSKI

INTERVIEW WITH DR. JEFF NISKER
Professor of Obstetrics and Gynecology and
Coordinator of Bioethics at the University of
Western Ontario Faculty of Medicine
By Helen Lewandowski, MEDS 2001
INTRODUCTION

Dr. Jeffrey Nisker is a
Professor of Obstetrics and
Gynaecology
at
the
University of Western
Ontario who was recently
chosen by the CBC' s Peter
Gzowski as one of the 13
"Best Minds of our Time".
Perhaps this is because Dr.
isker wears many hats in
addition to his hat as a
clinician. He has won
international awards for his
research into how cancer can be caused or prevented by
hormones, and has done work for Health Ca nada
Commissions in the area of reproductive technologies. He
is also the initiator of a novel approach to address ethical
issues through plays, stories and poems. He believes that
in an age of shrinking health care resources, clinicians and
health care students must find ways to retain their
empathy for their patients and deliver optimal
compassionate care. According to Dr. Nisker, "theater and
poetry and song ... can put us in the skin of a patient and
approximate empathy for that patient" . When
interspersed throughout medical education, Dr. isker
believes that this approach can help medical students
retain the intelligence, compassion and courage, which
they possess upon entry to medical school.
Dr. Nisker received his undergraduate and medical
education at the University of Toronto, and his training in
Obstetrics and Gynaecology at the University of Western
Ontario. He was awarded a Medical Research Council
fellowship in hormones and cancer and did post-graduate
at UWO, University of California and McMaster
University. Dr. Nisker is currently the coordina tor of
bioethics, spirituality and cultural issues in the faculty of
Medicine and Dentistry at UWO. His current national
positions include chair of the Ethics Committee of the
Society of Obstetricians and Gynaecologists of Canada,
Canadian Bioethics Society Council member, and Health
Canada's Advisory Committee on Reproductive and
Genetic technologies. Dr. Nisker has made other national
and international contributions such as on the Health

8

Canada Advisory Committee on Embryo Research and as
national director of the Society of Obstetrics and
Gynaecologists of Canada (SOGC), and was an author of
the International Federation of Fertility Society's "Ethical
Guidelines". Dr. Nisker is also actively involved on the
new London Health Sciences Centre (LHSC) Patient Care
Steering Committee.
Dr. isker has written numerous articles and book
chapters on scientific and ethical issues. He has also
written six plays covering issues from woman abuse to
HIV to moral decision development. He has also written
many short stories and poems to encourage
compassionate health care. His play, "Doctor's Call" has
been performed in Victoria, Vancouver, London, Toronto,
Halifax, New Hampshire and Nashville. In 1996 Dr.
Nisker received the Douglas Socking Award presented to
the UWO " member of faculty who, in the opinion of
medical s tudents has made the most outstanding
contribution to their medical education during the
previous four years".
RESEARCH IN REPRODUCTIVE TECHNOLOGY

In the words of CBC's Peter Gzowski, Dr. Nisker was a
groundbreaking cancer and reproductive technology researcher
when five years ago, an ethical crisis prompted him to give up
his research. Since then , Dr. Nisker changed his focus to
teaching medical students and doctors about ethics.
Dr. Nisker: I had been exposed as a resident in
Obstetrics and Gynaecology to what are called " midtrimester terminations", where women who are carrying a
gene for what they feel, or for what society feels, is an
abnormal condition, go through labor about halfway
through their pregnancy as part of their termination
process. It's absolutely horrible. Chemicals are injected
into the amniotic fluid to terminate the pregnancy, and
other drugs are given to induce uterine contractions .
Sometimes the fetus comes out alive, and it is a horrible
experience. So, it seemed logical that we could use the
technology that we were developing in our In Vitro
Fertilization program to be able to make these diagnoses
earlier so the women would never have to go through this
process. We would just not put in the embryos that were
affected with Tay-Sach's syndrome, for example. We 'd
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been experimenting in mice and abnormal multipronucleate human embryos for years to get us to this
stage. These are not human embryos, because they only
consist of several cells and we didn't want to experiment
with human embryos, since they can't give consent and
w e didn' t want to get into that. This whole process is
called "Preimplantation Genetic Diagnosis".
When we were doing this research, we were highly
criticized by the Canadian Feminist movement, which was
a very helpful and positive watchdog. They said that I was
being naive, and that although I thought this research that
we were doing at LHSC was for the good, a lot of people
were going to take the research and use it for cloning and
mass-producing human beings. As it turned out, they
were right.
At the time, the only centers doing this type of
research were the Hammersmith Hospital in London,
England and ourselves at LHSC at UWO. Now, this is
being done in at least 20 centres all over the world, mostly
in the US. Where we got into a problem was when the
technolog y that we were de v eloping was used by
scientists at George Washington University, and they did
their famous cloning experiment. They were taking eightcell embryos and making eight potential human beings
out of them . That was where the Canadian Feminist
movement said, I told you so, you can't do technology in a
void. That was when it hit me that we had this technology
and we were seeing what we could do with it instead of
letting society tell science what they wanted us to
in vestigate. As the Canadian Feminist movement was
clear in saying, technology would then shape society
instead of society shaping technology. I believe that this
was prophetic, that I wa s naiv e and that we are now
moving down those lines.
The problem is more than just cloning, it's the idea of
a perfect society. It's the concept of what you would do
genetic testing for . I could buy into doing this for TaySachs disease, where there's very little quality of life, but
wo uld we do it for baldness? Would we do it with
obesity? Where is it going to stop? Recently I read a piece
in a magazine about how an American company went into
Iceland, which is a small gene pool and a place where
there's only a quarter of a million people. They were
looking into taking genes from Icelanders and making a
ra ce of blond-haired, blue-eyed, long-legged women,
w hich would be commercially available. It's that type of
si tuation w hich really scares me, and that caused me to
give up my research and spend the past five years of my
life writing plays and addressing the moral issues that are
involved. 1
ON CANCER RESEARCH

Initially, the topic that had spurred Dr. N isker to become
active as a researcher was the effect of hormones on cancer. In
this area, the research he carried out contributed to significantly
improving the state of knowledge on this important issue.
Dr. Nisker: I come from a family where women don' t
live past the age of 50 because they all die of breast cancer.
So I w as trying to find a cure for cancer. We thought that
we had a way that we could detect breast cancer through

hormones, and prevent breast cancer through hormones,
but we did not. Instead we found a way to prevent
endometrial cancer through hormones, by giving
progesterone. We did it in rabbits, since it had been found
that rabbits could develop uterine cancer. Female rabbits
are the only animal species that don't have estrous cycles
and that don' t have progesterone. A female rabbit will
only ovulate during coitus. Thus, a female rabbit without
access to male rabbits is in the same situation as a postmenopausal woman, in that a post-menopausal woman
may still have estrogen especially if they take it in pills but
th e ir body never sees thi s protective hormone,
progesterone, because they don' t ovulate. So the rabbit
w a s a v ery e xact model, physiologically, for what
h a ppened . When the rabbits got cancer, I got the
pathology slides, randomized them and presented them to
our human pathologist who said that they looked exactly
the same as human cancers. When we gave half the rabbits
progesterone, the group that got the progesterone were
prevented from getting endometrial cancer but the group
w ho didn' t get the progesterone still got cancer. 1
MEDICAL ETHICS AND MEDICAL HUMANITIES

The "Yellow Brick Road" is a narrative bioethics pilot that
was initiated by Dr. Nisker at the Uni versity of Wes tern
Ontario. Every other Monday evening during the fall semester,
it provides thirty minutes of narrative presentation which
includes original plays, adapted plays, and "readers' theater"
fo llowed by discussion of relevant ethical issues. Local and
invited fa culty enrich the co nve rsation , and f ilming th e
performances fo r later use at Western and other universities
permits future in depth digestion of issues and more personal
debate.
Dr. Nisker: The program is named the Yellow Brick
Road after the Wizard of Oz, because I believe that people
w ho go into the medical professions have the brains and
the heart and the courage to be the great caregivers that
they want to be. Then, here we take these health care
s tudents, and we give them miles of medical ink to
memorize, tons of tutored words to carry with them, and
we dissolve their hearts, their brains and their courage.
Esp ecially their hearts, and this is in the name of the
science of health care. Actually, I got the idea for this not
from the Wizard of Oz, but from a little book by Antoine
de St-Exupery called " Le Petit Prince". While reading it to
my children, I noticed a gorgeous line in it that said, "It is
only with the heart that thou can see correctly what is
essential is invisible to the eye". That's why I feel that
theater and poetry and song can touch us in the heart and
can approximate empathy for a patient. We don't want to
have "That's the myocardial infarction in bed 10", we
wa nt to ha ve "That's James Jones ". At Wes tern, thi s
concept of health care humanities will be in volved in
teaching bioethics with soul in medical school, and will
also encompass spirituality, alternative medicine, history
of medicine, and what we can learn from the evolution of
medicine over the years.1
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ON WOMEN'S HEALTH ISSUES
Dr. Nisker: I think that women's health is a huge
issue, and as someone who takes care of the health of
women I believe it's extremely important for these issues
tQ be brought forward . There are so many of them... For
example, women and men are not the same. They have
different health needs and different expectations, and they
become ill differently. Thus the prevention of illness is
quite different in women. Yet, most of the research that
comes out has been done in men, and it makes quite a
difference in terms of the technology. For examp le, in
Canada it is extremely difficult to get a vaginal ultrasound
probe that's designed specifically for women. The one that
exists is basically a modified version of a rectal probe for
men, and it's used in clinics across Canada. I think that it's
a cruel instrument, and we've refused to use it. We used a
specific vaginal probe that was invented in Sweden but
that was extremely difficult to repair once it breaks. I
would have preferred that someone design an appropriate
vaginal ultrasound for women rather than having to adapt
one. That's just one example of how we need to be
cognizant of the fact that women's health is differen t than
men's.
The issue of genetic testing for cancer, and more
specifically breast cancer, is also important. This is
something that's not covered under our health care
system. There are women who have a family history of
breast cancer which is perhaps not strong enough to
qualify them as participants in studies where genetic
testing for breast cancer is done. But to them, it was
extremely traumatic to watch their mother or aunt die of
breast cancer. While that may not qualify them to be part
of a study, I think that funding should exist for a woman
to be able to be tested for the BRCAl gene if she wishes.
Many women may choose not to be tested, but right now
they don' t have that choice. Wealthy women can go to the
US to be tested but poor women can't do that and I think
that all women should have the same choices. Many
women with a family history of breast cancer come to me
with this question, because they're considering going on
Hormone Replacement Therapy. If they're carrying the
gene, they don' t want to go on HRT, but if they're not
carrying it they do want to go on it because they're having
hot flushes . Unfortunately I can't access that information
to help them choose, and that's an example of how women
aren't able to make choices because of a lack of
information.
I think another issue that's important right now in
women's health, if I take off my hat as a clinician and put
on my hat as an ethicist, is that the pregnant woman is
becoming a moral battleground. The case of Mrs. G., the
native woman in Manitoba who was arrested because of
her solvent addiction, has really shown the moral issues
that we're grappling with right now in Canadian society,
such as the rights of the fetus and the right to compulsory
medical care. I think that we have to be doing these moral
explorations in advance of pregnant women getting into
those types of situations. I chair the Socie ty of
Obstetricians and Gynaecologists' ethics committee and
we try to stay ahead of these questions but it's very
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difficult. In reproductive medicine, there's a tremendous
amount of issues and there are many complex situations
that women can be put into.
In general, prevention is a very important part of
women 's health, and one area that' s important with
respect to prevention is sexually transmitted diseases. In
the age of the birth control pill, condoms are used less and
probably with less proficiency than previously. It is
difficult for young women to ask their partner to use
condoms when he knows that she is on the pill. When a
young woman asks her partner to use a condom, she feels
that she is risking the relationship and will often chance
that he is not carrying HIV I gonorrhea / herpes or any
other potentially harmful organism rather than risk the
relationship. We must educate on this issue, even starting
in primary schools, to explain that if you care for someone
you must protect them, and that includes using barrier
methods even if pregnancy is prevented through the birth
control pill. I think that sexual education programs run by
health care students in high schools are extremely
valuable, both for the high school students and the health
care students. This way, health care students learn the
importance of prevention and gain the interpersonal skills
that will make them more communicative caregivers in
the future.
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AN EDITORIAL:
FEMALE GENITAL MUTILATION AND CULTURAL
RELATIVISM
By David J. Satin, MEDS 2001

As the Ethics Editor, I have chosen to write an
editorial on a subject raised b y an interesting paper
w hich appears elsewhere in this issue entitled, "Female
Circumcision or Genital Mu tilation: a Rational
Approach", w ritten by Reena Bhargava & Lubna
Tirmizi. I employ female genital mutilation as an
example of the interface between Cultural Relativism
and 'Women's Issu es' at large.
t is often difficult to question the ethical legitimacy of
harmful norms around us, for it is usually only
violations of norms, rather than norms themselves, that
draw that kind of attention. At the crossroads of such
fields as political science, anthropology, sociology, and
ethics lies a debate over Cultural Relativism. As its name
suggests, in a moral context this doctrine implies that "the
moral code of a society determines what is right within
that society, and it is mere arrogance for us to try to judge
the conduct of other peoples." 1 Evidence often cited in
support of Cultural Relativism includes the disparity of
ethical judgements about various acts throughout the
many cultures of the world. Cultural Relativism has in
turn been used as an ethical defense for many of these
acts, among them the practice of female genital mutilation
(FGM). 2
To better understand the overall strategy of this work,
that is analysing and relating token phenomena such as
FGM to types supported by Cultural Relativism, consider
the following analogy: From a valley, many rivers may
seem unconnected, yet upon ascending a mountain these
same rivers can be seen as parts of a network. Similarly a
number of physical phenomena such as planetary motion
and pendulum clocks conceived of as unconnected on a
practical level become one in the same phenomenon in the
context of Universal Gravitation. So too, practical ethical
debates over FGM, foot -binding, and augmentation
mammoplasty may be seen as special cases of a greater
debate over the types of support derivable from Cultural
Relativism.
Just as climbing the mountain might help us plan a
system of dams, ascending to a metatheoretical3 level may
provide the necessary perspective for one to more easily
locate, among a general class of cultu ral practices, the
ethical content of one's own. Lastly, considering how no
physical change can be effected from a mountaintop, it is
essential to return to the valley floor to begin construction.
So it will be important to return to the practical ethical
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forum of our cultural practices with the insight derived
from high atop our metaethical mountain.
ANALYSIS
"It's how things are"
One might argue that FGM is morally permissible
solely on the grounds that it is embedded within many
cultures - that is, in virtue of its entrenchment in the mores
of its practitioners/recipients and its virtually unanimous
acceptance as a way of life. 4 This argument is ground ed in
the general principle that social acceptability determines
morality (i.e. mores == morals). Let us examine how
consistent this principle is with our intuitions. Slavery was
a public way of life for many of our ancestors from biblical
times, through antiquity, well into the twentieth century.5 1
suspect that few would assert that slavery is morally good
(or neutral) in virtue of its public and widespread practice.
ow, if such a temporally and geographically popular
practice as slavery cannot gain moral support from its
cultural entrenchment, surely FGM cannot expect such
similar support. But the Cultural Relativist is not yet
forced to retract on this account, for she may still point out
the temporal disanalogy between FGM and slavery.
The Cultural Relativist and proponent of FGM may
argue that slavery is no longer a publicly supported
practice while, in many places, FGM certainly is.
Therefore, it is open to this proponent to claim that a given
practice may be justified for the period of time in which
that practice is publicly condoned and commonly
performed. That is, unlike slavery, FGM is morally
permissible because it is presently en trenched within
many cultures. Let us examine the implications of such a
principle. If we grant that a practice is morally permissible
because it is presently accepted within a culture, then we
must also grant that slavery was morally permissible in
early twentieth century America. Similarly, we must
accept that Apartheid was a just policy in the South Africa
of the nineteen-eighties, and if you happened to be living
in WWll Berlin you would be mistaken in assertiJ;l.g that
azism is wrong. Furthermore, in granting the Cultural
Relativist's updated principle we must accept that
whatever practices are currently entrenched is how things
ought to be ... at very best, an uncomfortable position
indeed. If one wishes to justify FGM on cultural grounds,
one had be tter have more of a story to tell - and the
Cultural Relativist certainly may.
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Ethics
"It works for us"

The Cultural Relativist and proponent of FGM might
argue that perhaps certain cultural practices have
powerful functional roles in societies. This functional role
may be cashed out in two ways-physiologically and
psychologically. What I call the physiological role aims to
justify FGM on the grounds that it has an ov erall
physiological benefit for the population (e.g . lower
incidence of STDs). As the physiological 'success' of a
given practice is largely a contingent fact, I will grant the
possibility of a society in which, through some mechanism
unknown to me, FGM results in a net physiological benefit
to the overall population. I therefore offer the following,
standard, 'in principle' counter-argument to the intuitive
defensibility of such an attractive social arrangement.
The structure of this hypothetical physiological
argument is as follows: practice X, which is harmful to a
given segment <p of population r, ultimately results in
greater physiological health for population r, thereby
justifying practice X. 6 This argument is grounded in a
na!ve utilitarian principle that achieving 'the greatest good
for the greatest number' justifies acts which, in
themselves, harm individuals. Consider H.J.McCloskey's
1965 counter-example, highlighting the injustice inherent
to a practice which harms individuals for the purpose of
the good of society:
Suppose a utilitarian were visiting an area in which
there was racial strife, and that, during his visit, a
Negro rapes a white woman, and that race riots occur
as a result of the crime, white mobs , with the
connivance of the police, bashing and killing
Negroes, etc. Suppose too that our utilitarian is in the
area of the crime when it is committed such that his
testimony would bring about the conviction of a
particular Negro. U he knows that a quick arrest will
stop the riots and lynchings, surely, as a utilitarian, he
must conclude that he has a duty to bear false witness
in order to bring about the punishment of an innocent
person.7

If one is swayed by the intuition that it would be
unjust to harm an innocent individual for the good a
larger group, then one cannot employ the physiological
argument in defense of social practices that are harmful to
a segment of the population-lest one sanction injustices.
The second role, the psychological role, ca n be
presented as justification for practices like FGM on the
grounds that the population gains psychological comfort,
stability, and a sense of identity through the maintenance
of culture. This argument, potentially confused with the
next argument, falls prey to the same counter-argument as
the physiological argument.

"Every thing has a right to self-preservation"
Justification via a 'social argument' is practically
orthogonal to the 'psychological argument'. One might
argue the very existence of a given society is dependent
upon its particular set of practices. The continuity of
cultural practices is, ipso facto, a constitutive property of a
14

society. 8 A 'social argument' in support of integral cultural
practices (harmful or not) can be extracted from the
judgement Lord Nelson rendered at the infamous British
criminal case of R. V. Brown. 9 As part of his judgement
Lord Nelson constructed the following analogy,
essentially outlining the 'social argument': A society, like
an individual, has the right to defend itself against danger.
Just as societies typically reserve their highest penalty for
treason so as to insulate themselves from foreign attack, so
too must a society defend against attack from within.
Manipulation of integral cultural practices constitutes a
form of treason, for the alteration of these specific
practices effectively destroys the old society, replacing it
with a new one. Just as an invasion of Britain by France
would bring an end to ' British society', replacement of
typically British practices by 'Neo-British' practices would
bring about a similar 'social extinction'.
A Cultural Relativist and proponent of FGM may
employ this argument to say that FGM is just such an
integral part of many of the cultures in which it is
practiced. Furthermore, since each culture has a right to
protect itself to ensure its survival, maintenance of its
integral practices, including FGM, is a right. To answer the
challenge of the 'social argument' we must once again
return to the slavery analogy. Slavery was an integral part
of many cultures, including North American. Today we
look upon slavery unfavorably and openly express
approval at this change of sociocultural practice. Societies
are composed of individuals, and just as individuals can
commit injustices, so too can societies.
Societies are dynamic entities . Today' s Canadian
society is markedly different from that of one hundred
years ago, yet would any of us liken this transformation to
treason? Who among us views our great innovators of art
and science as public enemies? Changes in sociocultural
practices can be beneficial or detrimental to a population.
There is no reason to believe that the most static society
ought to be the most ethical. Societies are composed of
people and it is people that have rights - not practices.
People have the right to stay the same and people have the
right to change. The choice to exercise one's rights will be
the focus of the final culturally relativistic argument we
will consider.
"But we choose it"
The Cultural Relativist and proponent of FGM may
argue that respect for choice distinguishes practices like
FGM from those like slavery and that by choosing a
harmful practice one effectively justifies the practice. The
Cultural Relativist might phrase the argument as follows:
An individual may freely choose X, and just because X
reflects a preference for their culture (not yours) doesn't
allow you to say that they shouldn't choose X. I will once
again grant the proponent of FGM the strongest possible
case. That is, a situation in which a woman, old enough to
make an informed choice, chooses FGM and quite happily
celebrates her culture through practice. The proponent of
FGM may now ask what could be unethical about such a
scenario.
To properly address this argument we must first ask
ourselves what could motivate a person to choose to
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undergo such a harmful procedure. The answer, in this
scenario, clearly reads that she does so as a "celebration of
her culture through practice". Before responding to this
answer, let us consider analogous practices from other
cultures. For a millenium, many Chinese women 'chose'
to bind their feet, enduring pain and incapacitation in the
name of fulfilling their cultural heritage. Eighteenth
century English women 'chose' to wear tight corsets,
restricting a range of physiological functions and inducing
bouts of fainting, for that was their culture. 10 These
practices have several things in common with FGM. Most
saliently however, is the way in which each is a 'chosen'
practice, yet the social penalty for choosing to forego the
practice is typically heavy indeed.
Nonconformity is frowned upon in most societies and
the coercive force of one's society is often unparalleled in
one ' s experience. Coercion can be a subtle process,
especially when it is endemic. This may help explain why
it is so easy to see the harmful practices of other societies,
yet so difficult to note them in our own. In many societies,
'choosing' to forego a social practice carries stigma,
thereby decreasing one's ability to succeed within those
societies. We can imagine how an English woman's choice
to forego a corset would certainly have lowered her social
status, thereby diminishing her chances of marrying
successfully, bearing children, and establishing the kind of
life many expect. The basic drive for social acceptance and
procreative opportunity may certainly constitute ample
motivation for conformity.
Returning now to our woman's choice to undergo
FGM, we must ask if the conditions for an uncoerced,
informed choice are present. Would she choose FGM were
there no social penalties associated with foregoing the
procedure? Would she prefer a society in which she could
celebrate the non-harmful aspects of her culture? Recall
that our analogous Chinese and English women,
immersed within their culture, may have been looking
forward to their respective practices since childhood. We
can however, imagine how these physically harmful
practices come to be identified with the social successes
they entail.
From the many judgements of the R V. Brown case
alluded to earlier, comes the principle that there are
criminal acts that cannot be decriminalized by consent
(e.g. irrespective of consent, it is illegal to duel to death or
dismemberment}. 11 So it is, I propose, with the morality of
harmful acts which cannot practically be chosen freely (i.e.
free of coercion). The Cultural Relativist may argue that
each culture provides its own unique brand of pressure
and no choice made within the context of a society can
truly be free from the coercive force of that society. Few
would debate this virtual tautology. Nevertheless, when a
society places a segment of its population in a position
where they must make a choice regarding a personally
harmful practice, of which the sole justification is the
choosing of that practice for sociocultural benefit, the tight
circularity of justification renders the entire system
suspect. We are thus lead to ask, "Why must a segment of
a population suffer harm for a sociocultural benefit
enjoyed by all?"
It seems as though there might be an inequality of
sorts built into the system. There may, however, exist a

society in which all segments of its population make
similar uncoerced, informed sacrifices for the sociocultural
benefit of all. 12 While it would thus seem that there is a
logical space in which practices such as FGM may be
justified on culturally relativistic grounds, one must
eventually descend from the metaethical mountaintop
and ask if such a hypothetical society actually exists.
While the actual existence of this hypothetical society
seems at best implausible, I must defer such research to
anthropologists.

COMPLEMENTARY CO NSIDERATIONS
As I've alluded to earlier, while our intuitions may
speak to us strongly about practices from which we are far
removed, (e.g. slavery, Apartheid, Nazism, foot-binding,
and corsets) it is the practices which surround us that we
are least likely to question. Having pitted (what I hope has
been) a complete set of culturally relativistic defences for
FGM against the aforementioned counterexamples, one
might just as well substitute a number of North American
practices for FGM. Prescinding from matters of degree, if
North American readers were under the impression that
FGM is the kind of practice that could never happen here,
perhaps we ought to reconsider.
In order to uncover some North American candidates
for "harmful practices, the sole justification of which is
sociocultural", one need only ask members of another
society.13 They might suggest that we address, as seriously
as FGM, the following questions: Considering the
immensely coercive force of the North American media
and our social infatuation with a given body image, how
might we justify the prevalence of cosmetic breast
implants for the otherwise healthy woman? How can we
explain the prevalence of such an immediately painful
and eventually harmful practice as bulimia? From the
mountaintop, one might group these phenomena under
the heading of 'harmful practices which improve social
standing'. Subjecting one's own practices to scrutiny
comparable to that of FGM may indeed allow for a more
introspective approach to not only FGM, but to one's own
values as well.

CO NCLUSION
Cultural Relativism is defensible insomuch as Ethical
Subjectivism is. There is nothing to stop a person from
valuing inequality, oppression, or slavery. However,
within this work I have argued that if one's core values
include equality and fairness, then barring the
aforementioned hypothetical society, one cannot defend
practices like FGM through Cultural Relativity. I have
grounded these arguments in intuition through analogy
and in principle via analyticity. I began by noting that it is
often difficult to question harmful norms that surround
us. Perhaps even more difficult for physicians, is
returning from the mountaintop to act in accordance with
one's beliefs, especially when they are contrary to social
norms. Mohandas Gandhi proclaimed, "In matter of
conscience, the law of the majority has no place." 14 There
may be no place where such wisdom is more applicable.
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A LOOK AT WOMEN'S HEALTH ON THE INTERNET:
By Rupinder Singh Sahsi, MEDS 2001

here are a number of excellent resources on the
World Wide Web related to the topic of Women's
Health. By no means can a single article capture the
vast amount of information that is available at a few clicks
of the mouse button. From the riches of the Internet, I offer
the following selections for your perusal.

T

Women's Health Interactive (WHI)
http://www.womens-health.com/
This site provides comprehensive resources for
patients and health professionals alike. Of note are the
WHI Health Centers that are designed to facilitate patient
education on issues like gynecology, cardiac health,
infertility, (peri) menopause, and nutrition. As well, web
surfers can tap into WHI's lis t of current consumer
research studies, indices of women's service providers,
and on-line discussion forums. This award-winning site
strives to be " an unique and interactive learning
environment where women gain knowledge and mastery
of their health through the multidisciplinary resources."
Definitely worth checking out and potentially a useful site
to refer to your more net-savvy patients.
Women's Health & Medical Info
http://www.cbull.com/health.htm
It is not exactly Yahoo!, but this site delivers 85+
kilobytes of links on online women's resources "for your
mental and physical health and well being." This site was
created after over a year of searching for women's health
and medical sites on the Internet. There is nothing fancy
here, but a straightforward alphabetized list of links to
medical sites that might even be slightly related to
women's health. This site is an offshoot of the "Best Sites
For Women" web site {http:/ / www.cbull.com) authored
by Claire Bull. Be warned that there is a lot of content
here, so if you're looking for something specific in a hurry,
this might not be the best place to start.

The American Medical Women's Association
http://www.amwa-doc.org/
The American Medical Women' s Association is an
organization of over 10,000 female physicians and medical
students "dedicated to the care of the woman patient and
serving as the unique voice for women's health." This web
site focuses mainly on the AMW A itself- annual meetings,
committees, programs, projects, etc. However, if you're

U. W .O. Medica/Journal

looking for information on health topics, scroll down the
main page to the little graphic of the red cross. It links you
to a series of online documents geared towards educating
the public. Although they are well laid out, the graphics
are nothing to get excited about. I found some of the
documents a little simplistic, but very effecti v e at
conveying the key messages that are fundamental for
patients.
Medscape Women's Health
http://WomensHealth.medscape.com/Homerfopics/
WomensHealth/WomensHealth.html
I
was
first
introduced
to
Medscape
(http: / / www.medscape.com / ) a while ago through the
advice of a colleague, and I've been hooked ever since.
From the makers of what is probably the #1 medical site
on the Internet, this page does not disappoint. While many
sites on the topic of Women's Health have a greater
patient-education focus, Medscape's page delivers the
information physicians are looking for. New articles
relevant to areas of women's health are posted daily with
access to full-text journal sources. In addition, there are
case challenges, clinical quiz questions, and the "virtual
consult" where peculiar but interesting cases are laid out
by the experts.
JAMA Women's Health Information Center
http://www.ama-assn.org/speciaUwomh/womh.html
This is another excellent resource for physicians and
health professionals looking for recent and accurate
information. The clear and simplified layout lets this page
load up lighting-fast, and enables you navigate the site
with ease. The Newsline gives you updates from Reuters
Health, special in-depth articles from major professional
sources, and coverage of key conferences from around the
world . Regularl y posted Journal Scans keep tabs on
women's health articles that appeared in the literature,
presenting abstracts organized by categories including
adolescent health, breast cancer, menstrual cycle, and
recurrent pregnancy loss to name a few . Full text articles
from AMA scientific journals are also available,
potentially saving one the bother of a full subscription.
Also of note are the STD and Contraception Information
centers. Don' t let the initially spartan appearance of this
site fool you, there is a lot of information available once
you make just a few simple clicks.
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And finally ...
When dealing with sensitive issues related to
Women's Health, health care professionals have to be alert
that increasing proportions of their patient population will
be referring to sites such as these prior seeking medical
advice. Many even prefer the autonomy and self-reliance
of being able to access such information on their own time.
It is helpful to keep an eye out for what information (and
misinformation) is floating around the information
superhighway, so that one can help direct patients to
authoritative sources. Furthermore, letting patients do
their own reading on the Internet is not only better for
their ability to process information at their own pace, but
will likely help to decongest some of the busy schedules
practitioners face everyday.

As always, the sites mentioned in this article, and
others on the subject, can be found in the Medical Links
database
of
the
Meds2001
Web
Site
(h ttp://meds2001.ga r age.o rg/), under the "Women's
Health" subject heading.
Q

Southwestern Ontario 's Leading Centre for Patient
Care, Teaching and Innovation

LONDON

Health Sciences Centre

Congratulates the UWO Faculty of Medicine
Graduates.
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By Najib Safieddine, MEDS 2001 & Mahmoud Sharaf, MEDS 2002
INTRODUCTION
The last decade has seen a rapid increase in the
number of techniques and treatments available to nonfertile couples for having children. Unfortunately, and
perhaps quite predictably, legislation has not kept pace
with medical science. Canadian family law finds itself in a
situation of great delicacy as it searches for guidelines that
will prevent the litigation nightmares now common in the
United States. However, just as important as the custodial
issue is the item of women's health.
THE
RO YAL
CO MMISSI O N
REPROD U CTIVE TECHN OLOGIES

ON

NEW

The Royal Commission on New Reproductive Technologies
(1993) issued a final report that proposed several
recommendations to standardize and simplify Canadian
law on assisted conceptions . Some of the proposals
included:
1. That the donor's rights and responsibilities of
parenthood are severed by the act of sperm donation;
2. That the male partner of the donor insemination
recipient, if he has given his written consent at the
time of insemination, be considered the legal father of
the child;
3. That the married or cohabiting male partner should
only be able to disavow paternity if he did not consent
in writing to the insemination; or he did not enter into
a parental relationship with the child knowing he was
not the genetic father; if he had acted as a father to the
child only because he believed he was the genetic
father of the child;
4. That if the legal mother of the child has no male
partner, the child has the legal status of " father
unknown'';
While providing valid recommendations pertaining to
legal custodial issues, the Royal Commission has not fully
addressed the im~lications of infertility treatments on
women's health. This comes despite critical input
provided by the Canadian Advisory Council on the Status
of Women in their brief to the Commission. 2 Specifically,
o v arian induction is an infertility treatment that
constitutes a possible health risk that was not seized upon
by the Commission.
HEALTH RISKS

raised concerns about the possible risk of ovarian cancer.34
Agents such as human menopausal gonadotropin (hMG),
follicle stimulating hormone (FSH), and FSH analogues
are not without certain " toxic" consequences. Ovulation
induction can lead not only to higher incidence of
spontaneous abortions, but also to diseases such as
ovarian hyperstimulation syndrome (OHSS) which results
in the secretion of supraphysiological levels of estradiol
and severe health complications, possibly requiring
hospitalization.5 Ovulation stimulation drugs have been
associated with hot flashes, multiple gestations, visual
disturbances, and cervical mucous abnormalities.
Thromboembolic disease is also suspected to arise from
OHSS.6 Evidence suggests that such treatments affect the
proliferation of epithelial breast cells and thus add to the
risk of breast cancer?
Although some of these risks have not yet been
absolutely confirmed to be the sole and direct result of
infertility treatment, and research is still underway, the
possible risks are too grave to ignore. This necessitates the
intervention of the legal system to address the issue
immediately.
CON CLUSION
In the past, the Food and Drug Act has empowered the
federal government to intervene in blocking potentially
risky drugs and therapies from being used in Canada until
properly studied and validated. It is necessary for Canada
to uphold its strict tradition of rigorous evaluation of new
drugs and therapies, particularly when it comes to
reproductive health. The Canadian courts and the public
ha v e shown a firm expectation that government and
business must not only prevent clear obstacles to national
health and safety but also anticipate them. In Hollis v. Dow
Corning, a case of silicone breast implant liability, the
Supreme Court confirmed legal responsibility of the
manufacturer despite little evidence at the time of the
inherent danger. In New Brunswick, the provincial
government was held liable for the adverse effects of DDT
pesticide use after the fact despite no convincing evidence
at the time. The ethical-legal principle of government
exercising due care for the health of the population at the
stage when treatments are only potentially problematic
should be appealed to. The urge to provide the choice to
infertile women to have children if they so desire can only
be outweighed by concern for their health and safety.

Many women faced with infertility are treated with
ovulation inducing medicines. However, evidence has
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WOMEN & INFERTILITY:
HISTORICAL PERSPECTIVE
By Kent Dunn, MEDS 2001

s infertility on the rise because women are delaying
childbearing in pursuit of career success? Does it affect
white women more than African-American women, or
the rich more than the poor? Has infertility reached
epidemic proportions among the educated and affluent?
Most would answer yes to these questions-and most
would be wrong.
The erroneous idea that current infertility rates reflect
a new phenomenon in orth American society provides a
di s torted image of the present and obscures the
relationships between contemporary ways of coping with
involuntary childlessness and those of past generations.
For example, in the seventeenth century few women
would have considered seeking medical advice as
infertility tended to be viewed as the will of the Lord or
the work of the Devil. 2 By the late nineteenth century,
physicians were performing surgery, such as ovarian
transplantation, in an attempt to restore fertility. 2 The late
twentieth century has seen the development of in vitro and
related reproductive technologies that have increasingly
severed reproduction from sexuality. Thus, throughout
the last three centuries, the inability to procreate has been
medicalized--converted from a socio-religious state into a
medical condition.
ln addition, the approach to infertility, whether
historical or contemporary, accommodates a persistent
gender bias: the tendency to view women's bodies as
inviting intervention and men' s as demanding caution.
This bias is manifest in relation to the form of medical
in v estigations and infertilit y therapy, and in the
enthusiasm and frequency with which they are
performed. This is exemplified by the fact that historically
many fertile women have been subjected to invasive, often
dangerous procedures, in order to enhance the capabilities
of a partner's weakly motile sperm.
Such relationships will be explored by examining the
ways in which the inability to conceive has been treated by
medical practitioners, perceived by society, and experienced
by individuals from the 17th through to 20th century.
From the 17th to the early 19th century, popular and
medical opinion alike held that female sexual pleasure
w as almost always essential for pregnancy to occur. u
According to Etmuller the "languishing" of a woman's
"venereal appetite" often caused barrenness. 1.3 Mauriceau
went so far as to cite "the insensibility of some women,
who take no pleasure in the venereal act as the most
frequent reason why this orifice opens not in this act to
receive the man' s seed" .3 Men on the other hand were
only held accountable if they were impotent or in some
way "unable to perform their marital duties".2
Therefore, barrenness was a woman's problem, and
self-treatment was the usual means employed to alleviate
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it. American women kept medicinal recipe books which
often contained specific preparations to treat various
menstrual irregularities that were believed to cause
barrenness and that could also be used for the prevention
of miscarriage. If self-treatment failed, a woman might
have consulted a midwife, who would have prescribed
various botanical prepara tions. 1.2
The first steps towards the medicalization of infertility
began with James Graham (1745-1794). Graham,
something of a maverick, built a fortune with his
ingenious linkage of sexual pleasure to electrotherapy in
order to cure sterility.4 On his return to Great Britain in the
late 18th century he constructed the "Temple of Health" in
London. Here an audience of men was seated in chairs
that provided mild electrical shocks (coined " magnetic
thrones") while listening to Graham lecture on potency.
Women who came to the temple heard lectures on fertility
given by a member of their own sex. 4 The well to do had a
further option -Graham's vibrating "celestial bed". The
"superior ecstasy which the parties enjoy in the Celestial
Bed ", promised Graham, was "really astonishing ... the
barren certainly must become fruitful when they are so
powerfully agitated in the delights of love". 4 The bulk of
his audience, no doubt, came to the Temple to be titillate
by the mild electrical shocks or by the lectures themselves.
In fact, it was hard for his contemporaries, as it has been
for generations since then, to take Graham seriously.4
In the 1860's and 1870's technological developments in
the form of new instruments and surgical techniques burst
onto the medical scene, thus providing new opportunities
for seein~, and for reconfiguring the interior of women's
bodies .2 · The use of instrumentation and surgery on
women's sexual organs became commonplace by the end
of this period, especially among physicians eager to
establish themselves as "experts" in an emerging medical
field . Women themsel v es, apparently in increasing
numbers, actively sought surgical treatment, both
demonstrating the existence of demand for these methods
and encouraging more physicians to provide them. 2 The
" women's surgeons" of the 1850's and 60's, and the
w omen who patronised them, had a profound impact on
what would become the specialty of gynaecology.
In terms of the history of infertility, two of the most
important "women's surgeons" were J. Marion Sims and
his assistant Thomas Addis Emmett. Both worked at the
Woman's Hospital in ew York- the first hospital devoted
exclusively to the surgical treatment of disorders of
women's reproductive systems. 2 Sims felt that the
overwhelming majority of the diseases of the female
reproductive system were structural, and therefore curable
b y surgery . Believing that most dysmenorrhoea and
sterility resulted from a mechanical blockage of the cervix,
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Sims thus reasoned that surgery to widen the cerv ical
opening should alleviate pain and allow conception. Sims
and Emmett performed countless "cervical incisions" in
order to make its opening into the vagina larger. 2
However, Sims did not consider pregnancy a measure of
success; rather, women were "cured" if the os was opened,
the cervical canal straightened, and any of the infections
that the surgery itself often generated, were alleviated. 2 In
fact, Marsh and Ronner 's historical analysis of Sim's
records revealed that some women received surgical
interventions even when they had no obvious symptoms
that might account for their sterility. Marsh and Ronner
concluded that much of Sims' surgery for infertility was
performed to 'correct' what seems to have been normal
organs.2 However, Sims did succeed in revolutionising
medical ideas about infertility, and in the process ushered
in a wave of technological innovation that contributed to
the rapid emergence of the field of gynaecology.
A number of societal trends following the Civil War
resulted in a decreased birth rate, and as more women
pursued higher education and careers, the people's views on
the aetiolo~ of sterility centred on women's 'inappropriate'
behaviour. ;s Harvard physician Edward H . Clarke's 1873
"Sex in Education " argued that young women w ere
educating themselves into sterility. He believed that young
women should not be putting in long hours of studying
difficult academic subjects, but should instead learn slowly
and completely, and rest their minds during their menstrual
periods. Education, he stated, had a "sterilizing influence" on
young women and in another generation, "the race will be
propagated from its inferior dasses". 6
By the end of the century, new ideas and evidence
began to suggest that infertility, rather than resulting from
women's refusal to bow to conventional behaviour, could
be accounted for by more specific physiological disorders,
particularly of the ovaries and fallopian tubes. Perhap the
most important single factor in accomplishing this change
wa s the dramatic alteration of medical views of
gonorrhea.2 As practitioners began to accept gonorrhoea
as a cause of sterility, they were forced to give more
attention to the existence of infertility in males. By the end
of the century, the idea of semen examination took hold
among a number of the field 's prominent practitioners
(although it did not become a routine part of arriving at a
diagnosis of infertility until the 1950's).2 The realisation
that men could be sterile marked an important shift in
attitudes among gynaecologists.
The discovery of estrogen in 1923 and progesterone in
1929, coupled with the newly discovered intricacies of
ovulation and implantation, marked the beginning of a
journey that led to the creation of the birth control pill, the
infertility drugs pergonal and clomid, and successful in
vitro fertilization. 5 Fertility (and infertility) in women
could now be understood and, in some cases, treated.
The period from the 1960's to 80's illustrates some
new dimensions of some aspects of infertility. After 1965,
birth rates would begin to plunge and larger numbers of
couples would choose to be childless; at the same time,
dramatic advances would occur in the ability to treat
infertility effectively.2 Attitudes towards the infertile were
also changing as antinatalist sentiments challenged the
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pronatalist consensus that had held sway among the postwar generation. Instead of sympathy, in the 1970's women
feeling anguish over their inability to have a baby might
be reminded that pregnancy was unattractive or that the
world was overpopulated anyway?·9 Such opinions did
not, of course, diminish the desires of the involuntarily
childless. And despite fears held by advocates of the
'traditional' family, a feminist movement that enabled
more women to attend university and succeed in careers
did not inevitably create a generation of women
antithetical to motherhood.2
This change in attitude is perhaps best illustrated
using in vi tro fertilization as an example : what was
heralded to be a technological miracle in the 40's, was a
morall y questionable endeavour in the 60's and had
become a veritable political minefield by the 70's? In fact,
by the mid 70's the Right to Life movement had succeeded
in shutting down American IVF experimentation . 2
However, work continued in England where Cambridge
University physiologist Robert Edwards and gynaecologist
Patrick Steptoe performed at least 80 in vitro fertilizations
before they effected the first successful implantation} thus
heralding the ultimate separation of the sexual and
reproductive acts. The first test-tube baby, Louise Brown,
was born on July 25, 1978 in Bristol, England.2
Present day technologies such as achieving pregnancy
post-menopausally, the possibility of harvesting and
freezing sperm post-mortem, and breaking the genetic tie
between mother and child through the use of donor eggs,
are among the practices that have made IVF controversial.
In addition, the daunting prospect of cloning babies is
now more than ever a possibility. Such new techniques
have further subverted the link between se x and
reproduction and challenged traditional verities. One
must remember that the desire to use these techniques,
like those employed in the past to assist infertile women to
conceive, is socially and culturally conditioned .
Employing a historical perspective contributes to one's
understanding and evaluation of the assumptions about
the roles of reproductive technology that underlie the
controversy over its use.
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UNWINDING THE SNAKES:
REDISCOVERING THE TRUE SYMBOL
OF MEDICINE
By Samir K. Sinha, MEDS 2002

hile medicine has been associated with ~erpent
symbolism since humanity began recording the
art, most authorities agree that the Aesculapian
staff is the true symbol of medicine. Although seen
frequently, few people are aware of its historical origins,
and its relation to the profession. If the Aesculapian staff
(around which one serpent) is entwined is the correct
symbol, why then is the caduceus of Hermes (around
which two serpents are entwined), so frequently adopted
as the symbol of medicine? And is the caduceus an
appropriate symbol for the medical profession? This paper
will explore these questions.

W

AESCULAPIUS AND HIS STAFF
Homer, in the flliad, mentions Aesculapius only as a
skilful physician; in later times, however, he was honored
as a hero and eventually worshipped as a god. The first
mention of Aesculapius occurred in a Greek inscription
recording the establishment of an Aesculapian shrine in
Athens in 420 BC. Aesculapius was the son of Apollo, the
primary god of healing in the Greek pantheon, and the
maiden Coronis. During his lifetime, Apollo passed along
his knowledge of medicine to Chiron, the son of Saturn. It
was Chiron who later helped to raise and instruct
Aesculapius in the art of healing using herbs, potions, and
incantations. 1 Further to the legend, after Perseus had
beheaded Medusa, Athene directed young Aesculapius to
extract blood from her headless body. Blood from her left
side was lethal to the touch, while blood from her right
side possessed unique powers to resurrect the dead. 2 With
these new therapeutic resources, Aesculapius now
achieved notable clinical successes, albeit in small nonrandomized control trials.
Aesculapius became so proficient in healing that he
soon surpassed his master. .Furthermore, his powers
became so well-known that people came from all over
Greece to see him . Aesculapius was frequ ently
represented in statues standing dressed in a long cloak.
His two most important attributes began appearing
together towards the end of the 4th century BC in the form
of the Aesculapian staff, with a single serpent coiled
around it. And, unlike the caduceus, its meaning seems to
have developed from a utilitarian standpoint rather than
as a sign of position or authority.
The snake itself has both a practical and metaphorical
meaning. The snake has always been considered sacred
and worshipped for its representation of wisdom. It also
came to symbolize the gods of fertility and since it could
shed its skin, it was thought to possess powers that
enabled it to live forever . Physicians in earlier primitive
cultures thus ate snakes, believing they would become
more efficient healers. 3 Aesculapius' later association with
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the serpent resulted from an incident that occurred while
he was in the house of a patient. Tradition states that
while he was deep in thought, a snake coiled itself around
his staff. He killed the snake and then another one
appeared with an herb leaf in its mouth and restored the
dead serpent to life. 4 As a result of this incident,
Aesculapius kept non-poisonous snakes in temples to help
heal the sick. In addition, the species of snake found on his
staff, Elaphe longissima, became an integral part of the
temples later built in his honour. Because of its natural
diet of rats, the priests used it as a biological pest control.
As they became a more prominent fixture, they began to
play an important part in the rituals of the temples. 5
The staff, the other symbol associated with
Aesculapius, was adopted as a symbol of sovereignty in
Egyptian and Sumerian cultures. While it denoted power,
the emblems attached to it were associated with the god
under whose name it was cast. 6 The staff symbolized plant
growth and was associated with both death and
resurrection of the dead. In this regard, the staff was very
much like the snake shedding its skin. Both indicated that
life was everlasting. The sturdy nature of the staff may as
well be seen as the traveller's staff, reminding us of the
long journeys of Aesculapius from his home in northern
Greece throughout the Hellenic world. It thus symbolizes
the inexhaustible willingness of the physician to travel
long and wearisome journeys to help the sick. 7
.
Aesculapius became recognized as a god because, m
ancient Greece, it was believed that anyone who recovered
from an illness was regarded as being resurrected from
the dead. On one occasion Aesculapius is said to have
raised a man from the dead and delivered him from
Hades, a privilege reserved for the gods. Because of this,
Pluto accused Aesculapius of diminishing the number of
souls in Hades. An enraged Zeus, fearing that Aesculapius
might make all men immortal, slew him w~th _a
thunderbolt. 8 Before his death, however, Aesculap1us 1s
said to have sired six children. Two of his daughters were
Hygeia and Panacea. The beautiful Hygeia was the
goddess of health and preventative medicine; Panacea
assisted her sister in the temple rites and tended the
sacred serpents. Aesculapius' two sons, Podalirius and
Machaon, were both physicians to the Greek armies
besieging Troy. (llliad II, 645-8)
The cult of Aesculapius originated in Thessaly where
he was worshipped as a healing saviour, and quickly
spread throughout Greece . The healing practices of
Aesculapius were passed down from father to son, each
generation being recognized as Asklepiads or healing
priests. The name itself is interpreted to mean "hea~g
soothinF,lY and deferring the withering that comes w1th
death." They practiced their skills in magrrificent temples,
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built in honour of Aesculapius . These temples are
generally acknowledged as the origins of hospitals. In
these temples, wounds were dressed and sanitation and
preventative medicine were rcracticed and taught,
intertwined with religious rituals. °For the ancient Greeks,
medicine and religion were inseparable. Over time more
than 200 asclepia were built throughout Greece, the
greatest at Epidaurus, where the theatre seated 20,000
persons.11
Ob v iously, Greek medicine was rooted more in
m y thology and theology than in science . It was
remarkable that the cult of Aesculapius was popular and
influential throughout Greece for about 1,000 years. In the
Roman Empire, the worship of Aesculapius was bitterly
attacked as Christianity gained popularity, though the cult
surv ived until the 6th century. 1 Secular medicine also
began competing with ecclesiastical medicine in Greece. In
his essay The Sacred Disease, Hippocrates, credited with
the liberation of medical ethics, attacked the theory that
illness is caused by the gods, and claimed that all diseases,
including epilepsy, had natural causes. Even Hippocrates,
h owever, occasionally advised prayer as an aid. 13 The
Hippocratic oath begins with the words "I swear by
Apollo the physician, by Aesculapius, Hygeia and
Panacea , and I take to witness all the gods, all the
goddesses ... ", though some no longer ascribe to it.
THE CADUCEUS

The caduceus, the staff around which two serpents are
entwined, ultimately came to be associated with the Greek
god Hermes . Hermes was the son of Zeus and Maia,
d a ughter of Atlas . Graceful and swift, he served a s
messenger to the other gods. Hermes was considered on
various occasions the god of commerce and merchants,
mes sengers, thieves and the underworld deity who
conducted souls to Hades. The caduceus represents the
w and of Hermes and connotes his patronage of peace,
trade, commerce and communication. In the account of the
origin of the caduceus, it was stated that Apollo gave his
staff to Hermes as a reward for Hermes' invention of the
lyre. According to Apollo, the staff had the power to unite
all beings divided by hate. When Hermes travelled to
Arcadia, he saw two serpents fighting. With dispatch, he
threw the staff between them and they wound around it in
a friendl y manner . 14 Wings were later added to this
emblem as a symbol of Hermes' speed and the caduceus
w as born. Because Hermes was the messenger of the gods,
his staff, which came to symbolize authority and peace,
became the herald' s wand in times of war. As warring
combatants might do today with a white flag as a symbol
of truce, the Romans expressed their desire fo r
negotiations with enemies under the caduceus.15
There are few actual references to healing functions
attributed to Hermes, although he was a god of
gy mna s tics and athletics, and was considered to be a
guardian of health.16 Hermes played some medical roles in
that he did assist in conducting the dead to the
underworld and also received some credit for relieving
pl a gues and epidemics in Asia Minor. In peacetime,
however, Hermes and his caduceus became primarily
associated with trade and pros perity, retaining their
wa rtime roles in negotiation and communication .
U. W. O. Medica/Journal 68 (1)
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Throughout Europe before the last century, the caduceus
was a purely commercial symbol without medical
connotation. Hermes carried over into Roman mythology
as Mercury. A good deal of our English language is rooted
in the commercial connotations of Hermes' function. The
words "commerce," "merchant," "market," "mercenary,"
and "mercantile" all come from Latin merx or mercis
(goods) and mercer (to traffic).
THE MIDD LE AGES AND THE ROOTS OF CONFUSION

In determining which god more accurately represents
the medical profession, most scholars agree that
Aesculapius wins hands down.17 After all, he was the god
of medicine, healing, and physicians. The caduceus, on the
other hand, is the symbol of Hermes, who had little to do
with medicine . Since the Renaissance, however, the
emblem of Hermes has often been confused with the staff
of Aesculapius in representing the profession. From this
unrelated past, how did Hermes and medicine get to be
bedfellows?
As noted, although Hermes had little to do with the
healing arts, his caduceus was adopted as a medicopharmaceutical emblem in the 3rd Century, as he became
increasingly associated with astrology, magic, alchemy,
theology, and philosophy . 18 Meanwhile, the cult of
Aesculapius fell into disrepute as Christianity gained
influence and power. Throughout the Middle Ages, there
was little if any reference to Aesculapius and his staff.
Resurrection of the image and its adoption as a symbol of
healing came with the Protestant Reformation and the
development of humanistic attitudes towards medicine
and an interest in ancient mythologic and historical
themes.19
Ironically, the caduceus was the first of the ancient
symbols to resurface; it was independently chosen as an
emblem by two printers of incunabula, Erhard Ratdolt in
1486, and Johann Proben, who actually did some medical
printing, in 1518. The caduceus also appeared in the coat
of arms given to Sir William Butts, physician to King
Henry VII, at his knighting. Other prominent physicians
soon chose the caduceus as an emblem. One theory holds
that the adoption of the caduceus as a medical symbol
derived partly from the fact that in the 16th and 17th
Centuries, the fields of pharmacy, chemistry and medicine
were not clearly defined. The Royal College of Physicians
of London also had an indirect influence in popularizing
the caduceus as a medical symbol. John Caius, President
of the College in 1556, presented ~o the college a small
"caduceus" to be carried by the President as an ensign of
honour by which he would be distinguished from other
Fellows.20 Nevertheless, when the medical writings of the
great Arab physician Avicennq were published in 1544,
the frontispiece was decorated with a bust of Aesculapius.
Other medical textbooks were also decorated with images
of Aesculapius, but by the last part of the 18th century
there was a decline in the use · of this symbol b y
publishers. 21
The caduceus first appeared in North America appropriately enough- in an advertisement that appeared
in the Boston Columbian Sentinel. Josiah Flagg, Jr. was one
of the first native-born dentists in the United States; he
used the caduceus in an advertisement on May 26, 1792,
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and later embellished the caduceus with crossed
toothbrushes.22 The staff of Aesculapius was first utilized
by the US Surgeon General's Office in 1818, and wa also
adopted by the British Medical Corps in the same year.
Medical historians have questioned the worthiness of the
caduceus as a logo for the medical profession .23 Its
acceptance as such in many parts of the world, especially
in the United States, is said to have resulted from an
omission on the part of the US Army in 1856. At that time,
a symbol was required for medical personnel in the field,
and as a result the caduceus was adopted by the US Army
as the insignia for hospital stewards. The caduceus served
well and in 1902 it was added to the uniforms of US Army
Medical Corps officers as well. One explanation for this
decision is that the caduceus is an administrative, not
medical, symbol; it signifies the neutral, noncombatant
" messenger" status of these personnel. It seems more
probable, however, that the caduceus was simply
confused with the Aesculapian staff which more properly
symbolizes the healing profession. In 1871, the caduceus
became the symbol for the US Public Health Service. This
move legitimized the case of mistaken identity, diverting
attention from the Aesculapian staff, and affirming the
caduceus' erroneous association with medicine. As a
result of such official use, many developing medical
organizations at the turn of the century incorporated the
caduceus into their crests. Hence, through the years, either
the caduceus or the Aesculapian staff have been adopted
as an emblem by numerous medical organizations.

In today's social, political, and economic climate, it
seems that medicine has placed healing somewhere off
center. The language of medicine is becoming increasingly
filled with terms like affordable health care, health reform,
cost control, malpractice, etc., and the list of terms keeps
growing. As well, the business of medicine is assuming a
larger importance in the preoccupation of each
practitioner. In some parts of the US there are more legal
than medical indications for procedures prescribed in the
handling of health problems. Advertising is becoming
almost as prominent now in " capturing" an ever
increasing "market share" than it was for Josiah Flagg, Jr.
Indeed, all of these ingredients fit well under Hermes'
emblem for those trafficking in medicine.
It is unlikely that the symbolic change induced a
change in the profession, but it may have changed the way
physicians view themselves as other pressures and society
have changed the philosophy and methods by which the
art of healing is practiced and its relationship to the
society it serves. We have two significant serpent symbols
now, and these symbols and the profession for which they
stand are in competition. However, within the setting of
increased competition, an image that harkens back to the
foundation of modern medicine, an image that conveys
commitment to the healing arts, which is essentially what
the Aesculapian staff embodies, should be the preferred
identity for all members of the medical profession.

ONE SNAKE OR TWO?
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A symbol is supposed to evoke recognition of
something it is associated with, and the caduceus means
medicine to much of the public, and- it seemsincreasingly to members of the profession. It ma y be
possible that a symbol may modify the thing it is meant to
symbolize and that medicine as a profession is just now
catching up to the newer symbol that it had adopted
within the past century, forsaking the longer heritage of
Aesculapius' staff.
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INTRODUCI'ION
enopause gives two signals to women-its onset
marks both the end of their reproductive years
and the beginning of potential, chronic health
concerns. The detrimental health effects of menopause are
due to concomitant hormonal changes, with the decrease
in circulating estrogen levels (primarily 17~-estradiol) as
the greatest threat to postmenopausal women's health
status. Average circulating estrogen levels in these women
can fall to less than 10% of premenopausallevels.1 Because
of the importance of estrogen actions to the maintenance
of the skeleton and protection of the cardiovascular
system, such a dramatic decrease in circulating estrogen
levels greatly enhances the risks for osteoporosis and
coronary heart disease (CHD).
Estrogen deficiency leads to increased osteoclast
activity, through a yet unclear mechanism that is mediated
by cytokines? Heightened bone resorption rate enhances
bone turnover, which leads to a net loss of bone mineral
density. And since breaking strength of bone is directly
proportional to bone mineral density, decreased levels of
estrogen increases bone fragility and the risks for bone
fractures.3 Although various bone fractures can result from
postmenopausal bone loss, hip fracture is the one of most
concern because severely compromises the independence
and quality of life of the affected and leads to increased
socio-economic burdens.
Besides enhancing osteoclast activity, low levels of
estrogen also cause postmenopausal women to have a
higher proportion of low density lipoprotein (LDL)cholesterol, increased fibrinogen and plasminogen
activator inhibitor (PAI-l), which is an essential antagonist
of fibrinolysis in humans.3 Such a profile elevates the
chances for the formation of atherosclerotic plaques and
blood clots, and conseqt~ently, an increased risk to CHD.
In the Western world, CHD is the leading cause of death
in postmenopausal women. 4· 5
•
In order to deal with these serious health implications,
estrogen replacement therapy (ERT), the administration of
estrogen or conjugated estrogens to increase circulating
estrogen levels in postmenopausal women, was
developed. Its effectiveness towards decreasing the risks
of bone fractures has been demonstrated in various studies
since the 1970's. 3 However, major concerns arose with
long-term ERT when unopposed estrogen consumption
after menopause was shown to increase the risks of breast
cancer, endometrial hyperplasia and endometrial cancer.1.3· 4
As a result, progestin was adopted as a compliment to
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ERT because it was found to be able to markedly decrease
the risks of endometrial hyperplasia and endometrial
cancer. But concerns remained as the use of hormonal
replacement therapy (HRT, the combination of estrogen
with a progestin regiment) for 5 years has been recently
associated with a 40% increased risk of developing breast
cancer. 6 Because of these associated risks with HRT, many
physicians have been reluctant in prescribing it to
postmenopausal women. 1 Given these factors that limited
its therapeutic and preventative application, HRT required
modifications and improvements to better manage the
health problems associated with menopause.
THE BIRTH OF SERMs
The search for safer and more effective HRT led to the
reevaluation of antiestrogens, a group of steroidal or nonsteroidal compounds designed to treat estrogendependent breast cancer via an antagonistic effect to
estrogen at the estrogen receptor (ER). The reason for
more extensive research into antiestrogens was that some
of them displayed tissue-specific agonist/ antagonist
actions at the ER, as supposed to being pure antagonists.
Consequently, some of these antiestrogens were
reclassified as the "selected estrogen receptor modulators
(SERMS)". Precisely, SERMs are antiestrogens that exhibit
a mixed estrogen agonist/ antagonist profile 1• 5• 7 The ideal
SERM should be an ER agonist in bone and lipid profile,
and an ER antagonist in mammary and uterine tissues.
FIRST GENERATION SERMs
The first antiestrogen that was termed a SERM is
tamoxifen ( olvadex®), which belongs to a class of
chemical compounds known as the triphenylethylenes.3 1ts
usage in the treatment of breast cancer began in the 1970's
and is now a part of standard adjuvant therapy.1• 7 The
tissue-specific estrogen effects of tamoxifen are well
documented in various clinical trials that assessed its
potency in preventing and treating mammary carcinomas.
The agonistic, or estrogen-like, effects of tamoxifen are
similar to those seen with traditional HRT therapy. Several
studies involving postmenopausal low-risk breast cancer
patients, women receiving adjuvant tamoxifen for
treatment of early s tage breast cancer, and healthy
postmenopausal volunteers provided evidence that
tamoxifen has a beneficial effect on bone mineral density
in the hip and spine.s- 10 Tamoxifen also shows favorable
influences on the lipid profiles of postmenopausal women.

- - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medica/Journal 68 (l) 1999

P r omot i o n

and

Preven ti on

Aside from the antagonistic
effects of raloxifene in endometrial
Table 1. Summary atd Comparison of First Geeration SERMs
tissues, its actions on mammary
tissues, skeleton, and lipid profile are
Estrogea Actions
IIKI'eased Risks
1st Generation SERMs Original Usage
very similar to those of tamoxifen.
Investigations using ovariectomized
-endometrial polyps,
Tamoxifen
-treatment of estrogen- -antagonist in breast,
rats demonstrated that raloxifene
hyperplasia, and cancer
dependent breast canc:er bone
preserves bone density of the axial
- partial agonist in uterine -liver tumors in rats
and appendicular skeleton, and is
tissues
able to lower total and LDL-agonist in lipid profile
cholesterol. 12· 13 One randomized,
double-blind, phase II study
1st Generation SERMs
COIIpCirisons willl TCIIIOxife~
CheMical Structure
involving
251
healthy
(T11110xifen Allalogs}
Relative to T11110xifen
postmenopausal women treated with
conjugated estrogen or raloxifene
Toremifene
-ethyl side chain chlorinated -reduced antiestrogenicity and antitumor potenc:y found that raloxifene treatment was
-reduced ability to induce rat liver tumors
analog of tamoxifen
equally effective as conjugated
-ability to inc:rease HDLcholesterol
estrogen in decreasing bone turnover,
and significantly lowered total and
ldoxifene
-4-hydraxylated
-inc:reased ontiestrogenicity
LDL-cholesterol levels. Although
- may hove less carcinogenic potential
analog of tamoxifen
raloxifene treatment did not increase
HDL-cholesterol levels as the
conjugated estrogen did, it
1st Generation SERMs
Relative Cllemical Stnctwe eo.p.isolls with Tc.oxift11
suppressed endometrial proliferation
(Derivatives of Tc.oxifee
based on results of histological
Metaboltes}
grading of biopsy material obtained
before and after treatment. 14 Another
TAT 59
-derivative of 4- reduced antiestrogenicity and antitumor poten<y more recent, double-blind, placebo
hydroxytamoxifen
study
that
involved
601
postmenopausal wOI;nen confirmed
- no induction of rat liver tumors
Droloxifene
-derivative of 3,4these findings. 15 As for actions within
dihydroxytamoxifen
-low bioovailobility uponoral administration
mammary tissues, there is strong
evidence from various investigations
that
raloxifene
presen ts an
Like estrogen, it lowers total and LDL cholesterol, but has
antiproliferative effect on estrogen receptor-dependent
little effect on HDL cholesterol?· 10
mammary carcinomas. 16• 17
Unfortuna tely, despite the beneficial effects of
The unique antagonistic effect of raloxifene 011 uterine
tamoxifen, it remains a partial agonist in the
tissues makes it one of the more promising SERMs. By
endometrium, which increases the risks of endometrial
conferring no detectable risks to gynecologicpl cancers, it
hyperplasia and cancer. 1' 4 ' 7' 11 Ano ther concern with
allows the possibility of preventing osteoporosis and
tamoxifen is its potential to ind u ce hep atocellular
coronary heart disease in all postmenopausal with the
carcinoma. Al though there is no huma n data that
bonus of breast cancer prevention. It eliminates the need
demonstra
tesshthe
hepatocarcinogenicity
studies
have
own
that tamoxifen .....;;..._of
_tamoxifen,
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
produces DNA adducts in rat liver. 1• 7 Table 2. Sunnary of Agolist/Aitagonists of Different Estrogen Receptor Ugands•·H 11 • 1'
As a consequence to these real and
potential adverse effects of tamoxifen, SERMs
Profile in Bone
Profile on Cholesterol
Profile in Uterus
Profile in Mammary
new analogs of tamoxifen that confer
Metabolism
ftSsue
less carcinogenecity (Tab le 1) and
second generation SERMs have been 17 ~-estradiol
agonist
agonist
agonist
agonist I
developed.
1 7 11
• •

SECOND GENERATION SERMs
The representative of this class of
SERMs is raloxifene, which is a
benzothiophene with the profile of an
ideal SERM. It is an estrogen
antagonist in mammary and
endometrial tissues, but exhibits
estrogen-like effects on the skeleton
and lipid profile in postmenopausal
women.

Pure estrogen
antagonists
{ICI-1 64,384,
1(1-182,780)

antagonist

antagonist

antagonist

antagonist

1st generation
SERMs (tamoxifen
& its derivatives)

agonist

agonist

partial agonist

antagonist

2nd generation
SERM (raloxifene)

agonist

agonist

antagonist

antagonist
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to restrict SERM treatment, as in the case for tamoxifen, to
those whose high risks of breast cancer outweigh the
increased risks of endometrial cancer. 11 Nonetheless,
raloxifene has its drawbacks. The presence of 6- and 4hydroxyl groups makes it ~ighl_Y vulnerable . to
glucuronidation within the gastromtestinal mucosa, which
limits its systemic bioavailability upon oral
administration. 11 • 18 Because of this, further research has
yielded the discovery of a ~on-st~roida! SE.RM that
embraces the ideal SERM profile, while havmg mcreased
potency. This new compound, currently known as CP336156, is undergoing clinical trials in postmenopausal
women. 18
GENERAL MECHANISMS OF SERMs
Classical Estrogen-Mediated Activity of the ER
The ER is a ligand-activated nuclear transcription
factor . Upon ligand binding, . ER . un~ergoes
conformational changes that allow 1t to dimenze. The
dimeric form of the activated ER then binds to an estrogen
response element (ERE), which is a specific DNA sequence
located in the promoter region of an ER-regulated gene, to
activate the expression of that particular ~en~. ' 4 A(B ~d
E domains on the ER represent the transcnption activation
functions AF-1 and AF-2, respec ti vely, while the C
domain is the DNA-binding domain that mediates the
binding between these transcr~ption act.iva~on ~cti<;>ns
and DNA. 1• 4 E domain is also mvolved m ligand bmding
with F domain, and it facilitate the binding of receptor
specific ligands, nuclear localization, and dimerization.
1

Current Understanding of SERM-Mediated Activity of
theER
The mixed agonist/ antagonist effects of tamoxifen
and raloxifene are partly attributed to fact that these two
SERMs, when bound to the ER, induce different ER-ligand
conformations than estrogen. These different ER-ligand
conformations lead to a varied effect on AF-1 and AF-2,
which may modify the DNA-bindingyr<;>ce.ss of. t~e
ligand-bound ER and result in different mtrms1c actiVl~
on gene transcription. Results fr<;>m McJ?onnell et al. 0
support this explanation for the ffilXed actions of SERMs.
McDonnell et al.20 observed, through varied susceptibility
of different ER-ligand complexes to protease degradation,
that different ligands induced structurally different ERligand complexes. The results of a more recent
investigation that studied the crystal. structtu:es .of the ~R
complexes with estrogen and raloxifene comCldes with
those of McDonnell et al. 20 • It observed that different
agonists and antagonists of the ER have ~fer~nt binding
modes, resul ting in distinct conformations m A.F-~ . 21
Another crystallization study ~eported simll~r
observations. Levenson and Jordan observed that tf
amino acid 351 (aspartate) of the ER is replaced by
tyrosine, raloxifene would lose its antiestrogenic activity
and become an ER agonist like 17~-estradiol. They
determined that amino acid 351, located within the ligandbinding domain (LBO) of the ER, is ~eeded to ~ydrog~n
bond with the nitrogen in the alkylammoethoxy stde cham
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of raloxifene to give raloxifene its antiestrogenicity, and
that there is no such hydrogen bonding between 17~
estradiol and the LBO. Consistent with these
aforementioned studies, while focussing on tamoxifen, is
the finding that tamoxifen-binding to the ER affected AF-1
and AF-2 differently than estrogen-binding. 1
Another explanation for the tissue-specific activi~e~ of
SERMs came from studies that observed an association
between co-regulatory proteins and transcription activity
of the ER. They showed that in addition to the direct
binding to EREs, ERs may inhibit or enhance tr~ription
by recruiting co-activator and co-repressor protems to the
transcription initiation complex depend~ng on the cell
type.23• 2 This observation helps to explam why SERMs
have tissue-specific activities because different cells may
have differing co-regulatory proteins in type and
concentration.23• 24
More recent investigations suggest a third avenue by
which SERMs exert their agonist/ antagonist effects. In a
study by Yang et al.25 that compared the ability of estrogen
and antiestrogens to induce transcription of. the TFG-~~' a
bone matrix protein with antiosteoclashc properties,
raloxifene-ER complexes were able to initiate TFG-~3
transcription even when C domain, the ~~A-bi!'~ing
domain, of the ER was mutated. Yang et al. Identified a
distinct region on the TFG-~3 promoter that inte~acted
with the raloxifene-ER complexes and called It the
raloxifene response element (RRE). These results are in
agreement with the earlier observation that tamoxifen
stimulates transcription of genes with promoters that
contain a non-ERE site, the AP-1 site, differently than
estrogen. In this investigation, Webb et al. 26 found that
tamoxifen ind uced ER-mediated transcription at AP-1
sites in cell lines of uterine origin, but not in cell lines of
breast origin, a finding that reflected differential activities
of tamoxifen in these two tissues. Thus, these results
collectively point to the possibility that ERE-independent
gene activation may be another way in ~hich SERMs
present distinct agonist profiles in different tissues.
Furthermore, the recent cloning of the second estrogen
receptor, ER~, in rats, mice and humans added another
level of complexity to the mechanism of SERMs .. Early
implications of multiple ER subtypes ~n the ~~arusm of
SERMs are available from several mveshgations that
explored the differential response of ERn, the classical
estrogen receptor, and ER~ to estrogen, antiestrogens, and
SERMs . In s ummar y, these s tudies collectively
demonstrated that ERn and ER~ show distinct responses
to the binding of the same ligands. Particular! y, 17~
estradiol binding to mouse ERn stimulates transcription at
the AP-1 site, while its binding to mouse ER~ has an
inhibitory effect. 27 The same stud y also found that both
tamoxifen and raloxifene interaction with either ERn and
ER~ did not induce AP-1 regulated transcription. The
distinct responses of two ER su btypes are further
exemplified in another investigation that probed the
differential response of the ER sub types to SERMs .
Barkhem et al. 28 reported that 4-0H-tamoxifen, an active
metabolite of tamoxifen believed to confer some of
tamoxifen' s effects, tamoxifen and raloxifene all acted as
agonists to human ERn, but were antagonists to h.w:n~n
ER~ . They attributed this observation to the posstbthty
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that ER~ lacks a portion of the AF-1 that has previously
been found to mediate the partial agonism of tamoxifen,
but not that of 17~-estradiol. As well , an earlier
investigation using mouse ER subtypes observed identical
res ults with 4-0H-tamoxifen and sugges ted the same
explanation for the observation. 23 Conseq u ently, the
evidence from these studies raises the possibility that the
agonist/antagonist profile of SERMs may be partially a
result of the different responses that they elicit through
tissue-specific distribution of ERa and ER~ . Also, the
o bse rva tion that ER~ can form homodimers and
heterodimers with ERa upon ligand-activation has opened
up two more potential pathways of estrogen signaling:
signaling through their homodimer and heterodimer
states. 24 It is possible that ER~ homodimers and ERa-ER~
heterodimers may interact with novel co-regulatory
proteins and response elements to produce various effects
of ligand-activation of ERs.4, 23
Although the aforementioned studies and various
others have helped to unravel some of the mystery behind
the mechanisms of SERMs, the current understanding of
the ways by which SERMs stimulate or inhibit ER activity
and their agonist/ antagonist profiles remains incomplete.
Because most research conducted on the mechanism of
estrogen, antiestrogen, and SERM signaling assumed the
existence of one ER, there is a tremendous need to
reevaluate those results a nd conclusions . The
development of antibodies for E R~, ER~ knockout mice
studies, and the phenotypic characterization of cells with
activated genes that are transcriptionally regulated by ER~
may pro v ide more precise information about th e
physiological role of ER~ and its importance in SERM
signaling.
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DOC, I HAVE T HI 5 PAIN IN MY NECK 1
By Nimesh D. Desai, MEDS 2000 and Kathryn Webert, MD

CASE PRESENTATION

n the early hours of the morning, the medicine intern
on call receives one last page before heading off to the
call room. A 54 year old female tobacco farmer from
Tillsonburg presents to the emergency room w ith a
history of a sore neck and fever. In the ER, you elicit a two
day rapidly progressive history of fever, exquisitely
painful neck and a red, hot, swollen right index finger.
Past medical history includes chronic osteoarthritis in her
cervical spine, knees, and DIP /PIP joints.
On exam, you observe that the patient is febrile with a
temperature of 39.00C, the right index finger is swollen
from the DIP joint to the MCP joint with proximal red
streaking along the dorsum of the hand. Heberden's and
Bouchard's nodes are seen in both hands. The PIP joint
appears particularly inflamed. There is also an
erythematous and edematous lesion, i.e. cellulitis, on the
dorsum of the right foot, which the patient was not aware
of before examination. There are no obvious breaks in the
skin to suggest a portal of entry for pathogens.
Respiratory, cardiovascular, abdominal, genito-urinary,
and neurologic exams were normal.

I

CONSIDER THE FOLLOWING QUESTIONS:
\

What are common causes of a red, hot swollen digit,
i.e. dactylitis?
2. Why is this patient's neck sore?
3. What are common sources of bacterial emboli?
4. How is septic arthritis treated?
5. What are the common clinical signs of infective
endocarditis?
6. Is there any indication for an emergency surgical
consult?
7. What is your initial management of this patient?
1.

1. Dactylitis may result from either infectious or noninfectious etiologies:
a) Non-Infectious:
on-infectious causes include trauma, sarcoidosis,
seronegative spondyloarthropathies, and gout. There is no
history of trauma. Dactylitis is occasionally a presenting
sign of sarcoidosis.! Sarcoidosis can present either acutely,
over a few weeks, or gradually over months. Acute
presentation typically includes fever, fatigue, anorexia,
weight loss, malaise and respiratory symptoms.
Seronegative spondyloarthropathies, particularly
psoriatic arthritis, Reiter's syndrome, and undifferentiated
spondyloarthritis, are the most common cause of
dactylitis.! It is rarely, however, the presenting symptom
and is typically seen only in well established disease.
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Gout and pseudogout are important causes to rule out
by history, serum uric acid, x-ray findings
(chondrocalcinosis seen in pseudogout), and joint
aspiration looking for crystals .2 Gout presenting as
dactylitis is invariably associated with other articular
manifestations, including knee and ankle. 1
b) Infectious:
Infection of the flexor tendon sheath can result in
dactylitis. 1 Infectious causes include gonococcal/nongonococcal septic arthritis, osteomyelitis, cellulitis, and
bacterial embolization from a deep-seated infection or
infectious endocarditis. Gonococcal arthritis typically
presents with a prodrome of migrating polyarthralgias
leading to tenosynovitis or furulent monoarthritis with a
sparse, often pustular rash. It is uncommon over the age
of40.3
Osteomyelitis is a possibility, but usually has a slow
progressive presentation with vague or evanescent local
pain and few systemic symptoms. 4 Cellulitis is a
superficial diffuse spreading infection of the skin.3 The
lesion is typically red and hot and classically, the source of
bacteria is throu~h a break in the skin, although this is not
always apparent.
Deep-seated bacterial infections and infective
endocarditis can shower emboli of bacteria into
extremities leading to localized abscesses, cellulitis, and
septic arthritis.4 Given that the patient is febrile, has no
new murmur, and there are at least two visible foci of
infection, one in the finger and one in the foot, a deepseated infection showering emboli is the most likely
diagnosis.

2. In the septic patient, bacteria tend to seed into joints
which are already damaged, making them more
susceptible. 5 This patient's longstanding history of
degenerative disease in the cervical spine may render
them vulnerable to a intervertebral disc infection (discitis)
or epidural abscess. A septic discitis leads to extremely
severe pain with movement of any kind.
A rapid onset of such pain with any indication of
sepsis or elevated ESR requires diagnostic imaging .
Suspected discitis should be evaluated with either a bone
scan or, preferably, MR1. 5
3. Bacterial emboli can be showered from vegetations
growing on heart valves, oropharyngeal abscesses, and
intraabdominal abscesses. 4 Since antibiotics may not
penetrate into significant deep-seated infections, a
meticulous search for a source with af>propriate imaging
and clinical signs should be conducted. 2 Knowledge of the
infecting organism may also delineate the source.2
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4. Septic arthritis is a medical emergency. Therapy
begins with immediate antibiotic therapy after blood is
drawn for culture and sensitivity. The drug of choice
depends on which organisms are most likely to be
involved. A reasonable approach would include starting
with an empiric therapy of a third generation cefalosporin,
and penicillinase resistant penicillin, thereby providing
extensive gram positive and gram negative coverage
including S. aureus. 3• 4 Once blood culture and sensitivity
is completed, switching to a more organism-specific
treatment is warranted.
Septic joints should also be asf.irated and cultured
daily to verify efficacy of treatment. Surgical incision and
drainage is warranted when there has been poor response
to appropriate antibiotics or there is difficulty aspirating
joint contents, as in a relatively inaccessible joint such as
the hip.
5. Infective endocarditis (IE) is fatal if untreated so ruling
this diagnosis out is crucial once empiric management is
started. Classical signs of IE include a new or changing
regurgitation murmur, fever, Osler nodes and painful
nodular erythematous lesions with central pallor, Janeway
lesions and macular, pustular, or purpuric lesions on the
palmar and plantar surfaces, splenomegaly, petechiae,
clubbing, Roth spots and oval retinal hemorrhages with
central pallor, and splinter hemorrhages under the finger
nails.6
The most useful tests to diagnose IE include positive
serial blood cultures and transesophageal echo, which has
greater than 90% sensitivity for detecting vegetations. In
comparison, transthoracic echo is about 65% sensitive for
IE. 6 There was no murmur or systemic manifestations seen
in this patient.

on

your

feet

vii) Request a chest X-ray if one has not already been done
and consider echocardiogram in the morning. In the
absence of a murmur, you may wish to consult with a
cardiologist before echocardiographic investigation.
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6. Yes! Deep hand infections can quickly spread between
fascial compartments in the forearm, wrist, and hand,
leading to irreparable damage . 3 When deep hand
infections are suspected, early involvement of plastic or
orthopedic surgery services may prevent devastating loss
of function from a spreading infection.
7.

A reasonable initial plan would include:

i)

Admit her. This patient is very ill and will need IV
antibiotics.
Obtain blood for culture and sensitivity. Throat swab
and urine for culture and sensitivity should also be
taken.
Gain IV access. Begin empiric antibiotic therapy as
soon as possible.
Perform lumbar puncture if neck stiffness is associated
with meningeal signs (Kernig and Brudzinski signs)
Review case with plastic / orthopedic surgery B joint
aspiration or incision and drainage may be required
immediately.
Treat any readily reversible concomitant conditions:
antipyretics for fever and fluid/ electrolyte
management.

ii)
iii)

iv)
v)
vi)
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MODERN MANAGEMENT OF THE
KING'S EVIL (An Ongoing Study)
By Jason Hirst, MEDS 2000

S

crofula is a cervical tumour that makes the lymph
glands inflamed and scirrhous. The word is derived
from the Latin, scrofa, related etymologically to the
Greek word for pig-the disease was common in children
in Hippocratic Greece; Aristotle records that sows were
prone to the disease. The term scirrhous was invented by
an unscrupulous pathologist during a game of Scrabble' in
the 1950s and has no etymological origin. Robert Koch, in
1882, was the first to demonstrate tubercle bacilli in
scrofulous lymph nodes, but Mycobacterium bovis wa not
universally accepted as a causative agent of cervical
adenitis until much later.1
For many centuries, it was widely believed that
monarchs (as divine representatives) could c ure
tuberculous cervical adenitis by "royal touch". Clo is of
France (481-511) was believed to be the first endowed with
this ability, wishing to draw attention from the fact he had
a comical name. Formal, public practice of the ceremonial
rite can be traced to St. Louis (Louis IX of Missouri) and
Edward III, who washed the diseased flesh with water and
gave the sufferer a copper talisman in exchange for
worthless gold pieces. According to the registry, Charles II
touched 92,102 people during his 22-year reign. While an
important source of royal revenue, claims of royal cure
may have been widely accepted because scrofula usually
represents a benign primary infection conferring
immunity from pulmonary tuberculosis 2 (an observation
known as Marfan's law). Shakespeare describes the royal
ceremony curing "the evil" in Macbeth (Act IV, Scene III).
The "good king ... solicits heaven" curing the "swol'n, and
ulcerous, pitiful to the eye" from " the mere despair of
surgery". Since millions of Frenchmen cannot be wrong
(except during World Wars) and Shakespeare was a
genius, it seems reasonable to conclude that male kings
~cure "the King's Evil". There is little historical
record of female kings curing scrofula, likely since
medieval doctors were biased against women
professionals. Since cure was thought possible due to
theosophic proximity, it seems reasonable to conduct a
study asking whether current surgical management of
scrofula obtains better results than modern medical
methods.
Full of uric and acetic acids, we hypothesized that
surgeons, having more God-like skills than in ternists,
would have improved prognoses for scrofula. A literature
search quickly revealed that "scrofula" is not mentioned in
Harrison's or Rubin and Farber. Indeed, this disea e is
rarely addressed in Ontario medical schools and
represents a clear gap in the curriculum. Clearly it is no
longer common-only 5% of active TB in Canada involves
tuberculous adenitis. Also, M. bovis is much less common
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than M. tuberculosis, accounting for about 1% of Canadian
cases (mainly among Indians and the Inuit, but
increasing)3 . It is also dear that isonizaid and rifampin are
effective at dealing with many forms of tuberculosis. But
when scrofula does arise, is this pharmaceutical approach
more effective than an aggressive operation? A more
conservative surgical approach?
Two hundred patients, to the very best of your
knowledge, were studied. Of these, one hundred patients
were diagnosed with scrofula by first-year medical
students who were told that "being able to stick out a
rolled-up tongue is pathognomic" for the disease. The
other group of one hundred patients showed no signs of
adenitis, but claimed to have a deep, academic interest in
scrofula, surveys and hyperchondria.
Each cohort of 100 patients was divided into four
equal groups. Thus, 25 patients were treated by aggressive
debulking and 25 were treated surgically by more
conservative measures. The third group was treated with
isoniazid; the fourth group by placeboes of identical
appearance to the drug, except shaped like Betty Rubble.
Half of the 100 patients allegedly undergoing surgery
were treated by orthopedic surgeons with an interest in
scrofula; the remainder were treated surgically by cardiac
or vascular surgeons. One-third of the patients who did
not undergo surgery were given drugs by cardiologists,
one-third were given medications by general internists,
and one-third were given prescriptions by family doctors.
In each case, the non-surgeon made sure to touch the
patient in a comforting and non-provoca tive manner.
Pathologists were permitted to examine any patient who
expired during the course of the trial.
Our results at this stage highly suggest a surgical
approach is more effective, but these are preliminary with
a P-value of P<0.05. (The P value, in this case, represents
the statistical Power, calculated by the Reagan variation of
the two-way ANOV A technique, which gives anecdotal
results). It dearly shows that orthopedic surgeons are the
most able to manage scrofula, followed by cardiac
surgeons, cardiologists, general internists, family doctors
and pathologists.
Orthopedic surgeons reported the best results, curing
all of their patients regardless of whether they used
aggressive approach (removal of the anatomical neck) or a
conservative approach (removal of the surgical neck).
They were said to enjoy the more aggressive approach
more, though, since it involved much larger saws and
more expensive reamers. Cardiovascular surgeons were
also quite effective at curing scrofula, curing 86% using an
aggressive approach (performing a neck bypass) but only
61 % with a conservative approach (offering support,
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reassurance and Snapple©), doing everything the
cardiologists did, plus surgery. The cardiologists reported
similar, but slightly lower figures . Gen eral internists
reported lower cure rates and had a much higher
incidence of complications such as sore tongue and
pyridoxine deficiency, in part since they were able to
recognize the six hand signs of sore tongue. They also
concluded that, for any given patient, "their epidermis
was showing". Family doctors reported higher rates than
pathologis ts, who saw no living subjects, did . These
results correlate well with a sister study4 that shows that
although doctors are more effective at curing scrofula than
social workers, they do not produce nearly as many "cool
graphs" with "lots of arrows and shapes" 5 .
Modern medicine does not know enough about
scrofula, and it cannot be concluded that surgeons are
more effective at curing adenitis because of di v ine
abilities. Clearl y, much more money and research is
needed to make this conclusion . Make your donations
payable to me (donations are fully deductible from your
savings).
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MEDICAL VOCABULARY
By Zakir Esufali, MEDS 1999

This section is designed to test and expand your
knowledge of medical vocabulary. How many items can
you correctly define?

Scoring:

[13-15] = Excellent,
[10-13] =Above average,
[8-9] =Good,
[5-7]= Fair,
{1-5] =Poor

1.
a)

False Pregnancy
The presence of a positive pregnancy test in the
absence of an embryo.
b) Development of all the signs of pregnancy without the
presence of an embryo.
c) A pregnancy in which the fertilized ovum becomes
implanted outside of the uterine cavity.
d) Simultaneous intrauterine and extrauterine
pregnancies.
2. Menometrorrhagia
a) Prolonged menstrual periods.
b) Excessive uterine bleeding at and between menstrual
periods.
c) Painful periods.
d) Excessive menstrual bleeding, occurring at intervals of
greater than 21 days.
3.
a)

Eclampsia
A toxemia of late pregnancy, characterized by
hypertension, preoteinuria, and edema.
b) Ectopic pregnancy.
c) Dilatation, expansion, or distension, as in the
collecting ducts of the mammary gland.
d) Convulsions and coma, rarely coma alone, occurring
in a pregnant or puerperal woman, and associated
with hypertension, edema, and proteinuria.
4.
a)

Melasma
An abnormally increased amount of melanin in the
skin.
b) Sharply demarcated, blotchy brown macules, usually
in a symme trical distribution on the cheeks and
forehead, often associated with pregnancy.
c) The passage of dark stools stained with altered blood.
d) A condition' characterized by dark pigmentary deposits.
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5.
a)

Mastopexy
Surgical fixation of a pendulous breast, with removal
of fat and lengthening of the nipple.
b) Plastic reconstruction of the breast, to either augment
or reduce its size.
c) Excision of the breast.
d) Atrophy of the breast.
6.
a)

Vaginismus
Failure by a female to attain or maintain lubrication
and swelling, or to feel excitement, during sexual
activity.

b) Persistently low level of sexual fantasies and desire for
sexual activity in a woman.
c) Painful involuntary spasm of the vagina severe
enough to prevent intercourse.

7.
a)

Sheehan's Syndrome
Oligo- or amenorrhea , anovulation, and hirsutism,
associated with bilateral polycystic ovaries.
b) Isolated gonadotropin deficiency, associated with
anosmia.
c) Destruction of the endometrium, usually associated
with postpartum hemorrhage or therapeutic abortion
complicated by infection.
d) Postpartum pituitary necrosis, reulting in failure to
lactate.
8. Climacteric
a) The transitional period of lessening ovarian activity.
b) The period of changing ovarian activity prior to
menopause and the first few years of amenorrhea.
c) The period of time after menopause.
d) The complete cessation of menses.
9.
a)
b)
c)

Oligomenorrhea
Dimunition of menstrual flow or duration.
Temporary cessation of menstruation.
Regular menses occurring at intervals of greater than
35 days.
d) Absence or abnormal stoppage of menses.
10. Chadwick's Sign
a) Softening of th e cervix and vagina, a sign of
pregnancy.
b) Softening of the lower uterine segment; an indication

- - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medica/Journal 68 (1) 1999

-

-

---- -

-

- -- - - - - - - -

Vocabulary
of pregnancy.
Purplish-red, congested appearance of the vaginal
mucosa, an indication of pregnancy.

3.

d ) Bluish discoloration around the umbilicus after
intraperitonel hemorrhage, as may occur after rupture
of the uterine tube in ectopic pregnancy.

4.

c)

11. Phyllodes Tumour
a) A large, locally aggressive, sometimes metastatic
fibroadenoma of the breast.
b) Carcinoma of the ovary, usually metastatic from
gastrointestinal cancer, with areas of mucoid
degeneration and the presence of signet ring-like cells.
c) A fibroid-like ovarian tumour containing yellow
(lipoid) areas derived from theca cells.
d ) A benign ovarian tumour causing masculinization,
composed of lipoid vacuoles.

5.
6.

7.

12. False Labour
a) Labour brought on by extraneous means, i .e .
mechanically or with IV oxytocin.
b) Labour in which contractions begin and then cease,
the fetus being retained for weeks or months.
c) The process in which a woman pretends she is in
labour.
d ) Pains resembling labour pains, not accompanied by
cervical dilatation.
13. Stein-Leventhal Syndrome
a) Familial early breast carcinoma associated with soft
tissue sarcomas and other tumours.
b) Oligomenorrhea or amenorrhea, anovulation, and
hirsutism, associated with bilateral polycystic ovaries,
but normal excretion of FSH and 17-ketosteroids.
c) Compression of the ureter by an enlarged or varicose
ovarian vein, usually in pregnancy.
d) Lymphangiosarcoma secondary to severe
lymphedema of the arm, after excision of the lymph
nodes; typically after radical mastectomy.

8.

9.

10.

11.

12.
13.

14. Define engagement (a s it relates to the bi r t h
process!).
15. De fi ne adenom y osi s, an d s tate the method o f
defini tive d iagnosis.

14.

ANSWERS TO M EDICAL VOCABULARY
15.
1.
2.

False Pregnancy: b) The presence of all the signs of
pregnancy without the presence of an embryo. (c)
Ectopic pregnancy; (d) Combined pregnancy.
Menometrorrhagia: b) Excessive uterine bleeding at
and between menstrual periods. (a) Menostaxis; (c)
Dysmenorrhea; (d) Hypermenorrhea.

Eclam p sia: d) Conv ulsions and coma, rarely coma
alone, occurring in a pregnant or puerperal woman,
and associated with hypertension, edema, and
proteinuria. (a) Preeclampsia; (c) Ectasia.
Melas ma: b) Sharply demarcated, blotchy brown
macules, usually in a symmetrical distribution on the
cheeks and forehead, and sometimes on the upper lip
and neck, often associated with pregnancy or other
altered hormaonal state. Also known as chloasma .
(a) Mlanoderma; (c) Melena; (d) Melanosis.
Mastopexy: a) Surgical fixation of a pendulous breast,
with removal of fat and lengthening of the nipple.
(b) Mammoplasty; (c) Mastectomy; (d) Mastatrophy.
Vagi ni s mu s: c) Painful involuntary spasm of the
vagina severe enough to prevent intercourse . The
cause may be organic or psychic. (a) Female sexual
arousal disorder; (b ) Hypoactive sexual desire
disorder.
Sheehan's S yn d r ome: d) Postpartum pit u itary
necrosis, reulting in failure to lactate . (a) SteinLeventhal Syndrome; (b) Kallman's Syndrome; (c)
Asherman's Syndrome.
Climacteric: a) The transitional period of lessening
ovarian
activity .
(b)
Perimenopa use;
(c) Postmenopause; (d) Menopause.
O li gomeno rrh e a : c) Abnormally infrequent
menstruation, with regular menses occurring at
intervals of greater than 35 days. (a) Hypomenorrhea;
(b) Menolipsis; (d) Amenorrhea.
Chadwick's Sign: c) A dark-bluish or purplish-red,
congested appearance of the vaginal mucosa, an
indication of pregnancy. (a) Goodell's Sign; (b)
Hegar's Sign; (d) Cullen's Sign.
Phy llodes Tumour: a) A large, locally aggressive,
sometimes metastatic fibroadenoma of the breast, with
an unusually cellular, sarcoma-like stroma .
(b) Krukenberg's Tumour; (c) Theca Cell tumour; (d)
Lipoid Cell Tumour of the Ovary
False Labour: d ) Pains resembling labour pains, not
accompanied by cervical dilatation. (a) Induced
Labour; (b) Missed Labour.
Stein-Leventhal Syndrome: b) Oligomenorrhea or
amenorrhea, anovulation, and hirsutism, associated
with bilateral polycystic ovaries, but normal excretion
of FSH and 17-ketosteroids. (a) Li-Fraumeni
Syndrome; (c) Ovarian Vein Syndrome; (d) StewartTreves Syndrome.
Engagement: Descent of the biparietal diameter of the
fetal head to a level at or below the pelvic inlet. The
obstetrically important anteroposterior diameter of the
pelvic inlet is the distance between the promontory of
the sacrum and the symphysis pubis.
Adenomyosis: The presence of endometrial glands
and stroma within the myometrium . Definitive
diagnosis is by histologic examination of the uterus at
hysterectomy.
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BREASTFEEDING:
Part of the Care Continuum
By Tess Pitre, MEDS 2000

INTRO DUCTIO N

here is little dispute that breastfeeding is an
important conclusion to the reproductive cycle. Few
other methods of preventative medicine have such
extensive benefits for mother, baby, and society as a
whole . The American Academy of Pediatrics (AAP)
recognizes the importance of breastfeeding and
recommends that women breastfeed their infants
exclusively for the first six months of life. 1 They go on to
advise women to continue breastfeeding their infants for
at least twelve months, and longer if desired.1 Managing
the breastfeeding patient requires a multidisciplinary
approach between lactation consultants, nurses, and
ph ys icians. This article is meant to serve as a basic
introduction to the clinical management of breastfeeding.

T

BENEFITS OF BREASTFEED ING

Human milk provides the ideal nutrition for infants. It
is species specific, easily digestible, and provides a
multitude of health benefits to the infant. 1 There is a
decrease in the incidence and severity of lower respiratory
infections, 2 otitis media / urinary tract infections, 4
diarrhea, 5 · 6 bac teremia / bac terial meningitis / and
necrotizing enterocolitis8 among breastfed infants. Se eral
studies also show breastfeeding to be protective against
sudden infant death syndrome, 9 "10 allergic diseases, 11 " 12
Crohn's d.isease, 13. 14 ulcerative colitis, 13 insulin dependent
diabetes mellitus, 15 ll mp h oma, 16 and other chronic
digestive diseases. 17"1 Cognitive development is also
enhanced in the breastfed infant. 19-21
Breastfeeding has many benefits for the mother.
Decreased postpartum bleeding, faster involution of the
uterus, lactation amenorrhea and an earlier return to
prepregnancy body weight are commonly reported . 1• 22
Research demonstrates that women who breastfeed have
increased bone mineralization postpartum, fewer
postmenopausal hip fractures, and a lower incidence of
ovarian and premenopausal breast cancer.23•27 Many
women also enjoy the convenience of breastfeed.ing (the
milk is always ready and the right temperature) along
with the strong bond it forms with the newborn.
The societal benefits of breastfeeding are potentially
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enormous. Healthier babies means lower health care costs
and decreased work absenteeism.1.28 It has been estimated
that annual health care savings in Canada could top seven
billion dollars in an exclusively breastfed population.2
The direct cost savings to the family are also significant, as
it costs about half as much to feed a breastfed infant as it
does one fed formula .1
BREASTFEEDING BASICS

Breastfeeding literature has put much emphasis on the
importance of a good latch because of its correlation with
breastfeeding success.29- 30 Surprisingly, attaining a good
latch may not be instinctive for mother and babl,, and may
require some initial education and support.29-3 Not every
physician needs to become a technical expert in
breastfeeding providing they understand the ba s ic
concepts. It is, however, important to know how to refer
women to a lactation specialist when required.
Correct positioning is the first step to successful
breastfeeding .33 Both mother and in fant should be
comfortable and relaxed.33 Although the possible positions
for breastfeeding are multiple, the two most common are
the cross cradle and the football hold (figure 1). Side lyin£
is also popular, especially after a cesarean delivery.
Regardless of the position chosen, the infant's head should
be supported at the level of the breast with the breast
positioned level with the infant's mouth. 33 •34 A pillow
positioned on the mother's lap often makes nursing more
comfortable.

Figure A.

Figure 1: A . Cross Cradle Position

Figure B.

8 . Football Hold

To initiate a Bood latch, the infant's mouth needs to be
opened widely . .JJ-34 To facilitate this, the mother ma y
stimulate the infant's rooting reflex by stroking her nipple
across the baby's lips. The entire breast should be offered
once the mouth is ~ened wide by quickly bringing the
infant to the breast. ;:n.34 The baby will take up to an inch
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and a half of areolar tissue with a good latch .
Breastfeeding requires co-ordination of the tongue and
jaw to rhythmically compress the sinuses; starting at the
tip of the tonw.e and rolling back to the palate in a wavelike motion. This compresses the lactiferous sinuses
under the areola and ejects the milk so that it can be swept
to the back of the mouth to be swallowed. 33 An audible
swallow may follow every suck, or may occur after
several sucks. A good latch is one in which the infant's
mouth is wide open with the lips fanged back, the tongue
is under the areola, and the baby is taking slow deep
sucks (figure 2} .33 - 34 A good latch does not hurt;
breastfeeding should not be painful. 30.35 If the latch does
not appear to be right, the mother should carefullls
remove the infant from the breast, and begin again .JJ. 5
Once mother and infant are experienced, initiating a good
latch takes little or no effort.
Figure 2:
N ursing infant w ith a good latch.

THE PHYSICIAN'S ROLE
The significance of breastfeeding in disease
prevention has moved many health care agencies to stre s
the physician's role as a breastfeeding advocate. 1.32.36 In
order to fulfill this role, physicians require adequate
education and clinical training.J7-40 Many researchers have
found serious shortcomings in the breastfeeding
knowledge and clinical skills among medical students,
residents, and primary care physicians. 37- 40 This is
unfortunate as studies have shown that primary care
physicians play an important role in a woman's decision
to initiate and continue breastfeeding. 40 Historically,
physicians unfamiliar with the appropriate management
of breastfeeding have failed to advocate breastfeeding for
their patients, and have had a tendency to recommend
formula feeding as a solution to any problems that arose. 23
It is now recognized that this approach is completely
inappropriate.

MANAGING THE BREASTFEEDING PATIENT
Most women who breastfeed make the choice to do o
while they are still pregnant. 40 Therefore, prenatal visits
are an opportune time to discuss breastfeeding, and
should become a routine part of prena tal care .

Art i cles

Breastfeeding should be recommended for all infants,
including premature and sick newborns. u 2 The only
exceptions to this are: infant galactosemia, illegal druB
use, active tuberculosis, and positive HIV status. 1•41 Some drugs are also contraindicated while breastfeeding,
however, listing these is beyond the scope of this article.
If the decision to breastfeed has been made it should
begin as soon as possible after delivery, ideally within one
hour . 1•23 •32 In cultures where breastfeeding is more
prevalent than in orth America, infants are left on the
mother's abdomen after delivery until they initiate their
own latch.31 It is believed that this increases the likelihood
of establishing a good latch (the correct sucking
technique), preventing the need for correction later. 31 The
newborn should remain with the mother throughout the
recovery period, w ith procedures that interfere with
breastfeeding or traumatize the infant kept to a
minimum. 1.3 2 Rooming-in should be encouraged both in
hospital and after discharge. 1.32
All newborns should be nursed on demand. 1 Signs of
hunger include increa ed alertness or activity, mouthing
and rooting. 1 It is important to understand that crying is a
late sign of hunger.
ewborns need to be nursed until
satiety eight to twelve times within a 24-hour period, and
should be roused to nurse if four hours have elapsed since
the previous feeding.1.23.32 At each feed the infant should
be allowed to nurse at the first breast until satisfied, and
then be offered the second.23
Several task forces have devised recommendations to
increase the success rates of breastfeeding. Research
recommends that no supplements (water, formula, etc.) be
given to newborn infants unless medically indicated, and
bottles (with expres ed milk) and pacifiers be avoided
until breastfeeding is well established, if used at all. 1.32.4J
Infants require only breastmilk (i.e., no other nutrition) for
approximately the first six months of life. 1 Breastfeeding
should continue for at least the first twelve months, or
longer if mutually de ired.1 If a mother chooses to wean
before twelve month the infant should receive ironfortified infant formula (not cow's milk) until one year of
age. 1• 44 Iron-enriched foods should accompany the breast
milk diet during the econd half of the first year. 1
ew mothers need to be made aware of the
breastfeeding support that is available in their
community, before they leave hospital. It is also
recommended that all women have a follow-up home visit
with a health nurse or lactation consultant within 48 to 72
hours after discharge. 1•23 The primary care physician
should see all newborns at three to five days of age.1.23 An
assessment of general health and infant weight should be
accompanied by an evaluation for evidence of successful
breastfeeding. The newborn should be assessed for
adequate hydration, urination (six per day) and
elimination (three to four stools per day), and should be
assessed for jaundice.1 The topic of breastfeeding should
be supported at each well baby visit, and women should
be advised to return to their physicians for a complete
breast examination once breastfeeding has been
terminated. 1
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TROUBLE-SHOOTING
Breastfeeding can be effortless and enjoyable for
some, and a difficult struggle for others. It is important to
have the skills and knowledge necessary to deal with the
difficult situations that may arise. Most problems occur
within the first six weeks, and with perseverance, most
infants and women become very proficient at it.35
Slow Weight Gain
In an otherwise healthy newborn, the most likely
cause of slow weight gain is insufficient milk intake.34-35 A
poor latch is likely the underl~g problem and needs to
be evaluated and corrected.n. 5 Nursing the infant more
frequently (at least eight times within 24 hours) may also
help.23 No additional supplements (formula, juice, water,
etc.) should be recommended.34-35 The infant and mother
s hould be followed carefully until successful
breastfeeding has been established. Note that it is essential
to rule out any organic cause of slow weight gain before
assuming inadequate intake. 23
Inadequate Milk Supply
Breastfeeding works on supply and demand.23 More
frequent nursing almost always increases the milk supply
sufficiently. 23 Using a breast pump immediately after a
feed may also be helpful in bolstering the milk supply.
Nipple Soreness
Breastfeeding should not be painful, yet nipple
soreness is common and the most likely cause of early
breastfeeding failure. 3:>-35 Nipples can become sore,
cracked, and may bleed. The most common cause is a
poor latch.34-35 New mothers tend to endure the pain of a
faulty latch because the infant appears to be feeding well.
Appropriate treatment should be based on educating the
mother and facilitating healing.34-35 Women need to be
reass ured that the nipples will adapt to the nursing
experience naturally, but that efforts can be made to ease
the discomfort (table 1}.
Candida Albicans
Candida has been called the hidden deterrent to
breastfeeding and is likely an underdiagnosed cause of
early weaning.45 Persistently red and sore nipples after the
first two weeks of breastfeeding should raise a red flag
and make the health care professional think about
Candida. 45 Candida albicans is a normal fungal organism
Table 1. Treating Nipple Discomfort
Check position and assure that infant has a good latch
Manually expreSs some milk before feeding to soften breast
Apply warm compresses before nursing
Begin nursing on the least sore side
Allow breast milk to air dry on nipple area after feeding
Leave nipples exposed to air
Avoid nipple shields
Do not allow infant to fall asleep at the breast
Use Lansinoh® if ointment is used
Avoid soaps and drying agents

40

Table 2. Signs and Symptoms of Thrush
Mother:
Red nipples and areola
Nipple itching
Persistent sore nipples
Burning/shooting pain in breast during and/or after
feeding
Cracked nipples that do not heal
White patches
Infant:
White patches on oral mucosa and tongue
Diaper rash
Refuses to nurse, or pulls away repeatedly during
nursing
Slow weight gain
Gas
Fussiness
Recent antibiotic use
found in the flora of mouth, skin, intestinal tract, and
vagina. However, when present in increased amounts, it
can cause oral thrush (and therefore nipple thrush) and be
a tremendous source of discomfort for both mother and
infant. 45 Thrush has several classic symptoms (table 2) but
patients can be asymptomatic. 45 The most likely route of
infection is vaginal delivery .45 Therefore, the mo s t
effective treatment is prevention, by treating pregnant
women with yeast infections during their third trimester.
Lactating women should be made aware of the symptoms
of thrush so they can seek medical attention. Treatment
includes antifungal treatment for mother and infant, with
mandatory follow-up. 45 Frequent hand washing, using
disposable nursing pads, washing bras daily and
sterilizing breast pumps, pacifiers, bottles and toys for 20
minutes helps to prevent reinfection.45
Breast Engorgement
Nursing mothers will likely experience discomfort
due to engorgement at some time . They should be
reassured that because their milk supply is driven by
demand, the breasts usually adjust quickly. Comforting
measures include: warm compresses, nursing frequently,
varying nursing positions, initiating let-down before
feedings, and massage the breast toward the nipple before
and during nursing. For severe breast fullness, a good
quality breast pump can be used after nursing followed by
cold compresses.
Mastitis
While mastitis is not nearly as common as it once was,
it can still be a result of early weaning. 23 Mastitis usually
presents with sudden, intense, unilateral pain and flu-like
symptoms.23 A lobe of the breast is usually red, hot and
swollen, and the patient is febrile. 23 The patient should be
advised to continue to nurse on both breasts, but to begin
each feed on the affected side. 23 The affected breast needs
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to be _em~tied thoroughly at each feed by nursing or
pumpmg. Bed rest is mandatory. 23 An antibiotic that can
be tolerated by infant and mother should be prescribed,
with a course of at least 10 to 14 days. 23 Ice packs or warm
packs can be applied for local relief, and acetaminophen
can be taken for pain. 23

CONCLUSION
The health and social benefits of breastfeeding are
now well established in the scientific literature. Breast
milk provides the ultimate nutrition for infants with the
best health, developmental, and psychosocial outcomes. It
is our job as health care professionals to become
knowledgeable and skilled in the clinical management of
breastfeeding in order to become enthusiastic
breastfeeding advocates for our patients.
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RESTORATION OF SELF THROUGH
RECONSTRUCTION OF FORM:
A Conceptual Review of Breast Reconstruction
for the Postmastectomy Patient
By Mason S. Ross, MEDS 2001

INTRODUCTIO N
Breast Cancer: Still a Major Health Concern
espite ongoing research efforts and advances in
oncologic therapy, carcinoma of the breast currently
remains a major threat to women. (Figure 1.) It is
estimateq that 19,300 new cases will be diagnosed in
Canada during 1998,1 securing carcinoma of the breast as
the female cancer with the greatest incidence, next to
malignancies of the skin. 1.2 Of even greater concern is that
5,300 Canadian females will succumb to the disease by the
year's end,' making it the second leading cause of cancer
mortality (lung cancer being first) .1.2 Indeed, a female born
in North America today has approximately a one in nine
chance of developing a primary breast tumour during her
lifetime.3 But, in addition to the psychological devastation
of living with the disease, coping with the physical results
of surgical treatment often adds insult to injury. It should
therefore not be surprising that breast cancer and its
associated illness experience are firmly entrenched at the
forefront of women's current healthcare concerns. Today,
several approaches are available in the attempt to restore
the body to normal form after disfiguring breast cancer
surgery. However, essential for a more profound
appreciation of breast reconstruction is an understanding
of the treatment of breast malignancy, the significance of
the breast to society, and the psychosocial consequences of
the loss of a breast. This review explores these topics, and
examines the surgical management options of breast
reconstruction for the postmastectomy patient.

D

Relevant Highligh ts of Treatmen t for Carcinoma of the
Breast
The TNM staging system by the American Joint
Committee on Cancer classifies patients with breast cancer
into different groups based on prognostic criteria.
Information regarding the size and invasiveness of the
primary tumour {T), regional lymph node involvement
(N), and existence of distant metastasis (M) determine
what stage grouping is appropriate.2 Stages are classified
from I to IV, increasing according to the severity of
disease.
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Figure 1. Carcinoma of the breast. This case is taken from 1976 to
illustrate an advanced tumour. Today, it is much less likely to see
breast cancer present in this marmer.

Tumour excision is an integral part of managing
carcinoma of the breast. Surgical procedures include either
total mastectomy (resection of entire breast) or
lumpectomy (removal of cancerous tissue with
pathologically negative margins). Although the role of
surgery is better documented for patients with early stage
disease, 4 where complete tumour excision is more
probable, total mastectomy with adjuvant radiation and
chemotherapy may be of therapeutic benefit for patients
with late stage disease as well. 5
Although lumpectomy offers a superior cosmetic
result when compared to mastectomy, initial concerns
were that the procedure might not be as effective because
of the decrease in tissue removal, and hence the decrease
in probability of removing all malignant cells. 4 However,
numerous studies indicate that breast conserving surgery
results in similar survival rates when compared to
mastectomy. 6,7,s,9 The medical community now generally
believes that, in properly selected patients, lumpectomy is
the appropriate surgical course of action.4 Nevertheless, at
least one third of patients may not be acceptable
candidates for the procedure .4 Contraindications for
lumpectomy include extensive primary tumours, inability
to obtain pathologically negative margins, occurrence of
multiple primary cancers, or the presence of a carcinoma
so large that there is no cosmetic benefit when compared
to mastectomy.10 Today, despite the compelling evidence
against the need for radical breast excision in many cases,
women often choose mastectomy based on the perception
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Figure 2. Before and after radical mastectomy.

of a more favo urable prognosis. Although the frequency of
lumpectomy is increasing, mastectom y remains the most
often performed surgery for breast cancer. 2 (Figure 2.)
Significance of the Breast
The female breast has been a powerful symbol of
feminini ty throughou t h istory. It represents fertility,
comfort, and sexuality 11 and is considered to be the most
important marker of a woman's gender.U As such, ~any
women have body image concerns after the amputation of
a breast. The postmastectomy patient commonly feels
mutilated and reports lower self-esteem. 13•14 She is likely to
experience depression 12•14 and studies ~ave s~own that the
majority of women report a decrease m desue for sexual
intimacy, often resulting in the cessation of sexual
intercourse. 13•15 Furthermore, the loss of a breast is often a
disfiguring reminder of the cancer diagnosis which
invokes fears of recurrence, adjuvant therapy, and most of
all, death . 15 People more likely to suffer greater
psychological trauma include single or younger ~omen,
patients who were critical of their breasts previous to
mastectomy, and those whose self-esteem is primarily
rooted in physical beauty.12' 14' 16
BREAST RECON STRUCTION
Background
After mastectomy, women are typically extremely
unsatisfied with the option of using an external prosthesis
to simulate the breast mound. External prostheses do not
improve body image, 17 _an~ often serve_to co_n stantlYs
remind women of theu hfe threatemng disease .
Consequently, there has been considerable interest in
breast reconstruc t ion . Top motivations reported by
women to pursue breast reconstruction are to regain
attractiveness, and to reclaim the sense of wholeness that
they perceive the disease has taken away. 19 Often ,
reconstruction is perceived as an affirmation of the desire
to keep living; a symbol of the commitment not to give in
to the disease. 20 However, the surgical community was
initially concerned over the possibility of wor~enin~ the
prognosis of breast cancer through reconstruction; either
via altered tumour biology or through increased risk of
wound complications. They theorized that tumour
biology might be altered by stimulating or masking cancer
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recurrence, or that the operation could weaken the
immune system. 4 Also, an increa_se in w~>U_nd
complications could potentially delay adJuvant radiation
or chemotherapy.4 Fortunately, numerou s studies have
failed to show significant differences in tumor biologi 1.22
or in wo u nd complications 23 •24 be t ween pa tients
undergoing mastectomy wi t h recons t ruction and
mastectomy alone.
There are two main conceptual approaches to modem
breast reconstruction. One involves silicone gel- or salinefilled prosthetic implants, and the other uses au togenous
tissue flaps. Both methods have inherent advantages and
disadvantages.
Implant-based recons t r uction holds less short-term
operative risk, but comes at a cosmetic and possibly a
long-term p rice
The usefulness of implants is to rep lace lost breast
volume. An implant placed deep to the pectoralis maj~r
muscle may be used immediately after mas tectomy If
adequate skin is available. However, if a skin sparing
mastectomy does not occur, then tissue expansion is used
to ensure adequate skin coverage for eventual
accommodation of the prosthesis. The insertion of an
implant or tissue expander typically takes less th~ one
hour, and is hence an attractive form of reconstruction for
the patient that has risk factors associated with surgery.25
Despite tha t advantage however, implants carry a high
failure rate due to infection, rupture, extrusion, or capsular
contraction.25 In addition, tissue expansion requires gradual
inflation (4 to 6 months) of the soft-tissue mastectomy
envelope to achieve a breast volume of about twice that of
the contralateral breast. This commonly results in
complaints of discomfort. 25 Su bsequ ently, anc:>ther
operation is performed to remove the expander and msert
the implant. Although attemp ts have been made to
elimina te the need for two procedu res by the use of
combination devices, further revisions are often neede<!
thereby invalidating the potential benefit from their usage.25
In addition, tissue expansion requires many follow-up
visits and, as such, may be more successful in the highly
motivated patient. 26 Cosmetically, many surgeons feel
silicone gel-filled implants provide a better approximation
of breast tissue than the saline-filled type. When compared
to silicone gel-filled implants, the shortcomings of s~e
filled implants include a tendency for fullness or wavmess
in the superior half of the breast mound, and a decreased
natural breast contour in the upright position.27
Controversy remains over w h e th er t he use of
implants is connected to a wide variety of non-spe~ific
symptoms and deficiencies of immune system function .
Although data do not curren t ly indica t e a causal
relationshi~ between implan ts and au t oimmune
disorders/ ·29 •30•31 •32 the lack of lon g-term data raises
concerns for implant safety. In addition, little is known
about the life span of implants beyond 20 years. For these
reasons, many women continue to be anxious over the
utilization of implants for reconstruction, and this should
therefore be viewed as an additional disadvantage for
their usage. 25 (Figure 3.)
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is important to keep in mind that not every patient desires
such a procedure, and therefore inadvertent coercion
should be avoided. However, if interest in reconstruction
is expressed, then the patient's health status is ascertained,
and weighed against what is technically feasible as
determined by body habitus. 26 Elderly women or patients
with comorbid disease are best treated with less invasive
procedures such as prosthetic implantation, possibly with
tissue expansion as well. 4 Moreover, reconstruction with
autogenous tissue is preferable in the otherwise healthy
patient, if her body habitus is suitable. 4 When multiple
options are approfria te, the patien t may select the
operative technique.
Immediate versus Delayed Reconstruction

Figure 3. Implant-based reconstruction . Slight asymmetry is
unnoticeable when the patient wears a brassiere.

Autogenous Tissue Reconstruction, Often the Procedure
of Choice
Modern autogenous breast reconstruction is
performed using myocutaneous flaps. The procedure
involves the replacement of lost breast volume and skin
envelope via the transfer of one's own muscle and kin
layers from a suitable region that retain their original
vasculature. The principal benefit of this type of
procedure is the avoidance of the potential complications
associa ted wi th foreign body implantation of internal
prostheses. Since documentation of the use of latissimus
dorsi myocutaneous flaps for breast reconstruction began
over 20 years ago, many other flap transfer procedures
have been described. Cosmetically, myocutaneous flaps
better approximate the quality of breast tissue when
compared to implants, resulting in more natural breast
contour and improved symmetry with the contralateral
breast.27 Although this type of reconstruction is more
complex and is associa ted with increased operative risk,
autogenous reconstruction is more durable over the longterm than implantation. 25
Today, the flap most commonly utilized for
autogenous breast reconstruction is the transverse rectus
abdominis myocutaneous (TRAM) flap. 33 (Figure 4.)
Specifically, the main advantages of the TRAM flap
underlying its popularity are that the abdominal donor
site is frequently of generous quantity to provide ample
tissue for reconstruction, and that the patient often
benefits cosmetically from an abdominal lipectomy at the
same time. In addition, ad ances in microsurgery have
successfully allowed free flaps (a flap detached from a
donor site for microvascular anastomosis at the recipient
site), such as the free TRAM flap, to be a common
selection of autogenous breast reconstruction in many
centres. 27

Historically, it was advised for the patient to delay
reconstruction for a time after mastectomy to determine if
the malignancy would return. However, this is no longer
the case as numerous studies have concluded that
immediate breast reconstruction is safe for selected
patients. 21 .2Z.35.36 In addition, it has been thought that a
woman must live with the mastectomy defect for a time to
appreciate her new breast. This view is not currently
accepted either, since immediate breast reconstruction,
when appropriate, has been shown to decrease the
psychological trauma associated with mastectomy.37 It is
generally felt that patient selection for immediate
reconstruction should be based on an understanding of
the reconstructive options, stage of the carcinoma, amount
of previous radiation therapy, and the surgical technique
planned for mastectomy. 4
Implant-based reconstruction, especially those
involving tissue expansion, involves multiple office visits
and can require subsequent revisions. Consequently, it is
necessary for the woman to be well informed about her
reconstructive options and be realis tic regarding the
outcomes of each, so that she may be better prepared for
complications. In patients with advanced disease, where
postmastectomy radiation of the chest wall is an integral
part of therapy, a delayed reconstruction is indicated to
avoid the risk of radiation necrosis in th e newly
constructed breast. 4 Radiation therapy before mastectomy

Selection of Technique
Because of the tremendous variability of implant type,
shape, and multiple adequate donor sites for autogenous
procedures, there are numerous reconstructive
possibilities, and as such, each case is unique. However, it

Figure 4. Before and after TRAM flap reconstruction. TRAM
flaps often provide a generous amount of tissue for
reconstruction.
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may also hinder the reconstructive process by decreasing
the probability that a local flap will take successfully,
decreasing tissue elasticity, and affecting the viability of
the pedicle of regional tissue reconstruction along with the
vasculature needed for microsurgical reconstruction. 4 If
the patient is at an increased operative risk due to
prolonged anaesthesia, then a delayed reconstruction may
also be appropriateY Obese patients, smokers, and people
w ith marked comorbidity such as diabetes mellitus,
uncontrolled hypertension, and cardiovascular disease are
also less ideal candidates for immediate reconstruction as
the y have an increased risk of developing
complications. 38.39
Reconstruction of the Nipple and Areola
Current methods of nipple reconstruction include
either taking a composite graft from the contralateral
nipple or using small local flaps to elevate tissue from the
breast mound . Areolar reconstruction can be
accomplished by grafting techniques or by tattooing.
ipple and areolar reconstruction can result in higher
levels of patient satisfaction not achieved by improving
physical contour alone.40 (Figure 5.)
Psychological Outcom es
Most women feel positive about their reconstructive
results. They often feel that the new breast represents a
commitment to the future; a desire not to give in to the
disease.41 However, although improvements in technology
and technique have enabled breast reconstructive results
to be more aesthetically pleasing today than ever before,
some women report disappointment that it did not return
them to their premastectomy state.42 To help overcome the
ri s k of this potential distre s s , the patient should
understand the purpose of reconstruction, and be realistic
regarding her ou tcome . In light of this, it should be
strongly encouraged that reconstruction not be presented
as a cosmetic triumph, but rather as an aid to restore her to
a sense of wholeness.

Figure 5. Reconstruction of the nipple and areola.

SUMMARY

As surgery often leaves women suffering from breast
cancer disfigured and depressed, reconstructi v e
procedures of the breast have evolved with the purpose of
improving form . Reconstructive techniques typically
involve implants or autogenous tissue flaps, and the
choice of method depends on factors including overall
health, body habitus, and patient preference . In the
otherwise healthy patient, autogenous reconstruction is
generally preferred because of the decrease in
complication risks and concerns associated with implantbased reconstruction, often providing a cosmetically
s uperior result a s well. Presuming realistic patient
e xpectations, p sychological outcomes of breast
reconstruction will tend to be extremely positive, showing
that reconstruction of form in the postmastectomy patient
can play a major role in a woman's psychological
recovery.
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THE ROLE OF ULTRASOUND IN THE
MANAGEMENT OF BREAST CANCER
By Jonathan Abele, MEDS 1999
Introduction

B

reast cancer is the most common malignanc y
affecting women in Canada, and currently is the
second leading cause of cancer-related female death.
The expected incidence per annum in Canada is
approximately 18,500, with approximately 5,000 expected
deaths. 1 As such, it is an illness of significant proportion.
While the prevalence of this disease is great, survival has
been improving in recent years. This trend is thought to be
due to a combination of both improved diagnosis and
treatment.
A key improvement in the diagnosis of breast cancer
has been the recognition of the importance of imaging
modalities in screeni ng. More specifically, numerous
studies have provided clear evidence that regular
mammography in conjunction with careful physical
examination can significantly decrease mortality due to
breast cancer. In fact, the combined data show a reduction
in mortality of at least 30%. 2 This information lead to the
development of the Ontario Breast Screening Program in
the late 1980' s. Current Canadian screening guidelines
include mammography at least every two years for all
women age 50-69. Regular mammography is also
recommended for those age 40-49 in high risk groups such
as those that have had a previous breast cancer or those
with a family history of breast cancer in first degree
relatives. 3
Mammography ha s thus been established as an
importan t imaging modality for breast cancer both
experimentally and clinically. Because of its success in
reducing mortality, an obvious question arises as to the
role of other imaging modalities in the management of
breast cancer. One modality which has been extensively
investigated is ultrasound.
In fact, there are multiple reasons why the breast may
be the most ideal organ in the human body for
examination by ultrasound. Its relatively small size allows
examination with high-frequency, high-definition probes.
Also, air and bone which can interfere with sonography
are not present in the breast. Finally, there is sufficient
variance in the sonic impedences of the tissues in the
breast that one can use this modality to differentiate
glandular tissue, fat, fascia, lymph nodes, and normal
sized ducts from one another. 4 Ultrasound can
demonstrate the skin, subcutaneous fat, breast
parenchyma, retromammary fat, pectoralis muscle, ribs,
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and anterior chest wall. 5 An advantage of ultrasound is
the capability for real-time scanning of the breast. This
quality is important in correlating images with physical
findings, as well as in biopsy and interventional
techniques. 6 Ultrasound also does not share the significant
albeit small radiation risk associated with x-ray use in
mammography . As a result of these characteristics,
ultrasound ha s become established as an important
imaging adjunct in the diagnosis and management of
breast disease.
Is there a role for ultrasound in screening for breast
cancer?
For ultrasound to be considered a useful imaging tool
for primary screening of breast cancer, it must display an
efficacy equal to or greater than the current
mammography program. At this point, there is no
research available to s upport s uch an efficacy. 5 •7•8
Ultrasound simply does not detect all cancers that are
visible mammographically. 8 Studies with high frequency,
real-time equipment in examination of known breast
cancers have shown false negative rates for ultrasound
ranging from 0.3% to 47% (mean 20 .7%). 8 There are a
number of reasons for this. Firstly, a significant number of
breast cancers are isoechoic with fat or breast tissue, and
thus difficult or impossible to visualize sonographically.5
Secondly, ultrasound has poorer resolution than
mammography for solid lesions . Ultrasound cannot
reliably detect solid lesions <1 em in diameter? In fact, in
one stud!' of 12 cancers <1 em, ultrasound failed to detect
11(92%). Finally, microcalcifications are not consistently
visible sonographically.7•9 Mammography, however, can
consistently detect suspicious microcalcifica tion s
regardless of location. Many of these microcalcifications
can be <O.Smm in diameter.10 Mammography is better in
both resolution and contrast, and thus is a better screening
tool.
While mammography is the accepted imaging
modality for breast cancer screening, ultrasound may yet
have a role. Recently, there have been a few retrospective
reports of malignant breast masses being initially detected
only by ultrasound after negative high-quality
mammograms and negative clinical examination.5 For
example, Gordon and Goldenberg at UBC reviewed 12,706
cases of breast ultrasound performed between 1989 and
1994 for evaluation of a palpable abnormality or a
nonpalpable, mammographically detected mass. 11 Of these
cases, 1575 "sonographically incidental" masses were
detected that had not been palpable nor seen on
mammography. Of these incidental masses, 44 (2.8%)
were surgically confirmed as malignant. A recent
prospective study presented by Kolb et al. at the
Radiological Society of North America Meeting in
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October, 1996 examined 2,300 women w ith
radiographicall y dense breas ts, negative finding s on
mammography, and a negative clinical examination.5
Ultrasound on these women revealed a breast cancer
detection rate of 4 per 1000. This is a significant rate for a
screened population.
In summary, combined evidence shows that
ultrasound alone is an inadequate imaging modality in
comparison to mammography in the role of primary
screening for breast cancer. The main reasons include the
inability to depict microcalcifications, difficulty in imaging
fatt y breast, inability to differentiate benign fr om
malignant solid masses, and unreliable depiction of solid
masses smaller than 1cm? Evidence has shown, however,
there may be a role as a secondary screening technique in
high-risk women. These include those women w ith a
strong famil y histor y of brea s t cancer, those wi th a
personal history of breast cancer, or those with suboptimal
mammography. 5 Further prospective research is needed to
better clarify this role.
What is the role of ultrasound in the diagnosis of breast
disease?
The primary and most important role for ultrasound
in evaluating breast disease is the differentiation of the
cystic vs. solid nature of a mass found by either palpation
or mammography (Figure 1). 5 •7 • •9 This differentiation
reduces the need and therefore the trauma and cost of
surgical biopsies. The significance of this is revealed in
that more than 500,000 benign breast biopsies are
performed per annum in the USA. 12 It is not unreasonable
to assume a similar relati v e pre v alence in Canada .
Ultrasound is reported to be 95-100 % accurate in
diagnosing a lesion as a cyst if all criteria are strictly met. 5
These criteria include a lesion which on ultrasound has no
internal echoes, smooth and sharp margins, and a round
or oval shape . Reactive shadowing at the edges a nd
posterior acoustic enhancement may also be present. If
these criteria are met on assessment of a mass, mos t
radiologists would consider it diagnosticY.B Sonographic
signs suspicious for malignancy include a hypoechoic
mass and margin irregularity. It is important that for any

Figure la: An example of a simple cyst diagnosed through breast
ultrasound
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suspicious solid lesion, or any lesion not strictly following
the classic cyst pattern on ultrasound, a biopsy must be
considered to confirm a diagnosis. 12
This capability is even more valuable in the evaluation
of a palpable breast mass in a woman younger than 30.
These women are not regularly screened b y
mammography and have an extremely rare incidence of
breast cancer. They are also more sensitive to radiation
than older women. For these reasons, many recommend
ultrasound as the primary imaging modality for palpable
masses in this age group .7,8 If the mass is a cyst, no
further evaluation is required. If not, then one would
obtain a mammogram and then a biopsy. While
ultrasound has a unique role for this age group, it should
be stress ed that for women older than 30, it is
recommended to begin imaging with mammography,
using ultrasound as an adjunct when indicated.
A second diagnostic indication for ultrasound is in the
investigation of women where mammographic sensitivity
is low. These conditions include radiographically dense
breasts, near prostheses, at the breast periphery in rare
cases of mammographic inaccessibility, in surgically
altered breasts, or in the breasts of pregnant or lactating
women . Ultrasound is not an alternative to
mammographic screening of these women, but is an
adjunct to be used when mammography is
contraindicated or of unacceptable quality.5•7.s
A third major role for ultrasound in diagnosis is as a
guidance mechanism for interventional procedures.13•14
Classically, open surgical biopsy has been the gold
standard for the diagnosis of a breast lesion. This can be
costly and traumatic as the standard of care has been
lesion removal by lumpectomy to both diagnose and
provide definitive treatment concurrently. More recently,
surgical intervention to this extent has been widel y
replaced by fine needle aspiration (FNA) or core needle
biopsy (CNB), so as to reduce trauma for benign disease.
While the efficacy of these procedures compared to
surgical biopsy has never been studied in a randomly
controlled trial, a retrospective study has reported false
negative rates as low as 0.04%·14 For readily palpable
lesions, these procedures can be guided by physical exam.

Figure lb: A solid mass proven to be malignant by ultrasoundguided core biopsy
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For non-palpable lesions discovered through
mammography, h owever, imaging g u id ance is
imperative. As well as ultrasound, needle biopsies have
been successfully guided via mammography, CT, MRI,
and nuclear medicine studies. The efficacy of FNA and
CNB appears to be independent of the imaging guidance
system if properly done.14 Ultrasound, however, has the
advantages of being relatively cheap, a traumatic, and realtime. It is currently a favored modality. 13•15
Wh at is the role of ultrasound in therapy fo r b reast
disease?
While ultrasound is primarily a diagnostic modality, it
does have some therapeutic indications. Ultrasoundguided cyst aspiration is performed not only for
diagnostic purposes, but is also indicated for the relief of
sy mptom s such as pain . 14 The real-time nature of
ultrasound is beneficial for these indications as one can
visualize cyst reduction. 9 Similarity, ultrasound can be
utilized for the therapeutic drainage of an abcess. 9
For solid masses, definitive treatment most often
in volv es surgery. Ultrasound plays a useful role in
imaging the pre-operative needle localization of a
malignancy.8 By using th e pre-placed needle as a guide,
the surgeon can then confidently excise the mass with
minimal trauma and disfigurement. This procedure is
especially useful for non-palpable masses.
What is the future of ultrasound in the management of
b reast cancer?
With technological developmen t and increasing
resolution ultrasound may eventually have a role in breast
screening as previously described. While it is unlikely to
ever replace mammography for primary screening, it may
eventually be a suggested adjunct for more efficacious
screening programs.
Better technology ma y also enable better
differentiation between solid masses. While ultrasound at
present is excellent in differentiating cystic from solid
lesions, it is not yet acceptable in distinguishing benign
from malignant states. Some authors have described
different characteristics of a solid mass which suggest
malignant vs. benign pathology . 16 Malignant
characteristics include spiculation, angular margins,
marked hypoechogenicity, shadowing, calcification, duct
extension, a branching pattern, and rnicrolobulation. More
benign patterns include an absence of these malignant
findings, intense hyperechogenicity, an ellipsoid shape,
gentle bi- or trilobulations, and a thin , echogenic
pseudocapsule. Stavros et al. go on retrospectively to say
that for solid masses with classic benign characteristics on
ultrasound the negative predictive value is over 99%.16
Furthermore, they state that these cases can be managed
with close follow-up imaging rather than biopsy. It is
important to note that there are no prospective data to
support this statement. 5 The current standard of care is to
biopsy any non-cystic lesion, at least via FNA, to obtain a
more accurate tissue diagnosis. This information does,
however, raise the possibility that perhaps with improved
technology and further research, ultrasound may account
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for a vast reduction in the number of unnecessary
biopsies.
Doppler ultrasound is another technology that may
develop further. The rationale for its use is the fact that
many cancers appear to ha v e far greater blood flow
through neovascularization than do benign lesions. In one
study, Cosgrove et al. state that 96% of benign breast
changes had no color Doppler signals. They state that
vessels were detected in 57 of 58 cancers. 17 According to
their study, one could conclude that "color Doppler
signals in a lesion otherwise thought to be benign should
prompt a biopsy, while the absence of signals in an
indeterminate les ion is reassuring " 17 • While thi s
conclusion has little clinical implication at present, it does
suggest that with future technology Doppler may have a
role in differentiating benign from malignant lesions.
Con clusion
Currently, mammography is the imaging modality
most widely associated with the management of breast
cancer. Ultrasound is an adjunctive modality which also
should be considered. While at present it has little value in
screening for breast cancer, it does have value in other
roles. Diagnostically, its most importan t uses include
differentiating cys tic from solid lesions, as well as in
guiding fine needle aspiration and core needle biopsy.
Therapeutically, ultrasound is useful in cyst drainage and
in needle localization of non-palpable masses for surgery.
Due to its many attractive features, further technological
development may expand the role of ultrasound, and
ultimately improve the management of this prevalent and
serious disease.
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THE

CLINICAL BREAST

EXAMINATION
By Briar Sexton, MEDS 2000

INTRODUCTIO N

s a third year medical student given the task of
performing a full physical exam on a female
patient over the age of 55, it struck m~ that a "full
physical" excluded a clinical breast exam: ~s .Pro~p.ted
an investigation into medical student trammg m Clinical
Breast Exam (CBE) skills, which suggested that the breast
examination does not receive sufficient emphasis in the
current curriculum and that more effective ways of
teaching it could be employed.
.
My research includes a review of literature concemmg
the importance of the Clinical Breast Exam and .the ~o~t
effective ways of teaching it and of ensurmg It IS
performed on all eligible patients. As well, I conducted a
brief survey of the UWO Medical School Cl~ss of 20~0
three weeks prior to the commencement of therr clerks~p
in order to assess their level of training and degree of skill
and comfort with respect to the CBE. As the pelvic and
rectal exams are also excluded from "full physical exams"
I asked students to exclude these exams when comparing
the CBE to other components of the physical exam. One of
the main purposes of the survey was to determine if the
increased number of times students performed other
clinical skills as well as the increased opportunity for
observation and feedback would make the students feel
more comfortable and proficient with them. A skill such as
auscultation of the heart is performed on virtually every
patient seen in the Phase II or second-year Clinical
Methods Curriculum. It may be unreasonable to attempt
this level of exposure to the CBE as it is more invasiv~ of
patient privacy, however, this in itself argues for ensurmg
the CBE is emphasized in the curriculum in other ways.
At the University of Western Ontario Faculty of
Medicine, pre-clerkship training on th~ clinic~! bre~ s t
exam consists of one three hour self-leammg sesswn usmg
a model of a female breast. There is no formal training on
patients, either actual or standardized. Students may reach
their clerkship without having performed a CBE . The
literature clearly demonstrates that this training is not
sufficient. A retrospective analysis using clinical clerks at
two different US medical schools showed that over 50% of
students had not had a single CBE supervised during the
course of their clerkship. 10

A

RELEVANCE OF THE CLINICAL BREAST EXAM

Breast cancer is the most common malignancy and the
second leading cause of death among Canadian women
over the age of 55. Breast cancer accounts for 30% of all
new cancers in Canadian women.1 While both genetic and
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environmental factors have been implicated as etiologic
factors, the cause remains unknown.
Breast cancer screening consists of a three-tiered
strategy which includes breast self-exa~ (BS~) by the
patient and clinical breast exam (CBE) and rmagmg of the
breast through either ultrasound or mammogr:aphy by the
physician. Current screening recommendations are for
women between ages 50-69 to perform a monthly breast
self-exam and to receive a l.earl~ clinical breast ex~ .a nd
a bi-armual mammogram. The rmportance of physiCians
performing a clinical breast exam in addition to
mammography has been underscored in a stu~y of the
two modalities' sensitivity for cancer detectiOn . The
sensitivity for cancer detection is 24% with CBE alone and
62% with mammography alone while the sensitivity of the
two methods combined is 75%.3 Furthermore, women may
learn how to perform a self-exam of the br~ast by
watching their physician . Alternately, havmg the
physician perform the exam may underscore to them the
importance of palpating the breast and thus encourage
them to monitor their breasts monthly.
Data in both Canada and the United States suggest
that physicians and students are not following the current
screening recommendations. 4 In fac~, the numbe~ of
women who report having a CBE at therr armu~ ~hysical
is decreasing.5 Studies investigating why p~ysiCian:' do
not perform clinical breast exams on all eligible patients
frequently cite a lack of physician comfort and skill as the
causal factor. 5•10•11 A study of 398 physicians in Minnesota
found that less than one third of them reported their skill
at performing a CBE as excellent and less than half of
them described themselves as "very comfortable"
performing the exam. Also of note was ~a.t in comparison
to their male counterparts, female physicians were more
comfortable and more likely to assess their skills as
excellent in numbers which reached statistical
significance. 5 Another study by the same authours f?und
that in addition to being more comfortable performmg a
CBE, female physicians also performed the exam .on more
eligible patients than their male counterparts. 6 This echoes
the results of another study which documented that
patients of female physicians were significantly more
likely to be screened by a clinical breast exam than
patients of male physicians and that neither group
screened all eligible women. 3 From this data, the lesson
can be drawn that first, there is a deficit in screening with
CBE. Second, physicians are less likely to perform CBE if
they are uncomfortable performing the skill. Third, t~e
reasons why female physicians are more comf?~tabl~ With
and more likely to perform a CBE must be elicited m the
hope of eliminating this gender disparity.
.
Unfortunately the trend of decreased screemng
numbers and gender disparity in physician comfort level
exists at the student level as well. For example, a
retrospective chart review of 111 women eligible f~r CBE
seen by internal medicine residents at George Washington
University Medical Centre showed that only 35 of them
received a clinical breast exam? An assessment of primary
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care residents from seven training program noted
performance deficiencies in breast examination skills and
lump detection sensitivity. There were significant
differences in the performance abilities of residents from
different training programs. The programs with poorer
performance in Clinical Breast Exam were also the
programs where the CBE was not emphasized in the
curriculum and the residents described the training they
received as "poor to fair" .8
A survey of students currently entering their clinical
clerkship at UWO posed the question "Relative to other
clinical skills (but excluding pap and rectal exam) h ow
adequate is the instruction you have received through the
Clinical Methods Curriculum?" Students were asked to
rate it as "Excellent, Good, Fair or Poor" O f 57
respondents, 50 (89%) considered it "Poor", 6 considered it
"Fair" and 1 considered it "Good". A second question
posed was "Relative to other clinical skills (but excluding
pap and rectal exam) how comfortable / relaxed do you
feel performing a clinical breast exam? " Of 57
respondents, 36 answered "Poor" and 14 answered "Fair".
Only 6 students answered either " Good " (n=4) or
"Excellent" (n=2). In response to the question "Relative to
other clinical skills (but excluding pap and rectal exam)
how confident do you feel about your ability to detect a
breast pathology by performing the CBE?" 38 respondents
said "Poor" and 16 said " Fair" and 3 said "Good". No
students felt their ability to detect pathology was
"Excellent" relative to their other clinical skills. This data
argues strongly for placing greater curriculum emphasis
on theCBE.

Patients (SP's) in which they performed a CBE, received
feedback and then practiced the CBE on the Standardized
Patient while receiving ongoing feedback . The
experimental group scored significantly for both skill level
and professionalism at an OSCE station for CBE in a
follow-up at the end of the twelve month clerkship.10
CONCLUSIO N
The conclusions to be drawn from this are clear. The
Clinical Breast Exam is a necessary part of women 's
healthcare which should be performed on all women
according to current screening recommendations. There
exists among both current and future physician s a
phenomenon of sub-optimal screening rates, skill level
and comfort level. This has been documented at UWO by
a student seU-assessment survey. Interventions to teach
the CBE can be simple and effective and thus curriculum
modification need not be extensive. It could mean
replacing the three hour self-learning session with a
supervised viewing of the video followed by supervision
of the CBE on the current model breast. Alternately, access
could be provided to the more sophisticated breast models
employed in the Breast Cancer Clinic. It may even be
possible to arrange for students to attend a pre-operative
clinic for women with carcinoma of the breast. As a
responsive and responsible medical school, the University
of Western Ontario should strive to address any and all
curriculum deficits. It is in the interest of women's health
and physician competence to enlarge the role of CBE in
the pre-clerkship curriculum.

TEACHING THE CLINICAL BREAST EXAM
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The most effective way to teach current and future
practitioners the CBE and to ensure they perform it on all
eligible patients has been addressed in a number of
studies with success. The medical school curriculum at the
University of Western Ontario could benefit greatly by
adapting successful strategies for teaching clinical breast
exam . The outcome would be more competent a nd
comfortable future physicians.
A compelling argument can be made that to improve
both the level of comfort and skill of medical students in
performing CBE need not be a time-consuming measure.
The impact of even one training session or intervention to
teach Clinical Breast Exam has been documented in
several studies. A study that used an office-based training
program targeted at primary care physicians improved
their ability to correctly detect lumps in a silicone breast
model. The mean number of correct lump detections in a
model With 5 lumps increased from .66 before to 3.2 after
instruction and the improvement was sustained at a six
month follow-up .
Utilizing standardized patients is an alternative
method by which some schools teach the CBE. A study
conducted using medical students compared the
performance of a control and experimental group. Both
groups received "traditional" instruction consisting of a
thirty minute videotape on the breast exam and assigned
readings immediately prior to commencing their clinical
clerkship. In addition, the experimental group received a
single 70 minute teaching program nu(by Standardized
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THE LINK BETWEEN ORAL
CONTRACEPTIVE USE AND BREAST
CANCER
By Fiona O'Sullivan, MEDS 2002

INTRODUCTION
reast cancer is a serious, prevalent disease affecting
women around the world. This is a health issue of
particular interest to researchers, since the incidence
of breast cancer in women has been increasing.1 A number
of researchers have investigated the possible link between
estrogen and the pathogenesis of breast cancer. More
specifically, research has been conducted to investigate the
relationship between oral contraceptive use and breast
cancer in women. This article is a review of recent research
on this topic.

B

ESTROGEN AND BREAST CANCER
It has been well established that hormones such as
estrogen play key roles in the development of breast
cancer. 1 It is thought that these hormones increase risk of
breast cancer via effects on cell division in breast
epithelium. Research suggests that "the cumulative
frequency of ovulatory cycles is a primary determinant of
breast cancer risk." 1 For instance, it has been found that
women with breast cancer tend to have shorter menstrual
cycles, earlier age of regular menstrual cycles, and later
age of menopause, than controls.1 There is also substantial
laboratory evidence that suggests that estrogen is related
to breast cancer risk. For instance, mice and rats exposed
to exogenous estropens have increased incidence of
mammary tumours. In humans, breast cancer patients
have been found to have up to four times as much free
estriol as controls.
Overall, there is strong evidence of a link between
estrogen exposure and breast cancer. Since such a link has
been established, there is reason to believe that oral
contraceptives, or other exogenous estrogens, ma y
increase one's risk of breast cancer. 1 This is an important
area of investi9ation, since a number of women use oral
contraceptives. This leads to the next section, which will
review the research findings to date on the relationship
between oral contraceptives and breast cancer.

ORAL CONTRACEPTIVE USE AND
CANCER

BREAST

In a review of research on oral contraceptive (OC) use
and breast cancer, it is reported that the majority of
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epidemiological research that was published prior to 1984
did not find evidence of OC use related to increased risk
of breast cancer.3 However, since 1984 there have been a
number of studies that suggest that some sub-groups of
women who use OCs have an increased risk of breast
cancer, along with several studies finding no such
association, resulting in contradictory, and difficult-tointerpret findings .
When studying women who have ever versus never
used OCs, research has failed to find a relationship
between ever use of OCs and breast cancer risk. 3 A group
of researchers have suggested that "ever" use of OCs is
likely too crude of a measure to reveal a link, if one exists. 3
They suggest that researchers consider sub-groups within
OC users, since positive links between OC use and breast
cancer are more often found in studies which focus on
particular subgroups of women. For instance, most of the
studies that have investigated OC use in women
diagnosed with breast cancer at a young age (under age
45) have found that OC use does increase the risk in this
subset of women. 3 In a meta-analysis of such studies,
researchers found an overall RR of 1.5 for young women
in one review of research, 4 and a summary RR value of 1.4
was found in another review. 5 Also, it appears that long
duration of OC use before full term pregnancy is
associated with increased risk of breast cancer, with
summary risk estimates being 1.7,4 and 1.4. 5
A prospective cohort study was recently conducted to
investigate the breast cancer risk associated with OC use
in a number of sub-gro ups of women. 6 This study
involved the Nurses' Health Study in the US, which
included 114 880 women. Of these women, 3 383 had
breast cancer. The researchers found a marginally
significant increase in breast cancer risk in women who
had last taken OCs within the past five years (RR = 1.20;
95%CI = 1.00 - 1.44). As the authors reported elsewhere,6
they also found increased risk of breast cancer associated
with current OC use (RR = 1.53; 95%CI = 1.06- 2.19). There
was no relationship between breast cancer risk and OC
use prior to first pregnancy, even when analyses only
included the sub-groups of women by age and parity.
Also, no relationship was found between duration of OC
use and breast cancer. 6
There are a number of strengths of this study. First of
all, this has been the largest prospective study to date on
this topic . Since the investigation was prospective in
nature, there was little likelihood of selection or recall
bias. 6 Secondly, the researchers controlled for many
possible breast cancer risk factors in their analyses (e.g.
age, BMI, age at menarche, etc.). In addition, the OC users
and non-users in this study were similar on most of these
risk factors. Finally, there were high follow-up rates of the
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study participants (at least 90%). 6
A weakness of this study is that there was limited
power in some analyses, since there were few cases in
some of the sub-groups.6 For instance, there were only six
OC users with breast cancer in the 30-34 year age group,
and 27 OC users with breast cancer in the 35-39 year age
group. The limited power here may explain why this
study did not confirm other studies' findings that OC
users under the age of 45 are at increased risk of breast
cancer. 6 The studies that found such a relationship tended
to be case-control studies, which had more cases, and thus
increased power.
In summary, these investigators found that current
and recent OC use is associated with increased risk of
breast cancer, a finding that has also been reported in
reviews and meta-analyses. 6 They did not find any
increases in breast cancer risk due to long OC use, or OC
use prior to first pregnancy, which is also consistent with
other recent studies. Finally, their one finding that was not
consistent with other research findings (lack of increased
risk for OC users under age 45) should be interpreted with
caution, since there was limited statistical power for this
particular analysis. Overall, the findings of this study w ere
consistent with the view that any relationship that may
exist between breast cancer and OC use is a short-term
effect only.
A large case-control study that was conducted fairly
recently found relationships that were consistent with the
findings of the previously discussed study. 6 This was a
population-based case-control study, with 6751 cases and
9311 controls? As with the previously discussed study, in
this investigation a number of potential confounding
variables were controlled . The researchers found that
recent use of OCs (within past 5 years) for women aged
35-44 years was associated with increased breast cancer
risk (RR = 2.0; 95%CI = 1.1 - 3.9). However, the authors
did not find a relationship between breast cancer risk and:
current use of OCs, age at first use of OCs, or long
duration of OC use?
Newcomb et al's case-control study has a numb r of
strengths .6 Firstly, they had more power than did
Hankinson et al's cohort study, 7 for they had twice as
many cases . Secondly, they had high questionnaire
response rates (80.7% for cases, and 84.2% for controls).
Furthermore, their questionnaire was quite reliable, for
when they retested it 6-12 months later, the Spearman
correlation coefficients ranged from r = 0.89 to r = 0.98.
Finally, they found that the recent cancer cases who were
0C users in their study were less likely to have undergone
mammography than the cases who were former users,
which allowed them to rule out the possibility that their
positive findin~s were due to increased surveillance in
recent OC users.
Overall, Newcomb et al found that recent OC u ers
who were aged 35-44, and / or had low BMI, were at
increased risk of breast cancer? However, duration of use
was not a risk factor. The researchers considered two
possibilities for their findings of an increased breast cancer
risk in recent OC users. Firstly, this finding could be
merely due to the fact that young women are more likely
to have used OCs recently, and they seem to be more
prone to OC effects. Secondly, the results could suggest
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that OC effects on breas t cancer risk are due to
promotional effects on existing tumours, rather than due
to triggering effects?
In summary, research that was reviewed by Malone et
al generally found that OC use for a long duration prior to
first pregnancy increases a woman's risk of breast cancer. 3
However, two large studies si nce then have not
corroborated these findings .6•7 What has been found in
most recent studies is that recent and/ or current OC use is
a risk factor for breast cancer. 6•7 This, combined with lack
of evidence for a relationship between long-term OC use
and breast cancer, suggest that OCs may play a small,
short-term promotional effect on existing cancer
tumours.6•7
CO NCLUSION
There are a number of aspects of the research that are
in support of a link between OC use and breast cancer.
First of all, carcinogenic effects of OCs on the breast is
biologically plausible, given experimental evidence .
Secondly, prospective cohort studies and case-control
studies have found a link between OC use and breast
cancer. Thirdly, findings that OCs play a role in breast
cancer is consistent with the descriptive epidemiology of
cancer, since breast cancer incidence is increasing as OC
use increases. However, there are a number of weaknesses
with the research to date. First of all, the research in this
area lacks consistency. Secondly, the strength of the
association in studies with positive findings tends to be
quite low. Finally, although the quality of research seems
to have improved, recent research still lacks enough cases
to have high enough statistical power for analyses of subgroups. The only conclusion that can be made thus far is
that OCs seem to have a small, promotional effect on
breast cancer in some sub-groups of women, such as those
who are young and are currently using OCs. There does
not appear to be evidence of long-term effects of OC use
on breast cancer risk.
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NAUSEA AND VOMITING IN
PREGNANCY: A BRIEF REVIEW
By Tammy Clifford
INTRODUCTION
ausea and vomiting during pregnancy (NVP),
better known as " morning sickness," affects
upwards of 50% of pregnancies.1-1 1 It is thought to
occur more frequently among nulliparous women in
Western populations and tends to recur in subsequent
pregnancies.3•12•13 In the majority of these cases, NVP is
clustered in the first trimester, but not necessarily during
the morning hours ?·9 Its occurrence is so pervasive that
VP is considered a hallmark of pregnancy . The
experience of NVP may include fatigue, irritability and
sleep disturbances . Although research has failed to
produce definitive conclusions regarding the aetiology of
VP, many believe it to be a normal physiologic
occurrence which results the sudden and substantial
physiologic changes which characterize the first few
weeks of pregnancy .12 Often, NVP subsides, without
residual effects, near the end of the first trimester.
In a small proportion of VP cases, however,
vomiting is so severe and prolonged that it interferes with
the woman's fluid intake and nutrition. This can translate
to significant weight loss (>5 % of body weight) and
electrolyte and acid-base imbalances which often bring
about hospitalization. 3 The prevalence of this condition,
known as hyperemesis gravidarum (HG), is estimated to
range from 0.5 to 10 per 1000 pregnancies.8•14•15 While some
may dismiss NVP as not being a legitimate medical
concern, research findings suggest that the experiences of
VP and HG affect the quality of women's lives. For
example, data from a Swedish survey indicated that in
12% of pregnancies, NVP was so severe that it precluded
continuous employment.7 Alarmingly, data from the
Motherisk program at the Hospital for Sick Children,
corroborated by the findings of Jarnfelt-Samsioe, indicate
that a significant number of women decide to terminate
their pregn<l!lcies as a result of their experience with NVP
and / or HG?·16 There are, however, many methodological
issues regarding the Motherisk study which are deserving
of mention. The first concern is how representative the
study sample is of the general populace, as women who
were enrolled as participants had voluntarily responded
to advertisemen ts placed in Canadian and American
newspapers, magazines and electronic media. It could be
that women who responded to the advertisement were
motivated, for whatever reason, to share their story. Thus,
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these results may not generalize to the general population
of pregnant women. Secondly, the study's retrospective
design may have biased some findings, as women who
elected to terminate their pregnancies may have been
searching for a reason and, upon reflection, the experience
of NVP was an easy reason to give. This is not to say that
these results are untrue but that caution should be used
when interpreting study results and that future works
must address these methodological deficiencies in order to
facilitate understanding of NVP. It is not doubted that, as
researchers from the Motherisk program suggest, this
finding is an "unacceptable combination." 16 It is evident,
then, that much work remains to be done in order to
improve our understanding of VP and HG and to
minimize its effects on the lives of pregnant women and
those around them.
DIAGNOSIS
Although NVP and HG can be thought to represent
opposite ends of a continuum, both are diagnoses of
exclusion; before establishing a diagnosis of NVP or HG,
clinicians must first rule out other potential causes of
nausea and/or vomiting, such as gastroenteritis,
cholecystitis, peptic ulcer, food poisoning, etc. The
experience of NVP is, undeniably, bothersome but is
usually a self-limiting condition. On the other hand, the
experience of HG can, if left untreated, be potentially lifethreatening. Clinical features of HG include intractable
vomiting which can lead to significant weight loss, severe
disturbances of electrolytes , depletion of mineral stores,
and hypovolemia. Laboratory findings indicate ketonuria,
hyponatremia, hypokalemia, hypochloremia, metabolic
alkalosis with paradoxical aciduria and elevations in urine
specific gravity, hematocrit, and blood urea nitrogen. 6
OUTCOMES
Substantial reductions in maternal mortality have
been made over the past few decades, owing to improved
understanding of the effects of HG and aggressi v e
treatment strategies which aim to restore maternal fluid
and electrolyte balances. Left untreated, complications of
HG include Wernicke ' s encephalopathy, 17 • 18 coma,
hepatorenal failure and death.
Historically, NVP was thought to be a positive
predictor of pregnancy outcome, specifically with respect
to birth weight and gestational age. 13•19 Recent findings
uphold the suggestion that the experience of VP is
associa ted with a reduced risk of miscarriage, stillbirth,
fetal mortality, preterm delivery, low birth weight,
perinatal mortality or growth retardation. 7•9 •20 The
outcome of HG, however, is not so definitive. While most
studies report no substantial deleterious effects of HG on
maternal and fetal outcomes/ ·9•13.2 1• 23 several studies report
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associations between severe HG and negative outcomes
such as fetal growth retardation, pre-eclampsia and smallfor-gestational age births. 8.2 1.24-26 Other reports have hinted
at an elevation in CNS and skeletal malformations in
children whose mothers experienced HG. 8.2 1.26.27 It has also
been suggested that maternal ketonemia, whether due to
HG or a metabolic disorder, adversely affects the
neuropsychological development of the infant. 28•29 It is
important to note, however, that the limitations associated
with the designs of these studies make it impossible to
infer a causal relationship. Additionally, it is expected that
prompt and appropriate treatment to address maternal
weight loss and electrolyte imbalances will reduce the
likelihood of adverse outcomes. 2
AETIOLOGY
In keeping with the established trend of uncertainty
and despite concerted research efforts over the past few
decades, the exact mechanisms underlying NVP and HG
are still unknown. Recently proposed mechanisms include
Helicobacter pylori infection, 30 vitamin B deficiency/1.32
endocrine imbalances/ 3- 36 alterations in serum steroid
hormone levels, 11 .26.37-J9 and psychological disturbance .3' 41}.
50
While each of these hypotheses has been studied
clinically, none has been proven definitively.
For example, an association between HG and human
chorionic gonadotropin (hCG) is plausible, given that the
incidence of HG in pregnancies of multiple gestation is
elevated, as is the concentration of hCG. The fact that the
onset of HG corresponds to the time at which hCG levels
reach their peak lends further support to this hypothesis.
Research findings, however, have been contradictory,
weakening the possibility of a causal association.3•11 .38.5 1-55
In terms of psychology, some researchers have sugge ted
the NVP and HG may stem from a "protest" reaction
against the pregnancy and/ or attempts by the woman to
elicit attention and sympathy from family and friends
while addressing hostility toward the father of the
baby. 40•41 •4 The absence of definitive research findings,
despite concerted efforts, may be attributable, in part, to a
failure to see NVP and HG as manifestations of an
interplay of biological, psychological and social factors .
Additionally, most studies have examined nausea and
vomiting as a single entity. This could introduce bias into
the research, particularly in retrospective works, since
nausea, as a subjective entity, is more difficult to recall
than vomiting. Future research must address these
limitations and utilize sound study designs if our
understanding of these condi tions of pregnancy is to
improve.

TREATMENT
The management of VP in mildly symptomatic
women typically involves reassurance, dietary
modifications and, in some cases, drug therapy.
Pharmacological measures may need to be considered for
the treatment of women whose NVP continues, even after
receiving reassurances and after modifying her diet. 1.2. 16 In
light of the thalidomide experience, however, it is
understandable that both physicians and their patients
continue to express concern over the safety of
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pharmacological agents, including anti-emetics,
administered during early pregnancy. Caution is
reasonable and it is accepted that medications be used
during pregnancy only when absolutely necessary. While
there are a number of options available to physicians, at
this point in time, Dilectin (doxylamine succinate +
vitamin 86) is the only medication approved by Health
Canada for use as an anti-emetic in the treatment of
NVP. 56
For women who experience HG, timely treatment
must address hypovolemia, electrolyte imbalances and
ketosis. Results of one study, which indicated that, relative
to controls, the mean dietary intake of most nutrients for
women with HG was less than 50% of the recommended
daily allowance, 57 highlights the fact that these patients are
at high nutritional risk. Nothing should be given by
mouth until dehydration is corrected and vomiting is
controlled. 58.59 If the episode is prolonged, consideration
should be given to vitamin supplementa tion, via the
parenteral route . 60 •61 ' 62 Emotional support, perhaps
including psychological therapy, is especially important
throughout this time.63•64
PREVENTION
From all perspectives, prevention is always better than
cure. In the case of NVP and HG, however, the absence of
a causal model translates into tremendous difficulty in
reducing the incidence of these conditions. Nevertheless,
results of a randomized, double-blind controlled trial of
periconceptual vitamin and mineral supplementation,
initiated to demonstrate the effect of these supplements on
the incidence of neural tube defects, indicated that these
supplements also reduced the incidence of NVP and HG. 65
Although this appears to be "good news," this hypothesis
remains to be proven in prospective randomized trials
initiated specifically to examine this particular research
question.
CONCLUSIONS
A wide variety of disorders have been implicated in
the aetiology of NVP and HG. Fut ure research must
address the likely interplay of biological, psychological
and social factors in the aetiologies of NVP and HG and
utilize prospective methods in representative, sufficientlylarge samples which would permit detailed examination
of a number of factors in multivariable models.
Until the scientific community can elucidate the causal
mechanism(s) underlying NVP and HG, clinicians must
ensure that patients are provided with prompt and
appropriate treatment(s) , thereby ensuring optimal
outcomes for mother and child.
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THE LONG TERM CONSEQUENCES
OF POLYCYSTIC OVARY SYNDROME
By Tisha Joy, MEDS 2001
olycystic ovary syndrome (PCOS), also known as
Stein-Leventhal syndrome, is the most common
endocrine disorder in women of reproductive age. 1
In fact, it is the leading cause of pathologic amenorrhea in
premenopausal women and is one of the leading causes of
female infertility. 2 Approximately 75% of women with
PCOS have fertility problems.3
PCOS is a heterogeneous syndrome characterized by
an increased LH:FSH ratio (>2.5), elevated androgens, and
anovulation.4.s Normally, LH stimulates ovarian theca cells
to produce androgens such as 17-hydroxyprogesterone,
androstenedione, and testosterone from cholesterol via
cytochrome P450c-17 alphahydroxylase. Ultimately, these
androgens undergo aromatization by the FSH-stimulated
granulosa aromatase. 6 However, in women with PCOS,
the high LH levels cause ovarian theca cell hyperplasia,
resulting in excess of these androgens and thereby halting
follicular development within the ovary. Since a dominant
follicle is not being formed, multiple cysts occur on the
ovary, eventually causing impaired estradiol production. 2
This abnormal secretion of estrogen results in chronic
anovulation, which may be manifest as amenorrhea,
oligomenorrhea, or dysfunctional uterine bleeding. In
addition to these symptoms, acne, hirsutism, and / or
male-pattern baldness may be present due to androgen
excess?
Androgen excess in PCOS may also occur due
to the adrenal glands, resulting in increased
levels of dehydroepiandrosterone (DHEA) and
dehydroepiandrosterone sulfate (DHEAS), the latter
hormone being a substrate for ovarian testosterone
synthesis.6 Although the exact role that adrenal androgens
play in PCOS and the mechanisms involved have not yet
been fully established, investigating the source of
androgen excess in any individual patient is important in
managing the symptoms of the androgen excess.
The prevalence of PCOS in the general population has
been estimated to be about 5-10%. It is interesting to note,
however, that a recent study of healthy women found that
22% of these women had ultrasonic evidence of polycystic
ovaries and 94% of these "normal" women with polycystic
ovaries had at least one other symptom indicative of
PCOS. 7 Yet, the importance of PCOS lies not in simply
diagnosing cystic ovaries but in also understanding the
associated long term consequences, including infertility,
insulin resistance, non-insulin dependent diabetes

P
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mellitus (NIDDM), cardiovascular disease, and
endometrial cancer.
INFERTILITY
PCOS is often undetected until a woman experiences
difficulty in conceiving .3 The improper secretion of
estrogen associated with PCOS causes cessation of
follicular development and thus, lack of ovum release.
PCOS is also a risk factor for repeated early spontaneous
abortion related to the high LH levels and obesity. 9 About
50% of women with PCOS are obese. 4 In fact, obesity and
hyperandrogenism contribute significantly to infertility
via increased peripheral conversion of androgens
(primarily, androstenedione and testosterone) to estrone
within adipose tissue, thereby adding to the already
abnormal estrogen secretion and menstrual disturbances
present in PCOS patients. 10 Fortunately, diet modification
and weight loss have been shown to improve these two
contributing factors and thereby improve cycle regularity,
ovulation, and fertility rates.11 •12
INSULIN RESISTANCE AND NIDDM
Women with PCOS have a greater likelihood of
having hyperinsulinernia and insulin resistance. 7 The exact
mechanism responsible for insulin resistance is still under
investigation. However, recent studies have shown that
peripheral insulin resistance in adipocytes from PCOS
patients may be due to decreased expression of the
insulin-mediated glucose transporter protein GLUT-4. 13•14
Although insulin resistance would be expected to be more
prevalent in obese women with PCOS, it was actually
found to be independent of obesity. 14 Interestingly,
patients with PCOS have double the risk of having
subclinical bulimia and it has been postulated that this
may also play a role in the insulin resistance in PCOS

patients. 5• 1 ~

Insulin resistance, common to most women with
PCOS, is important in the development of NIDDM, the
prevalence of which is seven times higher in PCOS patients
than in the control population. 16 Moreover, NIDDM
develops at an earlier age in women with PCOS (third to
fourth decades) than in the general population (sixth to
seventh decades). 1 Hyperinsulinernia is also a contributor
to infertility since suppression of insulin concentrations by
the use of metforrnin has been shown to improve fertility
rate. 12 As well, it is an independent risk factor for
cardiovascular disease due to its pro-atherogenic effects,
including promotion of lipid plaque formation, smooth
muscle proliferation, and growth factor production. 6 A
recent study has shown that weight control and dietary
intervention can increase insulin sensitivity (up to 93%) in
obese women with PCOS and thus potentially decrease the
risk of NIDDM or cardiovascular disease. 17
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CARDIOVASCULAR DISEASE
A number of risk factors for cardiovascular disease are
present in women with PCOS. PCOS patients tend to have
higher me~ serum triglyceride levels as well as lower
HDL levels compared to controls.18' 19 As discussed earlier,
women with PCOS are prone to developing insulin
resistance, hyperinsulinemia, and I or NIDDM, all of
which increase the risk for cardiovascular disease. Based
on the low HDL levels in women with PCOS and the
correlation between low HDL levels and cardiovascular
risk in the Framingham study, one author has estimated
that women with PCOS have a relative risk of about 3 for
cardiovascular disease compared with the gene ral
population. 20 However, s ince these risk factor s of
increased triglyceride levels, low HDL levels, obesity,
hyperinsulinemia, insulin resistance, and NIDDM tend to
cluster in women with PCOS, it would be reasonable to
predict that the actual cardiovascular risk may be much
higher, although no prospective study has yet quantified
this risk.
ENDOMETRIAL CANCER
The risk of endometrial cancer is also increased in
women with PCOS due to several factors: 1) lac k of
progesterone, 2) obesity, 3) hyperandrogenism, and 4).
hyperinsulinemia . The lack of cyclical progester one
secretion results in unopposed estrogen effects, including
endometrial hyperplasia . These effects may indeed be
worsened in obese women with PCOS due to conversion
of androgens to estrone within adipose tissue? It has been
found that obese women with an upper bod y fat
distribution have a 5.8-fold higher risk of endometrial
cancer than non-obese women or women with a lower
body fat distribution . 21 Thus, both obesity and the
distribution of body fat are important in assessing the risk
of endometrial cancer for women with PCOS.
H yperandrogenism may further contribu te to the
unopposed estrogen effect by ~oviding additi onal
substrate for conversion to estrone. The relation between
hyperinsulinemia and increased risk of endometrial cancer
may occur through production of excess androge ns.
Increased levels of insulin cause decreased sex hormone
binding globulin (SHBG) production, resulting in higher
circulating levels of androgens. 10•23 High levels of insulin
also cause a decrease in circulating levels of insulin
growth factor binding protein 1 (IGFBP-1), thereby raising
the levels of IGF-1. In response to LH, IGF-1 stimulates the
ovary, resulting in increased activity of cytochrome
P450c-17 alphahydroxylase, the enzyme responsible for
production of androgens. Thus, with the decreased SHBG
levels and increased IGF-1 levels, ultimately increased
estrone production occurs, thereby compounding the
unopposed estrogen effect on the endometrium and
promoting the risk of endometrial cancer.24
SUMMARY
PCOS is a relatively common female endocr ine
disorder tha t should be considered in all women
presenting with menstrual dis turbances, infertili ty,
and / or hirsutism. It is associated with an increased
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cardiovascular risk due to obesity, insulin resistance or
diabetes, high triglyceride levels, and low HDL levels.
Further, unopposed estrogen contributes to the menstrual
disturbances, anovulation, and infertility as well as to the
increased risk of endometrial cancer in these w omen.
Thus, the treatment and management of women w ith
PCOS focuses on preventing the long-term consequences
of PCOS by reducing obesity, decreasing androgen action,
normali z ing the endometrium, and correcting
anovulation.
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UNDERSTANDING PREMATURE
OVARIAN FAILURE
By Gina Rohekar, MEDS 2001
remature ovarian failure (POF) is a condition that is
characterized by elevated gonadotropins,
h ypoestrogenism and amenorrhea occurring in a
woman who is younger than 40 years of age.1 POF is not a
rare condition; indeed, the incidence of POF before the age
of 40 is estimated to be 1 in 100.1 Despite the rela tive
frequency of POF, there has yet to be found a definitive
cause for its occurrence. Many theories have been
proposed and researched as potential mechanisms for
POF, and in some cases, specific causes have been found.
However, for the most part, the etiology of POF remains
obscure. The following article is intended as a summary of
current theories used to describe POF.

P

I. Follicle Depletion
If the normal contingent of follicles attributed to an
ovary were somehow abnormally rapidly depleted, a
patient may present clinically with amenorrhea and POF. 1
Some potential causes of follicle depletion include:

•
•

•

WHATISPOF?
In the early research into causes of POF, it was
believed that the condition is a true "failure" of the ovaries
in the sense that it is irreversible. 1 However, it later
became evident that this is not the case. Follicle function
appears to be at least intermittently maintained in most
POF pa tients. 1 Studies have shown that follicle s are
present on pelvic ultrasound; as well, some POF patients
have even become pregnant. 1 Thus, POF is not a complete
termination of ovarian function. Rather, it is a condition of
termination of normal ovarian function.
Clinically, a set of guidelines help to identify a patient
as having POF. The patient must present with amenorrhea
before age 40.2 Laboratory criteria specify that amenorrhea
should be present for more than or equal to 4 months, and
that 2 serum FSH values of more than 40 miU I mL are
obtained at least 1 month apart from the patient.2 Of
particular note is that the progesterone withdrawal bleed
test is not diagnostic in POF. This is due to the fact that
some patients with POF may still intermittently produce
enough estrogen for a withdrawal bleed to take place.1
CAUSES OF POF
A convenient way to examine potential causes of POF
is by dividing the condition into two categories: i. patients
with follicle depletion, thus resulting in POF; ii. patients

with follicle dysfunction, thus resulting in POF.
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abnormally low initial follicle endowment (as in cases
of Turner's Syndrome or gonadal dysgenesis) 1
accelerated follicle atresia (determined in some cases
to be due to balanced translocations of the X
chromosome; two genes, POF1 and POF2 have been
proposed) 1' 3
enzyme deficiencies such as galactosemia (deficiency
in galactose-1-phosphate uridyl-transferase) which
lead to accelerated follicle atresia, as above 1
chemotherapy, irradiation, or exposure to
environmental toxins 1

II. Ovarian Follicle Dysfunction
The category of 'ovarian follicle dysfunction' includes
those patients with adequate gonadotropins, and follicles
and oocytes that appear histologically normal yet they fail
to have normal ovarian function. 1 This group consists of
many cases of unknown etiology. However, some patient
groups have been studied, leading to the discovery of a
growing number of specific causes of POF in patients.
These include:
• enzyme deficiencies, as related to defects in the
17a-hydroxylase enzyme, cholesterol desmolase,
17-20 desmolase and aromatase enzymes 1
• signalling defects (defects in gonadotropins or
gonadotropin receptors) 1
• immune-related dysfunction (association with
autoimmune diseases, antiovarian antibodies, steroid
cell antibodies, zona pellucida antibodies or
oophoritis) 1

MANAGEMENT OF KARYOTYPICALL Y NORMAL
PATIENTS WITH POF
For patients that present with POF and who are
karyotypically normal, there are a number of things that
the managing physician can do to help the patient
understand and cope with her condition. A general plan is
to: i) Inform; ii) Counsel; iii) Replace; and iv) Follow-up.1
i. Infonn
When diagnosed with POF, the patient should be
provided with accurate and up-to-date information. The
patient should be told that spontaneous remission of POF
can occur, but that there is currently no known treatment
forPOF. 1
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ii. Counsel
The patient who is concerned about having children
should be first advised to wait for the possibility of
spontaneous remission. Adoption or a change in life plans
should be offered as an alternative to couples. As well, a
couple may be counselled to consider ovum donation after
an appropriate waiting period. 1
iii. Replace
In all cases of POF, there are definite indications for
hormone replacement therapy to be implemented. 1 Full
hormone replacement will not only reduce the patient's
risks for osteoporosis and heart disease, but will also
alleviate symptoms (such as vasomo tor symptoms,
vaginitis, dyspareunia and urinary frequency) .1
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iv. Follow-up
There has been some evidence correlating POF to
autoimm une disorders and adrenal insufficiency . 1
Therefore, it is necessary to maintain a careful follow-up
schedule with patients with POF. 1
THE FUTURE OF POF

As molecular techniques are continuing to evolve,
new av enues into POF research are appearing on the
scientific horizon. Immunotherapies have been proposed,
as well as studies into the role of apoptosis (programmed
cell death) in POF.1 Furthermore, new developments in
the field of assisted reproductive technologies may
increase options for couples with POF. 1 Current research
at the University of Western Ontario is exploring the role
of intercellular communication through gap junctions in
the growing follicles in cases of follicular dysfunction (Dr.
G.M. Kidder, Departments of Physiology and Obstetrics
and Gynaecology) . Interestingly, knockout mice models
have been developed that are deficient in certain gap
junctions expressed in the follicle or oocyte-resulting in
fe male mice that are infertile, and express ovarian
histology similar to that of women with POF .4 • personal
cornmunicationa from C. Ackert and G.M. Kidder

Premature ovarian failure is a fairly common
condition that patients may present with both to the
fa mily physician and to the gynaecologist. Study into
causes of POF are continuously bringing to light new data
and theories. Hopefully, this brief review will help put
forth to medical professionals some of the current theories
of POF and information to pass on to patients.
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FEMALE

INFERTILITY
By Andrea A. White, MEDS 1999

INTRODUCTION
nfertility is a devastating problem for many couples. It
is defined as a couple ' s unsuccessful attempt at
conception after one year of unprotected intercourse.
Primary infertility is a diagnosis that describes an infertile
couple that has not previously achieved pregnancy, while
secondary infertility denotes a couple that has achieved
pregnancy prior to the onset of infertility.
Most industrialized countries report the combined
incidence of primary and secondary infertilitf to be
10-15% of couples in their reproductive years. Many
couples are delaying conception, which results in
increased risk of age-related infertility factors. There is
also a rising incidence of sexually transmitted disease,
which can result in tubal dysfunction. For these reasons,
there appears to be an increasing trend of infertility.
However, advancing technology, both diagnostic and
therapeutic, as well as decreasing access and availability
of alternatives, such as adoption, may prove this apparent
rising trend to be factitious, or at least exaggerated.
There are numerous factors that may contribute to the
etiology and pathogenesis of infertility in either or both of
the partners. Initial evaluation by the Family Physician
with appropriate and timely referral to a specialist may
help the couple feel more comfortable with the process
and prepare them for the possibility of further
investigation or assisted reproductive technology.2 The
investigation, diagnosis and management of infertility can
be difficult and frustrating for both the couple and the
physician.

I

ovulation and production of gonado tropin-releasing
hormone (GnRH), luteinizing hormone (LH), folliclestimulating hormone (FSH), estradiol and progesterone in
adequate quantity. These hormones regulate oocyte
maturation, ovulation, proliferation and preparation of the
endometrium for pregnancy, as well as amount and
quality of cervical mucus. Therefore, female requirements
for conception are proper hormone production and
response , patent and functional fallopian tubes,
appropriate uterine anatomy and effective oocyte-sperm
interactions.4
Consequently, infertility may be the result of an
isolated problem with any one physiological or anatomical
element, or a combination of factors, and may involve
either partner of the couple or both.
ETIO LOGY OF FEMALE INFERTILITY
Based on the assessment of contributory factors to
successful conception, it is apparent that there are diverse
causes of infertility. Common causes of female infertility
are summarized in table 1. Several important topics have
been selected for elaboration:
Table 1- Etiology of Female Infertility'
Mechanism

Condition

Absent gonadal tissue

Turner's syndrome
Pure gonadal dysgenesis

Impaired gamete
production and function

Hypogonadotrophic hypogonadism
Hypothalamic anovulation
Hyperprolactinemic anovulation
Androgen insensitivity
Polycystic ovarian syndrome
Premature ovarian failure
Resistent ovarian syndrome
Ovum retention
Oocyte factor' (aged oocyte)
Cytotoxic drugs
Other drugs
Irradiation
?smoking

Impaired gamete
transport

Malfunction of ovum capture and
cilia mediated transport
Tubal infertility
Endometriosis
Cervical factor
Antisperm antibodies

Impaired conception

Polycystic ovaries
Smoking
Abnormal sperm adhesion molecules

RecurrentnUscanriage

Chromosomal aberrations
Oocyte factor' (aged oocyte)
Coagulation disturbances
Polycystic ovaries
Gross uterine anomalies

PHYSIO LOGY OF CONCEPTIO N
Numerous factors contribute to success ful
achievement and maintenance of pregnancy .
Considerations for conception include both male and
female issues, such as anatomy, endocrinology and
metabolism, genetics, immunology, psychology and
behaviour. Based on the collective effect of these factors,
the statistical probability of conception in a given month is
estimated at 20-25% in the normal population of childbearing age.3
Male contributions to effective conception include the
capability of vaginal intercourse and ejaculation of an
adequate number of motile sperm . Therefore,
requirements are normal spermatogenesis, semen
production, as well as functional erection and ejaculation. 4
In order to conceive, females must achieve normal
folliculogenesis for development of a mature oocyte,
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Disorders of Ovulation
Dysfunction of ovulation is involved in 15 to 30% of
cases of couple infertility. 4 Hypothalamic disorders result
in anovulation and amenorrhea due to an abnormality of
pulsatile secretion of GnRH, which impacts upon normal
LH and FSH secretion. Approximately 20% of women
with amenorrhea are found to have a pituitary
abnormality, such as a prolactinoma .4 Other endocrine
disorders which can potentially lead to infertility are
th y roid dysfunction and adrenal gland disorders ,
including congenital adrenal hyperplasia, adrenal tumour,
Cushing's disease and Addison's disease.
Ovarian dysfunction ma y result in anovulation.
Polycystic ovary syndrome is commonly associated with
infertility. Aside from the anovulatory disturbances, this
condition is associated with hirsutism, obesity,
d ysfunctional uterine bleeding and endometrial
carcinoma. Investigations reveal elevated LH, normal or
low FSH and slightly elevated testosterone levels. Ovaries
contain multiple follicles arrested at 0.5 to 1.0 em
diameter. Resistant ovary syndrome, which results from
decreased sensitivity to FSH leading to failure of
maturation of primordial follicles, primary ovarian failure
and other ovulatory disorders are potential factors in
infertility . The 'oocyte factor ' 1 or ' reluctant ovum
syndrome' 4 refers to the aging oocyte's reduced capacity
to be fertilized and undergo normal division. Lower
pregnancy rate, higher abortion rate and rising incidence
of fetal chromosomal abnormality is associated with
increasing maternal age.1.4

Disorders of Transport
Impaired function or blockage of the fallopian tubes
have strong associations with pelvic inflammatory disease
(PID), tubal ligation, pelvic surgery, previous ectopic
pregnancy and endometriosis. Tubal factors are relevant
in 12-20% of infertility cases. 4 PID is caused by an
infection of the upper genital tract. Specific sexually
transmitted infections, such as Chlamydia trachomatis or
Neisseria gonorrhoeae are implicated in 60-80% of cases.5
The symptoms include pelvic pain, vaginal discharge,
fever, vomiting and abnormal bleeding. Signs include
cervical motion and adnexal tenderness, palpable mass,
fever, and cervical discharge. Pathology frequently shows
cervicitis, endometritis, pelv ic peritonitis, and, most
relevant to fertility, salpingitis . For each episode of
infection, there is a 10% or greater risk of tubal infertility
and each subsequent infection represents a cumulative
risk. For example, the risk of infertility is 35% with a
second infection and 75% with three or more episodes.5
Damage related to PID accounts for between 20 and 56%
of ectopic pregnancies, which can be a compounding risk
factor for infertility.6
Endometriosis is a common cause of infertility .
Although controversial, estimates of the incidence of
endometriosis among females of infertile couples range
from 20 to 50% and there is clearly a reduced rate of
conception among these women . 7 Even mild
endometriosis may result in reduced fertility by leading to
pelvic adhesions, ovarian or tubal damage. Mechanisms
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proposed for infertility include direct obstruction of the
tubes, prostaglandin-induced tubal dysfunction resulting
in decreased transport capacity, ovulatory dysfunction
and luteinized unruptured follicle syndrome, as well as
cell-mediated immune system alterations and increased
leucocytes in the peritoneal fluid that may alter
conception and implantation.7
Cervical mucus of inadequate quality and quantity or
containing antisperm antibodies may interfere with
mucus-sperm interactions and transport, although this
remains controversial as an isolated factor in infertility.8

Disorders of Implantation
Uterine pathology is a rare cause of infertility.9 Uterine
abnormalities, such as bicornuate uterus or uteru s
subseptus, Asherman's syndrome, intrauterine adhesions
endometrial ossification, leiomyoma and adenomyosis
constitute some of these etiologies. Hormonal disorders
causing decreased endometrial receptivity are other
potential mechanisms resulting in infertility.

Chromosomal Abnormalities
Although not initially presenting with infertility,
phenotypic females with chromosomal abnormalities such
as gonadal dysgenesis, including Turner's syndrome, and
androgen insensitivity, are sterile. Habitual abortion,
recurrent loss of 3 or more pregnancies, is experienced by
0.5 % of the population. Investigations have shown that in
10-20% of these couples one partner will have a
chromosomal abnormality, such as 47,XXX, 47,XXY or a
balanced translocation.10
Of spontaneous abortions occurring in the first 8
weeks of gestation, 50% are due to chromosomal
abnormalities of the fetus. Trisomy, polyploidy and 45,XO
are common karyotypes that may result in lethal
conditions. 10 Many women are not aware of the
pregnancy, and this may be perceived as failure to
conceive.

Behavioural and Psychological Factors
From a careful history , sexual behaviours and
misconceptions can be ascertained. Education regarding
normal pregnancy rates, timing of intercourse, adequate
penetration and drug and alcohol use may be required .
There is some evidence to suggest a delayed rate of
pregnancy among women who smoke. 1 Effects of other
lifestyle issues are less clear.
Psychological factors can have a great impact on
infertility. Whether or not they actually cause infertility is
controversial, but it is clear that they definitely contribute
to it. Questions regarding impotence, premature
ejaculation and decreased libido are important for the
male partner. Female issues include stressful life events,
anorexia nervosa, depression, anxiety, decreased libido
and vaginismus.

Unexplained Infertility
Idiopathic infertility is a diagnosis of exclusion that
applies to patients whose investigations have not revealed
a known etiology . With advances in diagnostic
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techniques, the incidence of infertility that remains
unexplained after appropriate diagnostic investigations
has been declining since the 1950's, when it was reported
at greater than 20% of infertile couples . II Current
estimations of idiopathic infertility range from 10 to
15%. 12•4 Possible etiologies include subtle sperm function
defects, subclinical endocrine abnormalities,
immunological factors and infectionY Without treatment,
there is a reported pregnancy rate of 60% within 3 years,
which evokes the theory that there may be no abnormality
at all, or one that resolves spontaneously. 13

Multifactorial Infertility
Approximately 20% of couples experiencing infertility
are shown to exhibit a combination of factors relating to
their difficulties. 14 Infertility may be attributed to more
than one factor in one partner or a combination of factors
in both partners . Although not addressed in d e tail
throughout this discussion, male factors contributing to
infertility may include disorders such as those listed in
table 2.

Table 2- Etiology of Male Factor Infertility 14
Mechanism

Condition

Endocrine disorder

Hypothalamic dysfunction (Kallmann's
syndrome)
Pituitary failure (tumor, radiation,
surgery)
Hyperprolactinemia
Exogenous androgens
Thyroid disorder
Adrenal hyperplasia

Anatomic disorder

Congenital absence of vas deferens
Obstruction of ejaculatory system

Spermatogenesis
abnormalities

Chromosomal abnormalities
Mumps orchitis
Cryptorchidism
Chemical or radiation exposure
Varicocele

Motility abnormality

Absent cilia (Kartagener's syndrome)
Varicocele
Antibody formation

Sexual d ysfunction

Retrograde ejaculation
Impotence
Decreased libido

DIAGNOSING FEMALE INFERTILITY
Evaluation of a couple's diagnosis of infertility
includes an attempt to determine the probable cause,
education, support, counselling for the couple and a
review of the treatment options. Both partners should
participate in all aspects of the evaluation and decisions
regarding treatment. This allows assessment of the
couple's relationship, level of understanding and ability to
cope. It is also an important indicator of the couple's
support and commitment to each other.
A thorough evaluation of the contributory factors to
infertilitX will reveal a probable cause in 85-90% of
couples . 4 The remaining 10-15% may have multiple
combined causes or a more subtle cause of their infertility
that leaves them with the frustrating diagnos is of
unexplained infertility.

The History and Physical Examination
The history should focus on the factors required for
successful conception. These factors include male and
female determinants. Both partners should be assessed for
factors involved in infertility. Onset, duration and primary
versus secondary infertility should be determined from
the history. The rest of the interview should be composed
of a review of presenting and associated symptoms,
previous obstetrical and gynecological history, including
sexual history, menstrual history, attitudes towards sex,
sexual practices (timing and frequency of intercourse,
method of contraception), general medical and surgical
history, medications and social history (smoking,
nutrition, weight, exercise, drug and alcohol use).
A complete physical examination must be done,
focusing on the signs and physical findings of the causes
of infertility. For example, polycystic ovary syndrome is
associated with hirsutism, acne, obesity, and acanthosis
nigricans. During the pelvic exam, enlarged or nodular
ovaries, uterine or adnexal masses or tenderness and
fixation of pelvic structures may be demonstrated in
relation to specific suspected diagnoses.
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Table 3- Common Tests for the Evaluation of Female Infertility 4
Test
Pregnancy test
CBC, Glucose
TSH
Prolactin
Serum FSH, LH
Testosterone
17-Alpha hydro.,. '1-''I.J);""'terone
Progesterone challenge
Post-coital test
Endometrial Biopsy
Hysterosalpingography
Laparoscopy

Hysteroscopy
Vaginal Ultrasound
Vaginal, cervical swabs

Factor Evaluated
Pregnancy
Underlying medical conditions
Thvroid disorders
Prolactinoma
Polycystic ovarian syndrome
Premature ovarian failure
Polycystic ovarian syndrome
Ovarian tumor
Adrenal hyperplasia
Endogenous estrogen
endometrial Qroliferation
Cervical mucus
Sperm motility
Secretory endometrium
Genital tract anatomy
Tubal patency and anatomy
Endometriosis
Adhesions
Intrauterine abnormalities
Polycystic ovaries
Infection

CBC=Complete Blood Count; FSH=Follicle Stimulating Hormone;
LH=Leuteinizing Hormone
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Investigation of Female Infertility
Aggressive eva luation is indicated in patients
presenting with abnormal uterine bleeding, amenorrhea,
endocrinological symptoms, longstanding infertility or
maternal age over 35 years. Pregnancy should be ruled
out in amenorrheic presentations. Often a suspected
diagnosis will present with the initial history . The
approach is determined by the wishes and availability of
the couple, the cost of the tests and the potential treatment
options. Table 3 summarizes the major tests for evaluation
of infertility and the factors being evaluated.
IMP ACT AND IMPLICATIO NS OF INFERTILITY
Few couples consider infertility until their attempt at
conception fails . In most cases, it is a diagnosis that is
unanticipated and interrupts longterm planning. Many
intense feelings may be associated with the realization
that they may not conceive as planned. Feelings of guilt,
grief, inadequacy and shame tend to dominate initially.
Similar to individuals experiencing death of a loved-one,
couples ma y cope with the diagnosis in progressi ve
stages, including denial, bargaining, anger, grief and
resolution. Anger can be accompanied by frustration, rage
or jealousy and resentment of other couples' successes.14
Dominant beliefs of society worldwide support the
view of parenthood as imperative for " personal
fulfillment, social acceptance, achievement of full adult
s ta tus , religious membership, s exual identity and
psychologic adjustment". 15 There is a social stigma that is
inflicted upon infertile couples for "failing to fulfill a
cultural norm". 16 According to Miall/ 7 orth American
socie ty is procreative and upholds two fundamental
philosophies: that married couples should have children,
and that married couples should want to have children.
Infertile couples can feel a sense of social isolation and a
loss of identity.
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Although some couples report difficulty in
relationships with family and friends, Danulik's 15 studies
suggest that investigation and treatment of infertility may
actually increase the level of trust, intimacy and
com munication percei v ed by the couple in their
relationship. Similarly, sexual satisfaction and functioning
were reported by Danulik 15 not to have been negatively
impacted by the diagnosis, or the investigations. Negative
consequences of investigations, however, have been
reported to be a loss of dignity and privacy.16 Other issues
raised were the impacts of the results of testing. For
example, perhaps the most frustrating diagnosis is that of
unexplained infertility. ot only do cou ples not have a
di sease process to blame, they do not have a specific
treatment plan.
Most couples agree on the importance of feeling free
to express their thoughts, fears, feelings and questions.
Both partners should have access to counseling and
support groups. Insight into feelings and behaviours can
help prevent depression, while strengthening existing
relationships. Many couples are comforted by hearing the
feelings and experiences of others in similar situations and
understanding that the y are not alone . Cou n seling,
s upport and education should be a primary goal of all
infertility eval u ations . There are various resources
available for this purpose (Figure 1).
MANAGEMENT OF FEMALE INFERTILITY
Managemen t of infertility includes medical or surgical
therapy in conjunction with counseling and education.
Choice of treatment options must be evaluated by the
couple and the physician on the basis of the investigation
results, diagnosis, time and effort commitment, treatment
side effects, psychosocial issues, expense, and the couple's
attitudes, experiences and wishes. Table 4 summarizes the
recommended treatments for specific e tiologies of

Figure 1 - Resources available for Support , Counselin g and Patient Information
What resources are available
Support Groups

1. Infertility Awareness Association of Canada (IAAC), Ottawa- Tel: 1-800-263-2929 or (613) 730-1322
2. Infertility Self-Help Support Groups, London- Tel: (519) 668-3895 or (519) 672-7605
3. Infertility Network, Toronto - Tel: (416) 691-3611
4. Gamete Donation Advocacy and Support Group, Toronto- Tel: (416) 762-0103
S.lnfertility/Adoption Helper, Toronto - Tel: (416) 690-9593 Email: helper@helping.com

Web Site
Information

http: / /www.cdnfertility.com/ fertility

Reading Materials 1. Surviving Infertility: A Compassionate Gui de Through the Emotional Crisis of Infertility, by
Linda P. Salzer. New York: Harper Collins, 1991.
2. M aking Babies - A Complete Guide to Fertility and Infertility, by Heather Pullen and Jocelyn
Smith. Toronto: Random House, 1990.
3. The Long-Awaited Stork: A Guide to Parenting Af ter Infertility, by Ellen Glazer. Lexington,
Massachusetts: Lexington Books, 1990.
4. Without Child - Experiencing and Resolving Infertility, by Ellen Glazer and Susan Cooper.
Toronto: 1988.
5. Adopting After Infertility, by Patricia Irwin Johnston. Indianapolis: Perspectives Press, 1992.
6. The Canadian Adoption Guide, by Judith Wine. Toronto: McGraw-Hill Ryerson, 1995.
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infertility and the respective success rates. In addition to
these conventional therapies, advanced techniques,
referred to as assisted reproductive techniques (ARTs),
may be considered. These procedures may be indicated, as
determined by specialists, in such conditions as fallopian
tube damage, endometriosis, cervical factor infertility,
unexplained infertility, male factor infertility and failed
conventional therapies.18

Table 4- Conventional Treatments for Infertility 1
and their respective Success Rates '
Etiology of Infertility
Ovulatory factors

Hyperprolactinemia
Cervical factors

In Vitro Fertilization (IVF)

The current preferred method of in vitro fertilization
and embryo transfer (lVF-ET) requires controlled ovarian
hyperstimulation in order to induce follicle maturation for
maximum potential yield of oocytes. Oocytes are removed
from the ovary, fertilized in vitro, and returned to the
uterus. This technique first resulted in the successful birth
of a child on July 25, 1978, to the credit of the British team
Steptoe and Edwards. 19 Since then, the success rate has
dramatically improved and has gained world-wide
recognition in the management of human infertility. The
pregnancy rate is approximately 20% per embryo transfer
per lVF cycle. 20 To increase the potential for pregnancy,
more than one embryo is transferred, and therefore,
increases the risk of multiple gestations.
Problems with IVF-ET include financial expense,
complications of multiple gestations or ectopic pregnancy, 21
as well as cancellation of cycles due to inadequate
response to stimulation, premature LH surging and
excessive hyperstimulation that promotes oocyte
dysmaturity. Excessive stimulation has been associated
with ovarian hyperstimulation syndrome, characterized
by ascites, pleural effusions, hypercoagulability and pain
secondary to ovarian enlargement.

Gamete Intra-Fallopian Tube Transfer (GIFT)
GIFT is a technology that uses the same techniques as
IVF for hyperstimulation and harvest of oocytes. The
oocytes are combined with capacitated sperm and
replaced in the fallopian tubes for natural fertilization and
development. Reported pregnancy rates of 20-30% per
cycle tend to be slightly higher than those of IVF
techniques, but normal tubal function is required. 20

When to Refer to a Specialist
Consultation by a specialist requires referral by a
family physician, gynecologist or urologist. Family
physicians should instigate initial evaluations. Surgical
treatment and medical therapy beyond administration of
clomiphene, bromocriptine and progesterone require the
expertise of a specialist. In addition, physicians not
comfortable in the role of counselor and educator should
refer their patients to a specialist, social worker,
psychologist or other professional 'trained in this capacity.
Recognition of when to refer is important in order to
minimize anxiety, discomfort and expense, as well as to
maximize potential success.
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Tubal damage
Adhesions
Endometriosis
Unexplained

Treatments
Clomiphene
Gonadotropins
Pulsatile GnRH
Bromocriptine
Estrogen supplementation
Intrauterine insemination
Tubal surgery
Lysis of adhesions
Surgical ablation
Clomiphene
Gonadotropins
Intrauterine insemination

Success Rate
50-90%

N /A
N /A
20-30%
50%
35-60%
3%

GnRH=Gonadotropin Releasing Honnone

The London Program for Treatment of Infertility

The Department of Gynaecology and Reproductive
Medicine at University Hospital Campus of the London
Health Sciences Centre offers numerous services and
programs for the management of infertility. In 1972, the
Therapeutic Donor Insemination program was developed
and since then, boasts more than 1200 pregnancies. The
lVF program was established in 1985 and proudly reports
over 850 births. The year 1993 saw the first baby born
following embryo cryopreservation. Subsequently, in
1994, the most recent addition to this internationally
renown centre became the intracytoplasmic sperm
injection (ICSI) program, for the treatment of male
infertility.
CO NCLUSION
The diagnosis of infertility is a devastating one. It
targets young, otherwise healthy individuals and strikes
without warning. It is important that couples have access
to accurate, updated information and adequate supports
in order to make informed decisions regarding their
futures. Research continues to make advances in the areas
of infertility diagnosis and treatment. These advances
promise better safety and improved success rates.
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THE ROAD AHEAD:
FEMA L E PHYSICIANS AS ROLE MODELS
By Rachel Rodin, MEDS 2000 and Romy Saibil, MEDS 2000

n the first two years of the University of Western
Ontario's medical undergraduate curriculum students
are exposed to a variety of clinical discipline and
professional teaching styles, which influence their choice
of electives and research projects during their early
medical education. Later, during the clinical clerkship,
students base their career decisions partially on the
contact they have had with clinicians from the various
specialties. Exposure to women physicians at both of these
stages is minimal, and female role models within
academic medicine (particularly at the senior level) are
lacking. Consequently, most students' vision of their
career forms without the inspiration and support of
female leaders. The lack of female lecturers and clinical
teachers reflects a marginal representation of women
across the board in the Faculty of Medicine and Dentistry
(Table 1).
As third year students we recently completed the inclass component of our training. We found exposure to
women physicians to be minimal. The picture for the next
two years of our education recapitulates that of the first
two years: a dearth of female physicians as role models
and mentors. While there is a high degree of female
representation in the planning of the new curriculum, the
outlook for first year students is not likely to vary from
our experience . Course coordinators can only elect
lecturers from the fund of women academics that exists at
Western-a fund which is limited and increasingly
overburdened.1.2
The medical school at UWO has 17 women who are
Full Professors. This follows the pattern of other major
medical schools in North America, which ha e, on
average, sixteen female full professors of clinical and basic
sciences. 3 At Western this figure compares to 259 full
professors who are men. At the senior academic level of
UWO, there is an eight to one ratio of males to females; at
the junior academic level, the ratio of men to women is
three to one (See Table II). If the junior faculty progresses
as expected along the academic path, the representation of
women at the senior faculty level should eventually
approach three:one as well. Unfortunately, research has
shown that female physicians often fail to advance at the
same rate as male physicians within academia. In a report

I

by Dickstein, it took an average of 20 years for women to
advance to the position of full professor while for men, it
took only 12 years. 4 Similarly, a national U.S. study by
Tesch demonstrated that, women are not as likely as men
to attain the position of associate professor or full
professor after approximately eleven years of faculty
service. 5 Even after adjustments were made within the
study to account for the fact that women reported less
academic productivity with respect to hours worked,
articles published, and grants received they were still
substantially less likely to be promoted than men. 5 Relying
on the slow movement of Western's junior academics up
into the senior ranks may therefore not be the best
solution to improving the representation of women on the
Faculty. If junior women are not yet qualified for specific
senior positions, which become available, an active effort
should be made by recruiters to encourage applications
Table 1-FEMALE vs. MALE REPRESENTATION IN MEDICINEAT UWO
Specialty
Male FetHie
IS
a. Anaesthesia
53
b. Neurological Sciences
34
7
c. Radiology & Nuc. Med.
64
9
d. Family Medicine
115
52
e. Medicine
160
26
f. Obstetrics & Gynecology 41
4
g. Oncology
28
8
h. Anatomy & Cell Biology 19
3
i. Epidemiology & Statistics 21
12
19
j. Pharmacology & Tox.
2

Specialty
Male ftMie
k. Ophthalmology
0
18
I. Otolaryngology
16
0
27
m. Paediatrics
so
n. Pathology
12
24
o. Psychiatry
108
32
p. Surgery
77
s
q. Physical Medicine
9
2
r. Biochemistry
34
s
s. Micro. & lmmuno. 37
5
I. Physiology
4
33

from qualified women at other institutions. There is,
however, a general consensus among members of the
Gender Issues Committee and Dr. McMurtry, the Dean of
Medicine and Dentistry, that this type of an affirmati ve
action program at UWO would not benefit the status of
women. If appointed in association with an affirmative
action program, a woman may not be viewed as having
earned a "right" to her position; in this way, her authority
in the position may be undermined, as may be her ability
to gamer collegial support. 2•6
T6 2• fBMll vs. MALE REPRfSENJAmN AT 1115810R 101181«. LEVB. (I UWO
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Positio1
Senior Faculty
(full and Associate Professors)
Junior Faculty
(Assistant professors, Lecturers and Instructors)

Male
370

281

97
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A number of reasons have been presented to explain
the under-representation of women in academic medicine.
First and foremost is the issue of choice. Many women do
not choose a career in academic medicine because of the
demands on their time and quality of life. It is important
to note that women physicians' choices are made from a
limited set of opportunities?
To root the rationale for Western's statistics solely in
women's individual choices, attitudes, and productivity
would be implying that education, recruitment and
promotion systems are always fair and based on merit
alone. As has been suggested by Dr. Nicole LeRiche,
Director of Admissions, and Chair of the Medicine
Admissions Committee, oftentimes a faculty selection
committee identifies "merit" based on an outdated model
crafted by men. Further, it is by and large men who sit on
the election committees at Western. For example, there
are currently two active selection committees . The
Oncology committee consists of nine men and two women
and the Physical Medicine and Rehabilitation committee is
composed of twelve men and no women.
In addition to accepting the need for a new definition
of merit, we would do well to recognize that medicine is
not a meritocracy and never has been. Choices for
promotion and hiring are based on personality, gender,
values, age, and sociocultural similarity to the inner circle
of the specialty, the so-called "locker-room advantage."
Similarity of a candidate's traits to those of the dominant
group are perceived to create the most trustworthy
colleague. 7
Since early in his term Dean McMurtry has strongly
advocated recruiting and promoting female staff. He has
also supported the activities of the Gender Issues
Committee (GIC) . The GIC is a committee primarily
concerned with policy and education issues related to
gender. A budget exists for promoting and helping with
activities of the GIC, but it has not been fully utilized in
the past.6 Other initiatives from the Dean's office have
included : the encouragement of physicians with sick
children to remain at home with them; the abolishment of
meetings held outside of work hours; and the recent
establishment of job sharing. Once the opportunity to job
share becomes widely known it will allow for careers in
highly demanding specialties to become more feasible for
women.
Belle Potts, the resource person for the GIC and
Counselor / Coordinator for the office of Student and
Equity Affairs, recounted two ways in which the GIC has
been active in the Faculty selection process. First, the GIC
developed a list of questions designed to assess all
candidates' sensitivity to gender issues. These questions
were given to the selection committee members who were
to interview candidates . Second, Dean McMurtry
requested that a member of the GIC sit on every selection
committee. 1 This GIC representation has proven difficult
due to the fact that the number of selection committees
frequently exceeds the number of GIC members . In
addition, members of the GIC are stressed by other clinical
and academic responsibilities. At some Canadian medical
schools, such as the University of Ottawa, there is a faculty
member who is appointed as Dean of Equity. Western's
Faculty would also benefit from the appointment of a
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person whose unique mandate is gender issues.
Working with selection committees to improve the
hiring and promotions process is only one way of opening
more doors to women in medicine. At the same time, the
Faculty of Medicine and Dentistry should actively
encourage contact between female faculty and medical
students as it is vital to the way in which young women
perceive their roles in medicine. Better contact can be
achieved through increased involvement of women in
clinical teaching and through mentoring. Little research
has been done on the possible impact of increasing the
exposure of women students to women consultants in the
early years of medical training. On the other hand ,
mentoring has been a topic of discussion in the literature
and there is evidence for its efficacy.
Mentors are those individuals who have been ahead of
u s on a given career, social or personal path .
Consequently, they are able to act as guides on that path;
they encourage, point out obstacles, reveal secret short
cuts, and introduce one to fellow travelers. Overall,
mentors can smooth the way for a newcomer and build a
ense of belonging. In particular, mentors may be helpful
to women because studies have illustrated that men and
women approach career development differently. Lorber
uggests that "Men are likely to have a sponsor during
training and to fall into serendipitous training
opportunities. Women tend to pattern themselves after
role models, who give only indirect guidance, rather than
active help." 7
Finding female mentors at Western may be a difficult
for some students, due to the lack of exposure to female
consultants on the lecture circuit and due to the limited
numbers of women in leadership and chair positions.
Historically, mentor-student relationships have been
underutilized by women often owing to the complications
of mixed-sex mentoring.8 In spite of the difficulties with
mixed-sex mentoring, it is important that it continues.
Mentor groups have been set up at the University of
Western Ontario wherein a faculty member is grouped
with several students from each year of medical school.
Together they form a "mentor group". The mentor group
does not always, however, provide one to one contact with
a physician in a student's discipline of interest. An
informal mentor group has also been set up among female
consultants and residents in Paediatrics. The Organization
for Medical Gender Awareness (OMEGA) was created in
1995 and has now been changed to the Medical Education
for Societal Awareness group (OMESA); this group of
undergraduate medical students also sets up programs
which bring female physicians into contact with female
medical students. All of these programs are set up to
facilitate mentoring.
Without a past degree, or personal connec tions,
students have their lectures, small groups, and career
nights on which to base their early decisions regarding
with whom to spend valuable elective and research hours.
The question arises as to whether female students will
view certain fields, and academic medicine itself, as a
realistic choice when so few women are present in the
cla room as well as the hospital teaching environment.
For instance, there were no female lecturers in the entire
second year Surgery block. It is difficult to imagine that
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this absence of female physicians would not have impact
on students, particularly female students in search of role
models.
Under-representation of female faculty at the lecturing
and clinical teaching levels, creates a paucity of women
role models for both female and male students. Although
the goal of this article has not been to evaluate career
choices and placement for residency training, our
contention is that a lack of female role models may be
discouraging to undergraduate female medical students.
Women's concept of their role in medicine crystallizes in a
relative vacuum of female leadership. It would be naive to
sugges t that networking exists less in the medical
profession than anywhere else. Thus, if advantages accrue
in medicine they begin at the undergraduate level and
blossom exponentially. This complex process of
accumulated advantages and disadvantages underscores
the importance of exposing medical school classes to both
male and female professors.
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Sh a r 1• n g lnformat •I 0 n WI• t h Young
Girls

and

Medica l Stud en ts
Menstruation

about

By jessica Baugniet, Lisa Calder, Kim Moore, Kathleen van Hooren, Susan Woo/house, Melissa Yuan-Innes, MEDS 2000
his project on menstrual education has distant
beginnings in the personal experiences of two of the
authors. In their high school years, they formed a
group with other young women to share their menstrual
experiences and attempt to remove the secrecy that
enshrouds the subject. A consensus was reached that
many women and men seemed to have a very negative
perception of menstruation in general. Four years later,
the two authors introduced these ideas to a group of
women in their first year medicine class at UWO. The
group's enthusiasm for these ideas developed into an
opportunity to do an honours PBL project, entitled
" Sharing Information with Young Girls about
Menstruation".
The overall aim of our project was to communicate the
experience, as well as the sociocultural and biological
meanings of menstruation through the use of an
integrated approach that embodied personal and
collective experiences, comfort with self, empowerment
and autonomy 1 • We addressed this objective in three
ways: evaluation of current menstrual education and local
resources for young girls; creation of a workshop for
y oung girls about menstruation; and creation of a
workshop for medical students about menstruation.

T

By examining available public resources as well as the
current public school curriculum and its implementation,
we were able to obtain a comprehensive picture of
menstrual education of young girls in London. While
teachers and public health nurses work hard at enacting
the curriculum, there remain the powerful influences of
media and the subtle effects of culture which engender a
negative attitude towards the menstrual experience. Thus,
we concluded there was room for a positive, womanfriendly approach to teaching menstruation beyond the
traditional biological perspective. The reviewed research
supported that young girls need positive, practical
information on menstruation and, in fact, it has been
shown that increased knowledge is correlated with a
positive menarcheal experience2 • Physicians and teachers
alike were supportive of this approach and recognized the
need. Our report also indicated that future physicians are
not made aware of menstrual issues beyond biology
through the UWO Faculty of Medicine curriculum. We
concluded that heightening the sensitivity and awareness
in these areas was in the best interest of all members of
an y health partnership . Based on the findings, we
proposed innovative workshops for both young girls and
medical students.

THE EVALUATIO N PHASE

THE MENSTRUAL WO RKSHOP FOR YOUNG G IRLS

We devoted the first year of our project to the
evaluation of current menstrual education and resources
for young girls. To accomplish this, we took a variety of
approaches, beginning with a survey of the resources
available at the London Public Library and a review of the
London Board of Education elementary school
curriculum. We followed this with interviews with local
schoolteachers regarding their views on menstrual
education. We investigated available resources and
programs offered through the London-Middlesex Health
Unit in addition to interviewing local family physicians
and a child psychiatrist regarding their approach to the
topic of menstruation with young girls in their medical
practices. Finally, we consulted the academic literature
about the psychological framework of menstruation, the
social context, and the cultural issues surrounding
menstruation.

In the second year of the project, we divided into two
groups to tackle the further development and
implementation of each workshop. The purpose of the
interactive educational session for young girls was to
communicate the integrated experience, sociocultural
meaning, and biological meaning of menstruation in a
positive, woman-friendly manner. Acting upon the
suggestion of a community member, we contacted the
Children's Aid Society (CAS) as a potential pilot group for
the workshop. Laverne Foran, social worker at the CAS,
recommended the "Pre-Teen Group", a counseling group
for 11-13 year old girls who have been the victims of
sexual abuse. While we were initially hesitant to
undertake the workshop with a group of girls having a
complex array of additional issues, after several
discussions and the encouragement from the CAS, we
decided to pursue the proposal. With the support of CAS,
we intentionally did not alter the workshop to address the
issues of sexual abuse; rather, we created a picture of
menstruation as a normal, healthy process in every young
woman's life.
We conducted the workshop over two evenings with
seven girls from the previously mentioned Pre-Teen
Group and the CAS Pre-Teen Group coordinators. On the
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first evening, we asked each girl to create and present to
the group a paper collage from provided maga zine
materials depicting what menstruation meant to her. It
was an excellent ac tivity to promote discussion of a
commonly silenced topic. This led into an interactive
discussion in which the girls identified the changes of
puber ty and subsequently added these changes to a
feltboard model of a pre-teen girl. Through the discussion
of secondary sex characteristic development and th e
biology of mens truation, this activity demonstrated
several misconceptions held by the girls in the group. In
fact, extra time was required to complete this activity in
order to provide the girls wi th correct informa tion
regarding the process of p uberty and menstruation. With
the knowledge base reinforced, we then discussed the
practical issues of the experience of menstruation such as
how a girl's period looks, feels, and smells.
On the second evening, we addressed many questions
from the previous session. Then we circulated a series of
menstrual supplies inclu ding pads and tampons for th e
girls to examine. A step-by-step interactive demonstration
was used for both pad and tampon use. This was followed
by the viewing of a video in which the presenters were
shown entering a drugstore and purchasing menstrual
products . While the opportunity to ask anonymous
questions had been provided, the girls felt comfortable
enough to ask them outright. The session was concluded
b y handing o ut a pamphlet that contained some
frequently asked questions abou t menstruation (Table 1).
After the worksh op was completed, the presenters
met with the CAS social workers for feedback . It was
noted that initially many girls seemed reluctant to discuss
menstruation in a group setting but tha t their comfort
level visibly changed after they p ut together their collages.
The openness and level of honesty of the presenta tion
seemed respected by the girls in the group and enhanced
the educational experience. In particular, the fact that
misconceptions about the physiology of menstrua tion
were revealed and dealt with was very helpful. The social
workers felt that having the pads and tampons available
for the girls to look at and touch helped prepare them for
their menstrual experiences. Another interesting finding in
the workshop was that many girls were unaware that they
could speak to their physicians about menstruation and
the encouragement of this dialogue seemed effective. The
girls write in journals after every session and the social
workers indicated that the entries reflected a valuable
workshop . The social workers were pleased wi th the
success of the works h op and expressed in teres t in
incorpora ting this kind of workshop into th eir regular
program. We are cu rren tly working with members of
Meds 2001 to bring this abou t for the 1999 spring session.
THE MENSTRUAL WORKSHOP FOR MEDICAL
STUDENTS

Table 1 -MENSTRUATION PAMPHLET FOR YOUNG GIRLS

Beginning to menstruate, or having your first period, is a natural event which
women experience. It may seem scary, as it involves changes in your body, but
knowing the facts con help you feel in control during this time of change.

Wlte• will I get my period?
Young women start menstruating at different ages, although many young
women hove their first period between the ages of eleven and fourteen. It's
normolthot some will hove their first periods earlier or Iuter. If you ore
concerned about your liming, you con ask your doctor.
Wht do periods feel like?
While some women ore unaware thotthey are having their periods, others may
feel a bit of blood leaving their vaginas. Women may feel cramps in their lower
stomachs. These cramps con often be relieved by exercising, having a hot both,
or using a hat water banle.
How muciJ blood is lost?
Not us much as it may look or feel like! Most women lose about o half a cup of
blood.
Wltat ltappens Hyou get your period at scllool?
It's a good ideo to keep a pad or tampon in your desk and bog in case of on
emergency. Your teacher or the office will hove supplies, if you hove run out or
don 't hove money to buy them . It's perfectly normal to hove very
unpredictable periods early on -so be prepared!!
Does it mean I am dirty wlten I menstr1111te?
Absolutely not!! Menstruation is o not o dirty process. As long os you keep up
with your normal doily hygiene (showering, changing pods every 4-6 hours
etc.) there should be no strong odour. Alinle odour, however, is normal. You
don't need to use deodorant pods or tampons because they can cause rushes.
Wlto can use tampons? Are tltey safe?
All girls con use tampons, but many wait until they ore o bit older because
using them tokes prodice. Remember, tampons cannot get lost or pushed up
too for. It is impartontto change o tampon every 4-6 hours because there is o
rare disease called Toxic Shock Syndrome that is associated with leaving
tampons in too long. Tampons ore useful because you con wear swimsuits and
swim while using one. You do not need to be sexually odive to use a tampon.
Wltat is P.M.S.?
P.M.S. or uPremenstruol Syndrome* is o mood change experienced by some
young women just before they get their period. Some women feel happy,
hungry, o bit sod, or just different. After lime, you will start to figure out what
is normal for you, and you con letthot feeling be okay.

If I ltave been abused, will tltat aHect my periods?
Abuse con be o very complicated issue - we encourage you to speak to your
doctor if you ore or hove been abused. They will hove information and
resources ovoiloble to help you.

We decided to create a workshop for medical students
because we believed it was important to address the
physician ' s role in educating young girls abou t
mens truation . When reviewing the literat u re , we
discovered several articles disc ussing the benefits of
menstrual education in terms of the impact on a young
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girl's menstrual experiences. Studies2 have shown that an
increase in knowledge about menstruation will decrease
the stress and trauma at menarche, a developmental
milestone in the lives of young girls. Several surveys3 have
demonstrated that girls and boys can develop negative
views about menstruation at quite a young age. Even
more disturbing is the fact that early menarche can serve
as a roufh predictor for increased risk fo~ eating
disorders . This seemed to reinforce the fact that grrls need
support and positive reinforcement from their physicians
about the facts of menstruation and the normality of the
experience.
The medical students' workshop was designed to
heighten their awareness of menstruation as it presents in
clinical practice with attention to the emotional, social and
cultural contexts of menstruation. The workshop began
with a case that included issues such as early menarche,
exercising during menstruation, menstrual product
options and body image. The students were asked_to
identify issues in the case and suggest ways of addressmg
them. After this opening discussion, we outlined the scope
of the honours PBL project and then cited some of the
findings from our search of the literature. We discussed
the psychological framework of the adolescent girl and the
complexities that formed the foundation for menarcheal
and menstrual experiences . The social context of
menstruation was reviewed in terms of the media's
presentation of menstruation in adv~rtising and co~on
social myths. A collage of advertisements depleting
various menstrual products was circulated to illustrate the
common themes of: ideals of femininity, the promotion of
cleanliness and conversely dirtiness of menstruation.
We also mentioned some of the cultural and religious
contexts of menstruation and how they can impact upon
women's experiences. An example is the orthodox Jewish
tradition of a ceremonial cleansing bath, the Mikvah. In
addition we elicited from the students some of the myths
they had heard about menstruation such as women not
being able to swim during their periods. We also spent
so me time talking about girls who undergo early
menarche, experience dysmenorrhea or premenstrual
syndrome symptoms. The session was concluded by a
summary of what girls need to know about menstruation
from their physicians (Table 2) . At the end of the
workshop, we handed out the same pamphlet that the
young girls received so that the medical students could
use it as a reference for their patients.
We received a lot of positive feedback from the
medical students in Meds 2000 and Meds 2001 who
attended the workshop. In particular, the male medical
students seemed to feel it was particularly beneficial to
learn about some of the practical issues surrounding
menstruation . They believed this would help them feel
more comfortable talking to their female patients about
menstruation. In the evaluation phase of our project, Dr.
Barbara Lent, a family physician at the Victoria Medical
Center, approached us about presenting the medical
student workshop with family medicine residents. During
one of the noon hour Family Medicine rounds at Victoria
Medical Center, we presented the workshop and it was
well received with active participation and discussion.
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Table 2
What girls need to know about menstruation fr0111 their physicians

• Menstrual physiology
• Menstrual hygiene
• The normality of menstruation - it must be distinguished from disease,
injury, and uncleanliness
• Feelings of fright and embarrassment girls experience at menarche must be
acknowledged as normal
• Negative aspects of menstruation (eg. PMS, menstrual cramps, inconvenience)
need to be discussed inorder to provide a balanced view
• Girls need support and reassurance at the lime of menarche
• Families need to be prepared to be informed, understanding, and accepting
• It is important to find out where girls hove obtained their information about
menstruation and question the accuracy of the source if necessary

CO NCLUSION
For an idea that began as a high school experience,
" Sharing Information with Young Girls about
Menstruation" expanded into a project that encompassed a
wide range of issues. There is evidence to support the
impact of educational intervention on a girl's menstrual
experiences. Armed with this information, we were able to
develop an innovative workshop that had a positive
impact on a group of young girls. Furthermore, we were
able to encourage future physicians to engage in similar
interactive discussions with their young patients. Given
that the non-biological issues of menstruation are often
overlooked in medicine, it is our hope that with this project
and this article we may give more health care providers
reason to consider them more carefully in their patients.
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4. Synthroid, like all medicines obtained from your doctor. must be used only by you and for the condition
determined appropriate by your doctor.
5. H may take a few weeks for Synthroid to begin worl<ing. Unlit ~ begins worl<ing, you may not notice any
change in your symptoms.
6. You should notify your doctor ~ you experience any of the following symptoms. or ~ you experience any
other unusual medical event chest pain. shortness of breath, hives or skin rash, rapid or irregular heartbeaL
headache, irritability, neiVOusness. sleeplessness, diarrhea, excessive sweating, heat intolerance, changes in
appetite, vomiting, weight gain or Joss. changes in menstrual periods, fever, hand tremors, leg aamps.
7. You should inform your doctor or dentist that you are taking Synthroid before having any kind of surgery.
8. You should notity your doctor~ you become pregnant while taking Synthroid. Your dose ol this medicine
will r ly have to be increased while you are pregnant
9. Hyou have diabetes, your dose of insulin or oral antidiabetic agent may need to be changed after starting
Synthroid. You should mon~or your blood or urinary glucose levels as directed by your doctor and report any
changes to your doctor immedia1ely.
10. Hyou are taking an oral anticoagulant drug such as wartam. your dose may need to be chqed after starting
Synthroid. Your coagulation status should be checked often to determine ~ a change in dose is required.
11 . Partial hair loss may occur rarely during the first Jew months of Synthroid therapy, but I is usualy lempolary.
12. Synthroid is the trade name for tablets containing the thyroid hormone levothyroxine sodium, manufactured by Knoll Pharma Inc. Other manufacturers also make tablets containing Jevothyroxine. Ne~r you
nor your pharmacist should change to another manufacturer's product without discussing that change with
your doctor first Repeat blood tests and a change in the amount of levothyroxine you take may be required.
13. Keep Synthroid out of the reach of children. Store Synthroid away from heal light and moisture.
Llboralory Tills:
Treatment of patients with Synthroid requires periodic assessment of thyroid status by appropriate laboratory
tests and clinical ewlualion. Selection of appropriate tests for the diagnosis and management of thyroid disorders
depends on patient variables such as presenting signs and symptoms, pregnancy, and concom~t
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medications. A combination of sens~ive TSH assay and free T4 estimate (free T4 index, FT4 I} are recommended to confirm a diagnosis of thyroid disease. Normal ranges for these parameters are age-specifoc in
newborns and younger children.
TSH alone or in~ may be useful for thyroid disease screening and for mon~oring therapy for primary
hypothyroidism as a ftnear inverse correlation exists between serum TSH and free T4• Measurement of total
serum T4 and T3, resin T3 uptake, and free T3 concentrations may also be useful. Antithyroid microsomal
antibodies are an indicator of autoimmune thyroid disease. P - microsomal antibody presence in an
euthyroid patient is a major risk factor for the development of hypothyroidism. An elevated serum TSH in the
presence of a normal T4 may indicate subclinical hypothyroidism. Intracellular resistance to thyroid hormone
is quite rare, and is suggested by clinical signs and symptoms of hypothyroidism in the presence of high
serum T4 levels. Adequacy of Synthroid therapy for hypothyroidism of pitu~ or hypothalamic origin
should be assessed by measuring free T4, which should be maintained in the upper hall of the normal range.
Measurement of TSH is not a reliable indicator of response to therapy for this condition. Adequacy of
Synlhroid therapy for congen~ and acquired pediatric hypothyroidism should be assessed by measuring
serum total T4 or free T4; these should be maintained in the upper haH of the normal range. In congen~l
hypothyroidism, serum TSH normalization may lag behind serum T4 normalization by 2 to 3 months or
Jonoer. In rare patients, serum TSH remains relatively elevated des~e clinical euthyroidism and age-specifoc
normal T4 or tree T, levels. (See Po4illrlc

- ->

11n11 Jmrocti-:
The ma{.tlitude and relative dinical importance of the effects noted below are likely to be patient-specific and may
vary by such factors as age, gender, race, interrurrent illnesses, dose of either agents, add~ concomitant
medications, and timing of drug administration. Ant agent that alters thyroid hormone synthesis, secretion. distribution. effect on tarvet tissues, metabolism, or eliminalion may alter the optimal therapeutic dose of Synthroid.
Levolflyroidne sodium absorption - The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydroxide, cholestyramine resin. colestipol
hydrochloride. ferrous sulfate, sodium polystyrene suHonate. soybean nour (e.g., infant formula}, sucralfate.
Binding to serum proteins- The following agents may e~r in hiM Jevothyroxine sodium binding to serum
proteins or atter the concentrations of serum binding proteins: androgens and related anaboiic hormones.
asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorou~ . furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone. perphenazine, phenylbutazone, phenytoin.
salicylates, tamomen.
Thyroid physiology- The following agents may atter thyroid hormone or TSH levels, generaly by effects on
thyroid hormone synthesis. secretion, distribution, metabolism, hormone action, or elimination, or attered TSH
secretion: arninoglutethimide. p-arninosalicylic acid. arniodarone. androgens and related anabolic hormones,
complex anions (thiocyanate, perchlorate, pertechnetate}, antithyroid drugs, &-adrenergic blodcing agents,
carbamazepine, chloral hydrate. diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids.
heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodinH:ontaining compounds.
levodopa. lovastatin, lithium. 6-mercaptopurine, metodopramide, mftotane, nitroprusside, phenobarbital,
phenytoin, resorcinol, rifampin, somatostatin analogs, suHonarnides, suHonytureas, thiazide diuretics.
AdrenOCQfticoids - Metaboiic clearance of adrenocorticoids is decreased in hypothyroid patients and
increased in hyperthyroid patients. and may therefore change with changing thyroid status.
Amiot/arone- Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.
AntX:oagu/ants {Dr.ll}- The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently
by increased catabolism of vitamin K-dependent clotting factors.
Antidiabetk; agents (IIISUiin, sulfonylureas) - Requirements for insulin or oral antidiabetic agents may be
reduced in hypothyroid patients with diabetes menitus. and may subsequently increase with the initiation of
thyroid hormone replacement therapy.
8-adrenergir: bloc/ring agents - Actions of some beta-blocking agents may be impaired when hypothyroid
patients become euthyroid.
Cyto/cines (interferon, interleulcin) - Cytokines have been reported to induce bolh hyperthyroidism and
hypothyroidism.
Di{Jilalis g/yoosides- Therapeutic effects of dig~lis glycosides may be reduced. Serum dig~lis levels may
be decreased in hyperthyroidism or when a hypothyroid patient becomes euthyroid.
~tJmine - Mar'<ed hypertension and tachycardia have been reported in association with concom~nt
administration of levothyroxine sodium and ketJmine.
Maprotiline- Risk of cardiac arrhythmias may increase.
Sodium iodide {'131 and "' 1). sodium pertechnetate Tc99m - Uptake of radio labeled ions may be
decreased.
Somatremlsomatropin- Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.
Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin.
Tlreophyfline - Theophytline clearance may decrease in hypothyroid patients and returns toward normal
when the euthyroid state is achieved .
Tricyclic antidepressants- Concurrent use may increase the therapeutic and toxic effects of both drugs,
possibly due to increased catecholamine sen~ivity. Onset of action of tricyclics may be accelerated.
Sympathornimetk; agents - Possible increased risk of coronary insuffiCiency in patients with coronary
artery disease.
LIMIItary Tnt hotellctl-:
A number of drugs or moieties are known to atter serum levels of TSH, T4 and T3 and may thereby influence
the interpretation of laboratory tests ol thyroid function (see Drv1 llllelldioos}.
1. Changes in TBG concentration should be taken into consideration when interpreting T4 and T3 values.
Drugs such as estrogens and estrogen-containing oral contraceptives increase serum TBG concentrations.
TBG concentrations may also be increased during pregnancy and in infectious hepatitis. Decreases in TBG
concentrations are observed in nephrosis, acromegaly, and after androgen or corticosteroid therapy. Famiial
hyper- or hypo-thyroxine-binding- globulinemias have been described. The incidence of TBG defiCiency is
approximately 1 in 9000. Certain drugs such as salicylates in hiM the protein-binding of T, . In such cases.
the unbound (free} hormone should be measured. Altematively, an indirect measure of free thyroxine, such
as the FT4 1, may be used.
2. Medicinal or dietary iodine interferes with in.m!llests of radioiodine uptake, producing low uptakes
which may not indicate a true decrease in hormone synthesis.
3. Persistent clinical and laboratory evidence of hypothyroidism despfte an adequate replacement dose
suggests either poor patient compftance, impaired absorption, drug interactions, or decreased potency of the
preparation due to improper storage.
CIRiiiOIJeoesls, Mm.-Js, llllillll)lllrment ol flrtllily:
Although animal studies to determine the mutagenic or carcinogeniC potential of thyroid hormones have not
been performed, synthetic T4 is identical to that produced by the human thyroid gland. A reported association between prolonged thyroid hormone therapy and breast cancer has not been confirmed and patients
receiving Synthroid for established indications should not discontinue therapy.
Prquecy:
Studies in pregnant women have not shown that Synthroid increases the risk of fetal abnormaities ~ administered
during pregnancy. H Synthroid is used during pregnancy, the possibility of fetal harm appears remote. Because
studies cannot rule out the possibility ol harm, Synthroid should be used during pregnancy only ~ cJearJy needed.
Thyroid hormones cross the placental barrier to some extent T4 levels in the cord blood of athyroid fetuses
have been shown to be about one-third of maternal levels. Nevertheless. maternal-fetal transfer ol T4 may
not prevent in...Jilml hypothyroidism.
Hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous
abortion and preeclampsia. and has been reported to have an adverse effect on fetal and childhood development.
On the basis of current knowledge, Synthroid should therefore not be discontinued during pregnancy, and
hypothyroidism diagnosed during pregnancy should be treated. Studies have shown that during pregnancy T4
coucentratious may decrease and lSH coocentratioos may increase to values outside normal ranges.
Postpartum values are sinD to preconception values. 8evalions in lSH may occur as early as 4 weells gestation.
Pregnant women who are maintained on Synthroid should have their TSH measured periodically. An
elevated TSH should be corrected by an increase in Synthroid dose. After pregnancy, the dose can be
decreased to the optimal preconception dose.
Norslng-rs:
Minimal amounts of thyroid hormones are excreted in human mi It Thyroid hormones are not associated
with serious advl!rse reactions and do not have known tumorigenic potential. While caution should be exercised when Synthroid is administered to a nursing woman. adequate replacement doses of Jevothyroxine
sodium are generally needed to maintain normal lactation.
PHillric Use:
Conoen~l hypothyrpidism: Rapid restoration of normal serum T4 concentrations ;s essential to prevent dele-

tenous neonatal thyroid hormone deficiency effects on inteligence, 0\lml growth, and development Treatment
should be initiated immediately upon diagnosis and geoeraly mairtained for life. The ther3peutic goal is to
maintain serum total T4 or FT4 in the upper half of the normal ranoe and serum TSH in the normal ranoe.
All initial starting dose of 10 to t5 mcoJkglday (ages ~3 months) will generally increase serum T4
coocentrations to the upper half of the normal ranoe in less than 3 weeks. Clinical assessment ol growth,
developmenL and thyroid status should be monnored frequently. In most cases, the Synthroid dose per
body weight wiN decrease as the patient grows through infancy and childhood (see DOSAGE AltO
ADMINISTRATION, Ptollllric D_,e, Tablo1 ). Prolonged use of large doses in infants may be associated
with temperament problems. which appear to be transient.
Thyroid function tests (serum total T4 or FT4, and TSH) should be monitored dosely and used to determine
the adequacy of Synthroid therapy. Serum T4 normalizalion is usualy lolowed by a rapid declile in TSH.
Nevertheless. TSH normalizalion may lag behind T normalization by 2 to 3 months or klnger. The relative serum
TSH elevation is more mar1<ed in the eartt ~ but can persist to some degree throughout life. In rare
patients TSH remains relatively elevated despite clirical euthyroidism and age-specific normal total T4 or FT4
IM!s. Increasing the Synthroid dosage to suppress TSH into the normal ranoe may produce overtreatmeot. with
an elevated serum T4 and clinical features of hyperthyroidism including: irritability. increased appetite with
diantlea. and sleeplessness. Another risk of prolonged overtreatmeot in infants is premature cranial synostosis.
Hypothyroidism permanence may be assessed wllen transient hypothyroidism is suspected. Levolhyroxine
therapy may be interrupted for 30 days after three years of age and serum T4 and TSH measured. Low T4 and
elevated TSH confirms permanent hypothyroidism; therapy should be re- instituted. nT4 and TSH remain in
the normal ranoe. a presumptive diagnosis of transient hypothyroidism can be made. In this instance,
continued clinical monnoring and periodic thyroid fln:lion test reevaluation may be warranted.
Acou red hyogt!Mojdjsm: The initial Synthroid dose varies with age and body weighL and should be
adjusted to maintain serum total T4 or free T4 1evels in the upper half of the normal ranoe. In general, unless
there are overriding cinical coocerns. children should be started on a tun replacement dose. Children with
underlying heart disease should be started at lower dosages. with careful upward titration. Children with
severe, longstanding hypothyroidism may also be started on a lower initial dose 1 - by an upward
titration, attempting to avoid premature epiphyseal closure. The recommended dose per body weight
decreases with age (see DOSAGE AIID ADMINISTRATION, Pediatric Dosage, Table 1).
Treated children may resume growth at a greater than normal rat! (period of transient catch-up growth).
In some cases the catch-up may be adequate to normalize growth. However, severe and prolonged hypothyroidism may reduce adutt height. Excessive thyroxine replacement may initiate accelerated bone
maturalion, producing disproportionate skeletal age advancement and shortened adutt stature.
Hypothyroidism permanence may assessed when transient hypothyroidism is suspected. Levothyroxine
therapy may be interrupted for 30 days and serum T4 and TSH measured. Low T4 and elevated TSH
confirms permanent hypothyroidism; therapy should be re-instituted. n T4 and TSH remain in the normal
ranoe. a presumptive diagnosis of transient hypothyroidism can be made. In this instance, continued
clinical monnoring and periodic thyroid function test reevaluation may be warranted.
ADVERSE REACTIONS
Adverse reactJons other than those indicative of thyrotoXICOSIS as a resutt of therapeutic overdosage, enher
innially or during the maintenance periods. are rare (see SYMPTOMS AltO TREATMENT OF OVERDOSAGE).
Craniosynostosis has been associated with iatrogenic hyperthyroidism in infants receiYing thyroid hormone
replacement therapy. Inadequate doses of Synthroid (levothyroxine sodium) may produce or fa~ to resoiYe
symptoms of hypothyroidism. Hypersensitivity reactions to the product excipients, such as rash and
urticaria. may occur. Partial hair loss may occur dumg the initial months of therapy, but is generally transient.
The incidence of continued hair loss is unknown. Pseudotumour cerebri has been reported in pediatric
patients receiving thyroid hormone replacement therapy.
DOSAGE AltO ADMINISTRATION
The dosage and rate of administration of Synthroid (Levothyroxine sodium) is determined by the indication.
and must in Mry case be individualized according to patient response and laboratory findings.
M1K Dosage:
Hmqtltmjdjsm:
The goal of therapy for primary hypothyroidism is to achieve and maintain a cinical and biochemical euthyroid
state with consequent resolution of hypothyroid signs and symptoms. The starting dose of Synthroid, the
frequency of dose tHration, and the optimal full replacement dose must be individualized for every patient
and wit be influenced by such factors as age, weighL cardiovascular status. presence of other inness, and
the severity and duration of hypothyroid symptoms.
The usual tuM replacement dose of Synthroid for younoer. healthy adutts is approximately 1.6 mco/kg/day
administered once daiy. In the elder1y, the lui replacement dose may be altered by decreases in T4 metabolism
and levothyroxine sodium absorption. Older patients may require less than 1 mco/kg/day. Children generany
require higher doses (see PHillric Dosall)- Women wllo are maintained on Synthroid dumg pregnancy
may require increased doses (see PRECAUTIONS- Pregnancy).
Therapy is usually inniated in younger, healthy adults at the anticipated full replacement dose. Clinical and
laboratory evaluations should be performed at 6 to 8 week intervals (2 to 3 weeks in severely hypothyroid
patients). and the dosage adjusted by 12.5 to 25 meg increments until the serum TSH concentration is
normaized and signs and symptoms resolve. In older patients or in younger patients with a tistory of
cardiovascular disease. the starting dose should be 12.5 to 50 meg once daily with adjustments of 12.5 to
25 meg every 3 to 6 -'<5 until TSH is normalized. n cardiac symptoms develop or worsen. the cardiac
disease should be evaluated and the dose of Synthroid reduced. Rarely, worsening angina or other signs of
cardiac ischemia may prevent achieving a TSH in the normal ranoe.
Treatment of subclinical hypothyroidism may require lower than usual replacement doses, e.g. 1.0
mco/kglday. Patients for whom treatment is not initiated should be monHored Yeartt for changes in clinical
status. TSH. and thyroid antibodies.
In patients with hypothyroidism resuling from pijuitary or ~ disease, the possililily of secondary
adrenal insuffiCiency should be considered, and npresent. treated with glucocorticoids prior to intiation of
Synthroid. The adequacy of Synthroid therapy should be assessed in these patients by measuring FT41,
which should be maintained in the upper half of the normal ranoe. in addnion to clinical assessment.
Measurement of TSH is not a reliable indicator of response to therapy for this condnion.
F1!W patients require doses greater than 200 meg/day. M inadequate response to daily doses of 300 to 400
meg/day is rare. and may suooest malabsorption, poor patient compliance. and/or drug interactions.
o- Ofllirul ,.placomont is lcfliond, cllolcal anti lalloratory onllllli- sllotold bl C8lldoocttd at
Joost 1110111ty Of wtleftnlr wanranlld lly a clllllll in pllloot slltn. Lnatllyrutloo sotllom prodocts
from dille,.nl manlflcll,.rs sllooll~ not bl -d inltfdla...ably onloss relntint ol tbl patient anti
relltllllon of tbl ~-· · n nociSSiry, accompanies tho protloct nritdl.
Syntkoid Injection by the intravenous or intramuscular route can be substituted lor the oral dosage form
when rapid repletion is required or oral administration is precludied. The initial parenteral dosage should be
approxrnately one-half the previously established oral dosage of Synthroid Tablets. Close observation of the
patient is recommended, with adjustment of the dosage as needied. Administration of Synthroid Injection by
the subcutaneous route is not recommended as studies have shown that the influx of T4 from the subcutaneous
sne is very slow, and depends on many factors such as volume of injection, the anatomic sne of injection,
ambient temperature. and presence of venospasm.
Myr,IPI CD"":
Myxedema coma represents the extreme expression of severe hypothyroidism and is considered a medical
emergency. tt is characterized by hypothermia, hypotension. hypoventilation, hyponatremia, and bradycardia
In addnion to restoration of normal thyroid hormone levels, therapy should be directed at the correction of
electrolyte disturbances and possille inleclion. Because the mortality rate of patients with untreated myxedema
coma is high, treatmelt must be started immediately, and should include appropriate supportive therapy and
corticosteroids to prevent adrenal insufficiency. Possible precipitating factors should also be identified and
treated. Synthroid may be given via nasogastric tube, but the preferred route of administration is intravenous.
A bolus dose of Synthroid is given immediately to replete the peripheral pool of T4, usually 300 to 500 meg.
Although such a dose is usuany well-tolerated even in the elderly, the rapid intravenous administration of large
doses of Synthroid to patients with cardiovascular disease is clearly not without risks. Under such circumstances. intravenous therapy should not be undertal<en without weighing the atternat! risks of myxedema
coma and the cardiovascular disease. Clinical judgement in this situation may dictate smaller intravenous
doses of Syntllroid. The initial dose is 1 - by daiy intravenous doses of 75 to 100 meg unti the patient
IS stable and oral administration is feasible. Normal T4 levels are usuany achieved in 24 hours. followed by
progressive increases in T3. Improvement in cardiac output, blood pressure, temperature, and mental status
generally occur within 24 hours. with improvement in many mannestations of hypothyroidism in 4 to 7 days.
TSH SgPcrpfol! In Umpld Clncrt 11M Urrrplt /fodrlrs:
The rationale for TSH suppression therapy is that a reduction in TSH secretion may decrease the growth and

function of abnormal thyroid tissue. Exogenous thyroid hormone may inhibit recurrence of tumour growth
and may produce regression of metastases from weiHiifferentiated (lolticular and papillary) carcinoma of
the thyroid. tt is used as ancillary therapy of these condijions following surgery or radioactive iodine therapy.
Medullary and anaplastic carcinoma of the thyroid is unresponsive to TSH suppression therapy. TSH
suppression is also used in treating nontoxic solitary nodules and multinodular goijers.
No controlled studies have compared the various degrees of TSH suppression in the treatment of either
benign or malignant thyroid nodular disease. Further. the effectiveness of TSH suppression for benign nodular
disease is controversial. The dose of Synthroid used for TSH suppression should therefore be individualized
by the nature ol the disease, the patient being treated, and the desired dinical response, weigMlg the potential
benefrts of therapy against the risks of iatrogenic thyrotoxicosis. In general, Synthroid should be given in
the smallest dose that will achieve the desired dinical response.
For well-differentiated thyroid cancer, TSH is generally suppressed to less than 0.1 mUlL Doses of
Synthroid grea er than 2 mcoJkg/day are usuany required. The ellicacy of TSH suppression in reducing the
size of benign thyroid nodules and in preventing nodule regrowth alter surgery is controversial.
Nevertheless, when treatment with Synthroid is warranted, TSH is generally suppressed to a higher target
range (e.g.. 0.1 to 0.3 mUll) than that employed for the treatment of thyroid cancer. Synthroid therapy may
also be considered for patients with nontoxic multinodular goijer who have a TSH in the normal range, to
moderately suppress TSH (e.g., 0.1 to 0.3 mUll).
Synthroid should be administ!red with caution to patients in wllom there is a suspicion of thyroid gland
autonomy, in view of the fact that the effects of exogenous hormone administration wil be additive to
endogenous thyroid hormone production.
Pediatric D.....:
Cooqenjtal or acgujred hypothyrojdjsm: The Synthroid pediatric dosage varies with age and body weight.
Synthroid should be given at a dose that maintains T4 or free T4 in the upper haH of the normal ranoe and
serum TSH in the normal ranoe (See PRECAUTIONS, PHinic Use.) Normalization of TSH may lag significantly behind T4 in some infants. In general. despije the smaller body size of children, the dosage (on a
weight basis) required to sustain fuH deYelopment and general thriving is higher than in adutts. See Table 1.
Therapy is usually initiated at the lui replacement dose (see Table 1). Infants and neonates with very low
(< 5 mcg/dL) or undetectable serum T~ IMis should be started at higher end of the dosage ranoe (e.g.50 meg
daiy). A lower dose (e.g.. 25 meg daiy) should be considered for neonates at risk ol cardiac failure, increasing
every few days until a lull maintenance dose is reached. In children with severe. longstanding hypothyroidism, Synlhroid should be initiated gradually, with an initial 25 meg dose for two weeks. then increasing
by 25 meg tNery 2 to 4 weeks until the desired dose, based on serum T4 and TSH levels, is achieved.
Table 1: Dosa11 Goldolinos for Pedlllrtc ~olllyroldlsm
Age

0-3 months
3-6 months
6-12 months
1 - 5 years
6 - 12 years
> 12 years
Growth and puberty complete

Daily dose (meg) per kg
of body weight •
10-15
8 - 10
6-8
5-6
4-5
2-3
1.6

'To be ldjusted oolhe bosis oldinicol rosponse and labof1lo<y tests (see PRECAIITlOIIS, PMIIdric - ).
Serum T4 and TSH measurements should be evaluated at the following intervals, with subsequent dosage
adjustments to normalize serum total T4 or FT4 and TSH:
2 and 4 weeks alter therapy Miation,
every 1 to 2 months during the first year of Ide,
every 2 to 3 months between 1 and 3 years of age,
every 3 to 12 months thereafter until growth is completed
Evaluation at more frequent intervals is indicated when cornpliance is questioned or abnormal laboratory values
are olltained. Patient evaluation is also advisable approximat!ly 6 to 8 -'<5 alter any change in Synthroid dose.
Synthroid Tablets may be given to infants and children wllo cannot swallow infact tablets by crushing the
tablet and suspending the freshly crushed tablet in a sman amount of water (5 to 10 ml), breast milk or
non-soybean based formula. The suspension can be given by spoon or dropper. DO NOT STORE THE
SUSPENSION FOR AN'f PERIOO OF TIME. The crushed tablet may also be spmlded over a smal amount ol
food, such as apple sauce. foods or formula containing large amounts of soybean, fibre, or iron should not
be used for administ!ring Synthroid.
AVAILABILITY
Synthroid4t (Lnolllyroxino SOtliom) Ta"ots: round, colour coded, scored tablet debossed with "FLINr and
potency. Synthroid Tablets contain the following inactive ingredients: acacia, confectioners sugar, lactose.
magnesium stearate, povidone and talc. The strengths available and the colour additives by tablet strength
are as follows:
Strength (meg)

Tablet Colour

25
50
75

orange
whHe
violet

88

olive

tOO

yellow

112
125

rose
brown

150
175

blue
lilac

200
300

pink
green

Colour Additive(s)
FD&C Yellow No. 6
none
FD&C Red No. 40
FO&C Blue No. 2
FO&C Blue No. 1
FO&CY.-No. s
D&C Yellow No. 10
D&C Yellow No. 10
FO&C Yellow No. 6
D&C Red No. 27 & 30
FO&cY.-No. s
FO&C Red No. 40
FO&C Blue No. 1
FD&C Blue No. 2
FO&C Blue No. 1
D&C Red. No. 27 & 30
FO&C Red No. 40
D&C Yellow No. 10
FO&cY.-No. 6
FD&C Blue No. 1

All strengths are available in bottles of 100 tablets each; 50. 75, 100. 125. 150. 200 and 300 meg strengths
are also available in bottles of 1000 tablets each.
Store at controlled room temperature 15'- 30'C (59"-86t). Synthroid Tablets should be protected from
light and moisture.
SynthroioJ4t (Lnatllyruxine SOtliom) lnjoctiOII is a lyophilized powder. Inactive ingredients indude: 10 mg
Mannnot, USP, sodium hydroxide, 1.75 mg tribasic sodium phosphat!, anhydrous. Levothyroxine sodium
powder for reconstitution for injection is a sterile preparation. is supplied in a 10 mL single dose colourcoded (yellow) vial containing 500 meg levothyroxine sodium, USP. Store at controOed room temperature
15'(59"- 86t).
Diroctl0111 for Roc~i..: Reconstitute the lyophilized ievothyroxine sodium by aseptically adding
5 mL of 0.9% Sodium Chloride Injection, USP only. DO NOT USE BACTERIOSTATIC SODIUM CHLORIDE
INJECTION, USP, AS THE BACTERIOSTATIC AGENT MAY INTERFERE WITH COMPLETE RECONSTITUTION.
Shal<e vial to ensure complete mixing. Lise jmmediiLJely alter reconstitution. Do not add to other inlr.M!nous
ftuids. Discard any unused portion.
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RECOGNITION AND MANAGEMENT
OF THE ABUSED WOMAN IN THE
EMERGENCY DEPARTMENT
By Jim Grochowski, MEDS 2000
reating victims of domestic violence has always been
part of emergency room work. Major emergency
departments offer 24-hour access and relative
anonymity for victims of domestic violence. Emergency
room staff occupy a unique position in the health care
system and are strategically positioned to effectively
intervene in the abuse of a woman by her pa r tner.
Although the ER is often a woman's first opportunity for
disclosure of abuse, a literature review revealed criticism
of current management of battered women.
This article will review current knowledge on
domestic violence, effective screening processes, useful
assessment techniques, the development of a safety plan
and available support services in the community.

T

EPID EMIOLOGY OF DOMESTIC ABUSE
In 1993, Statistics Canada estimated that 25% of
Canadian women who have been married or lived
common-law have been assaulted by their partner. 1 It is
difficult to obtain accurate data on this crime because of
significant underreporting and the exclusion of couples
who do not meet the legal definition of marriage/
common-law. 2 The problem is likely much more serious.u
In Ontario, 87% of those charged with domestic violence
are men. 3 The author acknowledges that men too can be
victims of domestic abuse but this article will only discuss
female victims.
Socio-economic status, ethnicity, sexual orientation
and pregnancy offer no exemption from experiences of
abuse to women. 3 It has been reported that for 40% of
abused women the abuse begins during pregnancy and
39% of women report that their children witness the
violence. 1 It is known that children who grow up where
there is spousal abuse are more likely to be in violent
relationships when they are adults and the risk of being an
abuser is three times hiqher for men who witnessed
violence by their fathers . It should be clear then that
domestic violence is not an individual problem but
instead a societal issue that affects us all.
Over 20% of women who use the emergency room are
battered women and almost half of the injuries sustained
by women who present to the ER are the result of
domestic violence. · 4 The abuse is not an isolated incident

in 2/3 of the cases. 1 Forty percent of abused women seek
medical attention on at least five different occasions .2
There clearly exists an excellent opportunity by
emergency room physicians and staff for intervention in
domestic abuse.

ABUSE
Woman abuse is defined as the intentional and
systematic use of tactics to establish and maintain power
and control over the thoughts, beliefs and conduct of a
woman. 3 Abuse can be physical, sexual, psychological/
emotional and financial in nature. 3 It can involve
intimidation, isolation, and threats, using the children and
using social status.3 The Power and Control Wheel in
Figure 1, adapted by the London Battered Women's
Advocacy Centre, London, Ontario, from the Domestic
Abuse Intervention Project, Duluth, MN, is a useful tool
for understanding the various forms of abuse. The
intentional nature of the abuse is confirmed by the shifting
of abuse tactics according to what abusers believe will
work in a given situation, the mood they are in and the
response they are looking for from their partner.3 The
tactics may appear to be random and inexplicable, but
become fully explainable in the context of the abuser
attempting to establish power in a relationship.
Emotional and psychological consequences of abuse
have been identified by abused women as being far more
damaging then the physical assault itself.S Emotional
abuse kills the spirit, and prevents the woman from
succeeding later in life, to feel deeply and to make
emotional contact with others. 6 In fact, battering accounts
for 1 in every 4 suicide attempts by women.2 All forms of
abuse result in the loss of dignity, control and safety, and
the feeling of powerlessness and entrapment. 3
Tactics of control can begin very slowly as coercive
tactics that may not be criminal in nature.3 This makes it
far more difficult for the women, as well as friends, family,
or professionals to recognize it as abuse.3 Physicians
should keep in mind that abusers often can present
themselves as charming. This could influence a
physician' s assessment.7 Abuse typically escalates in
frequency and severity and once abusers use physical
violence, they are likely to intensify the abuse. 3

INTERDISCIPLINARY HEALTH CARE TEAM
ABOUI' THE AUTHOR
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Coordination among health care professionals is
paramount to developing a consistent and
interdisciplinary health care team. A study by Shields et a/.
showed that when physicians, nurses, and social workers
collaborated, the outcome appeared to be more
comprehensive, and the emotional symptoms of the
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abu ed woman were more likely to be discussed. 8 It has
also been found that an interdisciplinary team approach
heightens the professional expertise of each member.8
The emergency room nurse is the abused woman's
first contact with the health care system. In many cases, it
is a nurse who brings suspected cases of domestic abuse to
the attention of the physician.8 When a patient indicates
she is being abused, referral to a social worker for further
a essment is extremely important. Other health care
providers can assist the team by maintaining a nonjudgmental attitude. 8

DOMESTIC VIOLENCE SCREENING

At i cles

Table 1-Raising the Level of Suspicion of Domestk Abuse 2. l. 7• 11

These eves should alert a physician to the possibility of abuse and prompt the
initiation of direct S!reening:
1) Frequent use of emergency deportment (typically 5pm-4am; though some
women may wait until the next day when their children are in school)
2) Recurrent trauma history with injuries especial~ to the head, neck, torso,
breasts, abdomen or genitals.
3) Abrasions and contusions are more common~ seen in battered women.
4) Physical injuries that are muhi-site and bilateral do not normally occur in
accidents.
5) Delay in seeking medical treatment.
6) Signs of old untreated injuries.
7) Behavioural cases such as depression, suicidal ideation, anxiety, sleep
disorders, panic attacks, symptoms of post traumatic stress disorder,
substance abuse problems, chronic headaches and chronic pain of no
apparent etiology.
8) Apartner who seems over protective answers for the woman or will nat leave
her side.

A study in 1987 suggested that the detection of
domestic violence in the emergency department resulted
in only one abused woman in twenty-five diagnosed .2
More recently, routine screening has been shown to be
effec tive in identifyin g abused women. 9 It has been
suggested that p hysicians routinely ask all patients about
the possibility of domestic violence. 3
However, a survey in 1994 suggests this is
not occurring; only 13% of 198 Canadian
hospitals surveyed said universal
creening was part of the ER protocol. 10
A physician should always ask about
the possibility of abuse in cases when a
woman's physical injuries are not
consistent with her explanation for them; if
there is unexpec te d or unexplainable
stress, anxiety, depression, or substance
abuse; or if there are chronic unexplained
symptoms? Table 1 is a summary of cues
which may lead to an increa ed level of
suspicion for domestic abuse.
Women confi d e m os t ly in friends,
neighbours and family (44%) about being
abused; only 25% of abused women tell a
doctor. 1 A study by Hayden eta!. showed
that 89% of abu ed women surveyed
would feel comfor table in disclosing the
abuse to healt h care professionals if
asked. 12 Placing pos ters about domestic
violence in the waiting room, washrooms,
and examination rooms is recommended
in emergency departments and indicates
an openness to the discussion of abuse. 7
Screening should be done with the woman
alone in a priva te area.3 Occasionally, her
partner refuses to leave her side and this
can present a problem for screening. The
nursing staff should be informed of th e
suspicion of abuse and the attempt that is
being made to separa te th e patient from
the partner. O ne technique successfu lly
u ed in the emergency room is to tell the
patient and her partner that x-rays will be
needed (radiographs are not actually done
unless necessary).13 The physician can then
Figure 1
meet the patient la ter in the x-ray
Power and Control Wheel used by London Battered Women's Advocacy Centre,
department a n d screening can be done
London, Ontario.
without the intimidating pre ence of her
U. W.O. Medical Journal
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Table 2-Saeening 2. 3, 13, 14

1)
2)
3)
4)
5)

Screen alone in a safe environment.
Use a non-threatening, nan-judgmental apprOCKh.
Build trust and rapport by making goad eye £ontact with the patient.
Use questions that are dired and easy to understand.
If the woman does not speak English, do not use family members or a person
known to her; use a professional fluent in her longuage.
6) Use a leading statement su£h as: •aetause violen£e is so £ommon in so many
women's lives, I've begun to ask about it routinely. • Or "We have seen many
women with similar £omplaints and injuries presenting to the emergency
department, and some are victims of violen£e at home.*
7) Follow up with more spedfi£ questions: "I am £omerned that your injuries
have £ome from someone hurting you, is this what happened to you?•,
•Have you ever been hurt or hit by someone dose to you?•, •1notite you
have some bruising or your breasts and abdomen. Can you tell me what
happened? Did somebody hit you?•
8) Use the word "partner*if the abuser's gender is unknown.
9) Resped that she may refuse to give information or reteive help.
10) Regardless of out£ome, retard that abuse streening was done.

partner. Table 2 provides a summary of screening
techniques and examples of ways to approach the
question of abuse.
The victim must first come to understand that what is
happening constitutes abuse, then to see that it is
unacceptable, and finally to confide in another person.3
Screening should not be considered a failure if the woman
does not wish to disclose.3 It is important to remain
empathetic if this happens and inform the patient to
return if they need someone to talk to or to contact a local
woman's shelter. It should be made clear to the woman
that all cases of abuse are unacceptable and that her health
and safety are important . Most women are very
vulnerable at the time of disdosure. 3 They can be fearful,
embarrassed, or in a state of emotional shock. 3 At this
time, many women will be overly compliant with the
suggestions; it is not the physician's role to solve the
problem for her but rather to support the woman in
making decisions. 3 Nevertheless, encourage her to contact
the police. 13 Always document that domestic screening
was done for reference in the future.3 It cannot be stressed
enough that the physician's response to a disclosure of
abuse sets the stage for both the current intervention, and
for future interactions with health care providers. 3
EXAMINATION AND DOCUMENTATION

Table 3-Signs of Physical Ab.se 01 Physkal Ex• 3• u

1) Injuries (often multiple) found on head, fa£e, throat, £hest, breasts, bo£k,
abdomen, genitals.
2) The following types of injuries: abrasions, bruises, burns, dislo£ations,
la£erations, bites, frattures (nose, jaw, davide, ribs, arms, fingers),
strangulation.
3) Eviden£e of old bruising and radiographi£ suggestion of past fractures.
4) Soreness and general body pain from being hurled or shoved.
5) Unusual affed or manner of £ommuni£ation - she says nothing, minimizes
the injury, avoids eye £ontact, anxious about a minor injury.

Table 4 - Creatilg a Safety Plan l. 4• '

Asafety ~an should indude:
1) Asking what she wonts to do, whether she mn stay with frientls/family or go
to a shelter.
2) Alist of resour£es and brO£hures (wallet-sized) whi£h £ontain emergency
phone number (pali£e, hospitals, shelters and help lines) and the IO£ation of
nearby shelters.
3) Information about edutational servites, legal and/or immigration assistaoce.
4) Suggest she alert a supportive family member or friend of her situation.
5) Prepare an estape pa£koge by having her gather the following items and
keep them in an O((essible hidden plo£e or at a friend's home in £ose she has
to leave in a hurry: important dO£uments, some money/bonk or £redit £artls,
£lathing for herse~ and £hildren, plus the £hild's favourite toy.
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Proper assessment should begin with taking a history
of her presenting complaint and using the patient's own
words to describe the injury I illness. She should be asked
about other abuse, associated illness such as depression
and self-medication / substance abuse. The physician
should always ask about suicidal ideation?
A thorough phys ical examination should be
performed with the patient disrobed. 3 The woman who
appears to only have a broken arm might not mention the
multiple bruises on her back or the bite mark on her
shoulder. 14 More importantly, an incomplete exam may
miss areas of tenderness that may indicate internal injuries
that are not detected on only a cursory exam. 3 A pelvic
exam is necessary if sexual assault is suspected. 15 Table 3
provides a listing of signs often present on the physical
exam of an abused women. Proper documentation is
important. It not only serves as a legal medical document
but also guides the user through the steps needed for
effective intervention. Suspected domestic abuse should
still be recorded in the patient's chart.
A good medical record of domestic abuse would
include: the presenting complaint or injuries (including
dates, times, and locations of incidents), past injuries and
frequency, body map documentation of injuries (type,
location, size, color and age), and a description of other
health problems that may be related to the abuse . 3
Photographs of the patient's injuries should be arranged
after obtaining written consent if possible.2 Documentation
of an assessment of her safety and the development of a
safety plan is required once abuse has been diagnosed.3•15
THE SAFETY PLAN

A safety plan is composed of strategies which increase
the woman's present safety and help her to be prepared in
advance for the possibility of future v iolence .3 The
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physician's role is to inform the patient of her options and
respect the decisions that she makes which help her to
take control of the situation. 3 It is important to remember
that safety intervention should reflect the reality that there
are risks attached to every decision abused women make.3
Finally, make it clear that although you suppor t her
decision to return, you do not expect the violence to end. 3
Assess the threat of violence for the women and her
children. Immediate risk can be evaluated by inquiring
about access to guns, past use or intimidation with
weapons, recent escalation of violence, threats to kill, the
presence of substance abuse, extreme jealousy, and
whether there has been a separation (or threat of
separation), job loss, a pregnancy, or a change in finances
recently? The more of these questions that are confirmed,
the more immediate risk to the woman. It is necessary to
ask about suicidal ideation and whether the woman has
considered a plan to kill the abuser. 7 Any time violence
has occurred or is strongly suspected, the team must
assume that the woman is at risk and assist her in devising
a safety plan. The prescription of tranquilizers and pain
medication for management of real medical needs must be
balanced against maintaining her ability to react to
dangerous situations. 3 Finally, never hesitate to arrange
immediate admission or delay discharge if it is the only
anctuary available to the victim. 2
SUPPORT SERVICES IN THE COMMUNITY
It is a physician's duty to go beyond treating the
physical injury . He or she must demonstrate greater
commitment to aiding victims by knowledge of other
professions who may offer psychosocial treatment and
other services for the abused woman and other family
members. In addition to specialized training in
counseling, social workers link women to the resources
they need.
An updated list of community services in all practice
areas will help provide continuity of care. Small
pamphlets or wallet-sized cards that can be easily
concealed are helpful. 3 Resources should include: police,
hospital services, crisis lines, counseling, shelters, legal
and financial aid, immigration assistance, First Nations
services, parental relief programs, Crown Attorney's office
and family police consultants?

CONCLUSION
Abused women will likely come in contact with a
health care professional for the first time in the emergency
department. The treatment of a battered woman's medical
and / or surgical problems without recognizing that she is
being abused and without offering services is simply bad
medical care. The more skilled physicians can become at
recognizing the pattern of abuse in its early stages, the
more opportunity there will be to prevent illness,
pregnancy complications, permanently disabling injuries
and even death. The utilization of an interdisciplinary
team to treat victims of domestic violence increases the
detection rate of abuse and significantly improves the care
women receive in the emergency department. A busy
emergency room physician who remains open, empathetic
and has a genuine interest in the women's safe ty and

health will build trust and greatly enhance the possibility
of disclosure of abuse. A thorough physical exam, proper
documentation, the discussion of a safety plan and referral
to community services is the standard of care for abused
women. It is the author's belief that maintenance of a high
level of suspicion in the emergency room and continued
discussion of this once taboo topic will be the key to
making a significant difference in these women's lives.
ACKNOWLEDGMENTS
The author would like to thank Dr. Bill McCauley, Dr.
Jane Upfold and Helen Padega from South St. campus,
London Health Sciences Centre and Megan Walker
(executive director) from the London Battered Women's
Advocacy Centre for their time in reviewing this article
and interest in making constructive suggestions.
REFER£ CES
1. Rodgers K. Wife assault: the findings of a national survey. Juristat . Cat 85002 , 14(9) , Canadia n Centre for justice Statistics. Otta wa, Ontario:
Statistics Canada.
2. Morrison L] . The battering syn drom e: A poor record of detection in
the emergency department. The ]oumal of Em ergeucy M edi cine
1988; 6: 521-526.
3. Reynolds C and Schweitzer A . Responding to Women Abuses: A Protocol for
health Care providers. London Battered Women's Advocacy Centre, 1998.
4. De Cherney AH and Perroll ML. eds. Current Obstetric and Gynecologic
Diagnosis and Treatment Btl! ed. Appleton and Lange, U.S.A . 1994.
5. ]erzierski M . Abuse of women by male partners: Basic knowledge for
emergency nurses. journal of Emergency Nursing 1994; 20: 361-368.
6. Davidhizar R and ewman-Giger J. Recogn izing Abuse. International
ursing Review 1996; 43(5): 145-150.
7. Ferris LE, orton PG, Dunn EV, Gort EH and Degani N. Guidelines for
Managing Domestic Abuse W1ren Male and Female Partners Are Patients of
the Same Physician . JAMA 1997; 278(10): 851-857.
8. Shields G, Baer ], Leininger K, Marlow], and DeKeyser P. Interdisciplinary
Health Care and Female Victims of Domestic Violence . Social Work in
Health Care 1998; 27(2): 27-48.
9. Grrmfeld A, Ritmil/er S, Mackay K, Cowan L, and Hotel! D. Detecting
domes tic violence against women in tlte emergency department: A nursing
triage model. journal of Emergency Nursing 1994; 20:271-274.
10. Hotclr D, Grunfeld A, MacKay K, and Ritch L. Policy and procedures for
domestic violence patients in Canadian emergency department: A national
survey. Journal of Emergency Nursing 1996; 22(4): 278-282.
11 . Padega H. social worker, London Health Sciences Centre, South St., London,
Ontario, persanal communication, Oct 1, 1998.
12. Hayden S, Barton E, and Hayden M . Domestic violence in the emergency
department: How do women prefer to disclose and discuss the issues? The
Journal of Emergency Medicine 1997; 15(4): 447-451 .
13. Upfold J. emergency room physician, London Health Sciences Centre, Soutlr
St., London Ontario, persanal communication, Oct 1, 1998.
14. Bates B. A g uide to physical examination and history taking 6th Ed. ].A.
Lippincott Company, U.S.A. 1995.
15. TC Krewis , CG Warn er, LM jacobs, Jr. eds. Emergency M edicine. A
comprehensive review 3rd ed. Raven Press, New York, U.S.A. 1993.
il

U. W.O. Medical Journal 68 (1) 1 9 9 9 - - - - - - - - - - - - - - - - - - - - - - - -

81

Feature

Art i cles

FEMALE CIRCUMCISION OR
GENITAL MUTILATION:
A Rational Approach?
By Reena Bhargava and Lubna Tirmizi, MEDS 2000
Note: Certain aspects of the descriptions of the following
procedures are directly from informal interviews with several
fem ale members of the local Muslim community of Lo_ndon,
Ontario (Con sidering th e perso nal nature of the zss ue,
anonymity was maintained)
INTRODUCTIO N
exuality remains an obscure area, mined with cultural
taboos and loaded with anxiety and fear . Thus it is
not s urprising the subject of genital mutilation
provokes emotional reactions both from advocates of it as
a justified cultural practice and from the Western w orld
that wants to see the practice outlawed. Female Genital
Mutilation is a general term used to describe any sort of
physical manipulation performed by a person ( wRether it
be a physician or a midwife) on the genitals of a female.
There are four types of manipulations ( ritual, "Sunna",
clitoridectomy and infibulation ) but often fe male
circumcision is used as a collective descriptive term for all
four types.4 The issue of female circumcision is complex
and has led to a debate between cultural determinism and
health. It is an almost universal belief that changes are
needed in the conditions and practice of female
circumcision but the extent of these changes is still not
determined.

S

DESCRIYTIO N AND TYPES OF CIRCUMCISIO N
Female Circumcision or Female Genital Mutilation can
be divided into four basic types, each varying in its degree
of genital manipulation.2' 4 The least severe type is called
ritualistic circumcision, where the clitoris is merely nicked.
This causes bleeding , but little mutilation or long term
damage. The second form is simply called circumcision, or
"Sunna" by the Muslims. This involves the removal of the
clitoral prepuce-the outer layer of skin over the clitoris,
sometimes called the "hood"; the glans and body of the
clitoris remain intact. Occasionally, the tip of the clitoris
itself is removed. Sunna has been equated with male
circumcision, because the clitoris itself is generally not
damaged. Thus, it is the only type of mutilation which can
correctly be called circumcision.
A third, more harsh form of the practice, is called
excision or clitoridectomy. This is the most common form
and involves the removal of the glans of the clitoris-
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usually the enti re clitoris-and often parts of the labia
minora as well.
Finally, the most severe form of the practice is
infibulation, or "Pharaonic" circumcision, where virtually
all of the external female genitalia are removed. With this
type of circumcision, a dramatic excision is performedremoving the entire clitoris and labia minora-and in
addition, much or most of the labia majora are then sewn
together with acacia tree thorns, and held in place with
catgut or sewing thread. 4 The entire area is closed up _b y
this process leaving only a tiny opening, roughly the SlZe
of a match stick to allow for the passing of urine and
menstrual fluid . The girl's legs then are tied togetherankles, knees, and thighs- and she is immobilized for an
extended period, varying from fifteen to forty days, while
the wound heals and scar tissue forms. 8
EPIDEMI O LO GY
CIRCUMCISION

AND

C O NDITI O NS

OF

The World Health Organization (WHO) estimates that
85 to 114 million women across the world have been
circumcised and 80 000 procedures are said to be
performed in Somalia alone. ' The countries concerned
number more than twenty in Africa, from the Atlantic to
the Red Sea, the Indian Ocean and the Eastern
Mediterranean .' An area of particular interest to
international health officials has been the spread of
traditional circumcision practices to Europe, Australia,
United States and Canada by emigrants. The Centers for
Disease Control and Prevention estimated that in 1996
more than 150 000 women and ~Is in the United States
were at risk of genital mutilation.
In most parts of the world, the procedure is performed
almost entirely by women; generally local midwives or the
elderly in the villages or towns. The age at which girls are
circumcised varies both geographically and ethnically. It
varies from a few days old (for example, the Jewish
Falashas in Ethiopia, the nomads of the Sudan, and some
parts of Nigeria), to about seven years old (as in Egypt and
many countries of central Africa), to adolescence (among
the lbo of Nigeria). 4 It seems the specific beliefs and
practices may vary from country to country. Although ~ot
common, the surgery is sometimes performed by medical
personnel in health clinics or hospitals. Usually only the
affluent members of society can afford having the
procedure in such health care facilities.
The instruments used for circumcision range from
kitchen knives, old razor blades, broken glass, and sharp
stones used in villages, to scalpels used in local health
clinics.4.8 These instruments are rarely sterilized before the
operation, and, except in certain urban areas, anaesthesia
is almost never used in the process. The incisions are
usually made while the girl, often held down by several

- - - - -- - - - - - - - - - - - - - - - - - - U. W.O. Medical Journal 68 (1 ) 1999

Feature
women is lying down on a mat or is in a sitting position.
The wounds are frequently treated with herb mixtures,
ashes, animal dung or mud to stop the bleeding. 4
ORIGINS OF THE PRACTICE
Although documentation is difficult to find, it is
believed that female circumcision has been practiced for
nearly 2500 years- prior to the birth of either Islam or
Christianity. The cultural and geographical origins of the
practice are unknown. The incidence is, however, so
geographically dispersed and occurs among such a variety
of cultures that it is reasonable to assume that the practice
arose independently among different groups of people.4 It
is interesting that circumcision is commonly assumed to
be a part of Islamic beliefs when in fact it existed before
the religion of Islam. Islam believes in the circumcision of
males as being "Sunna" (blessed) but there is no mention
of the circumcision of females in the Qur'an. 7 It seems
plausible that Islamic doctrine was interpreted through
cultural traditions thus extendi ng the practice of
circumcision to women. 7 In the tribal societies female
circumcision, as with male circumcision, was initially part
of the traditional puberty rites, in which young women
and men were introduced into the adult world-a "rite of
passage".2
Infibulation, the most extreme form of female
circumcision, has been traced by some anthropologists
and historians to ancient Egypt, hence, the name
Pharaonic circumcision. 4 Analysis of Egyptian mummies
has shown that women were infibulated during this time,
some believe that the practice may have originated there.
Others believe that the practice may have existed long
before- among herders as protection against rape for
young girls who took animals out to pasture, or as a
custom among the stone-age people within Equatorial
Africa . It may have also been an outgrowth of human
sacrificial practices, or the result of early attempts at
population control. 4
JUSTIFICATIONS FOR THE PRACTICE
The reasons and justifications for female circumcision
are numerous and complex. As with most traditional
practices, the ideological basis lies in the society's cultural,
traditional, historical, political, economic and religious
background . The commonly given reasons for the
persistence of the practice include: sexual control over
females, religious requirements, mythical beliefs, and the
need to maintain a tradition that has been with these
cultures for thousands of years. 4.s
In contrast to the reasons for male circumcision, one of
the most frequently given reasons for female circumcision
is the control of the sexuality of females.8 This is the case
especially in areas where the practice is carried out on
infants and very young girls, clearly not old enough to be
initiated into the adult world . In these cultures,
circumcision serves primarily to discourage promiscuity
by reducing a woman's sensitivity and desire for sexual
intercourse. 8 The primary function of infibulation is to
guarantee a bride's virginity. The preservation of virginity
is essential for determining a woman's social position in
these societies. For a young girl it is a practical choice not
U. W.O. Medical Journal
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to resist being circumcised because she is made to believe
that her only role in life is to be a wife and a mother. If she
does not find a husband, she may never be able to survive
economically or otherwise. Thus if a girl does not undergo
circumcision she may believe that her future will be
tainted. In the interest of social position, family honor, and
economics within some cultures, it is believed that the
sexuality of women must be controlled.8
The view that circumcision is a valid means of
controlling the sexuality of women has been recently
questioned. It is suggested that female infibulation is no
guarantee of a woman's virginity at the time of marriage:
an unmarried woman can have sexual intercourse and
then be re-infibulated (also called the "Aladal operation")
prior to marriage to disguise the fact from her husband. 5
A second reason often given as justification for female
circumcision has been religion. 4 This response was
especially common for males interviewed. The religion
that seems to have incorporated the practice most heavily
into its culture is Islam .8 In Africa, the operation is
performed by Christians (Catholics, Protestants, and
Copts), Muslims, Jews, Animists, and atheists, although
the practice does not exist in the teachings of any formal
religion.4
A third justification is based on the following folk
myths: the clitoris represents the male sex organ and if not
cut will grow to be the size of the penis; females are sterile
until they have been excised, and the operation will
actually increase fertility, as well as the number of live
births; the operation is a biologically cleansing process
that improves the hygienic and / or aesthetic condition of
female genitalia. In Sudan, it is believed that a woman is
naturally "polluted" and can only be cleansed, and suited
for marriage and childbirth, by being excised.4
One of the myths helping to perpetuate the practice
stems from the "Pharaonic belief in the bisexuality of the
Gods". All males and females have both masculine and
feminine souls that are represented in their sexual
characteristics. The prepuce, or foreskin, of the penis, it is
believed, represents the feminine soul in the male, while
the clitoris represents the masculine soul in the female.
According to the myth, adolescents cannot be admitted
into the adult world until they have been rid of the
physical characteristics of the opposite sex-hence the
justification for both male and female circumcision.4
The most widely held justification for the continued
practice of female circumcision is the importance of
tradition .8 In a questionnaire given to five rural
communities in Nigeria, 280 men and women were asked
about their experiences with the practice. In addition, their
thoughts as to why the practice continues to exist was
queried. The dominant reason given by both men and
women was the need to maintain tradition. 4 In some
cultures female circumcision can also be accompanied by
elaborate ceremonies and joyous celebrations. There may
be days of preparation, including cleansing, praying,
consuming special food and drink, and performing rituals,
such as dancing and singing. The girls are frequently
given gifts and are showered with praise and words of
support for being brave and becoming women.8 Although
maintaining tradition is often used as justification for the
physical manipulation of a young girl's genitals, this point
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of view has drawn much opposition from the
international community.
MEDICAL COM PLICATIONS

Immediate complications from the female circumcisal
procedures can be many and varied. Haemorrhage may
occur internally from the pudental and dorsal arteries of
the clitoris. There may also be risk of post-operative hock.
The resistance of the child may cause cuts in other organs:
the urethra, the bladder, the anal sphincter, vaginal walls
or Bartholin glands. Also since the instruments used have
rarely been sterilized, tetanus (frequently fatal ), and
septicaemia often result. It is also important to note that
the procedures are done without anaesthetics thus are
extremely painful for the female involved. The severe pain
may cause psychological distress and trauma for
especially young girls.2
The long-term complications range from infections to
maternal mortality. Chronic infections of the vagina and
uterus are frequent because the vagina (in the case of
infibulation) virtually becomes a semi-sealed organ of the
body. A Keloid or dermoid cyst may form on or around
the vulva . Other grave complications include
dysmenorrhoea, since the menstrual flow cannot e cape
freely through the minuscule opening. In some cases the
menstrual flow mal be fully blocked and would require
surgical correction.
The most severe result of excision is the development
of a neuroma of the dorsal nerve of the clitoris. ulval
abscesses can also develop. Mutilated women can b come
sterile due to infections which ascend into the
reproductive organs.
Further complications during childbirth are
unavoidable for infibulated women. Splitting of the car is
always needed to let the baby out. A long labour may
result possibly leading to intrauterine foetal death, or birth
trauma.'
Anonymous reports from local physicians of Muslim
origin, emphasize the growing interest in the relationship
be tween the practices of female circumcision and the
spread of AIDS. They state that Infibulation has probably
become an extra risk factor in the spread of the HIV-virus
by predisposition to formation of small mucosal tears
during intercourse caused by the abnormal vulval
anatomy and through a higher incidence of anal exual
intercourse. It is clear that more data needs to be collected
on the role these traditional practice might play in the
transmission of the HIV-infection.

themselves and their daughters they may reconsider
circumcision. There also needs to be education regarding
the risks of the unsanitary operating conditions. At least if
the conditions are improved there may be a decrease in
some medical complications such as infections. There is
concern that banning of female circumcision at the
government level will ca u se an increase in unsafe
underground circumcision practices. Hopefully with more
information and education, decisions affecting the lives of
women will be made by women, and not by cultural
beliefs.
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FUTURE 1M PLICATIONS

An ultimate end to Female Genital Mutilation may not
be in the near future but practical steps can be taken to
change the current conditions. Basic health education for
women and health personnel of the countries where FGM
is practiced should be a primary concern for the entire
world. If women are aware of increased health risks for
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HORMONE REPLACEMENT THERAPY
IN THE PREVENTION OF
CARDIOVASCULAR DISEASE
By Daniel G. Hackam BSc and J. David Spence BA, MBA, MD, FRCPC, FACP
INTRODUCTIO N
s recently as 15 years ago, cardiovascular disease
was considered a much more important cause of
morbidity and mortality in men than in women.
Few of the early longitudinal studies on the epidemiology
of atherosclerosis even included women; hence for many
years, heart disease and stroke was often regarded a
di ease of middle-aged and elderly men. Today we know
that cardiovascular disease is the o. 1 cause of death in
women, 1 outranking cancer by a factor of 2 to 1; women
also have a worse prognosis than men after myocardial
infarction, 2 and following surgery for coronary heart
disease (CHD).3
Although cardiovascular disease is the leading cause
of death in both sexes, women tend to develop the clinical
manifestations of atherosclerosis about 10 years later than
men. 4 Among younger women, the risk of heart disease is
one in nine, and by age 65, the risk climbs to one in three.
It has long been thought that this difference in the rate of
progression of atherosclerosis between women and men is
due to estrogen, an advantage that obviously declines with
the onset of menopause. This review focuses on the
biological and clinical evidence regarding the role of
hormone replacement therapy (HRT) in the prevention of
v a cular disease, and addresses concerns about the
po sible effects of estrogen on the risk of breast cancer.

A

BIOLOGICAL EVIDENCE
The experimental evidence for estrogen's effectiveness
as a cardioprotective agent is extensive. The best
documented effect is estrogen's action on blood
lipoproteins. Estrogen acts in the liver to raise prod uction
of HDL cholesterol and reduce circulating levels of LDL
cholesterol. Hence less cholesterol is carried to the
v a scular endothelium and more cholesterol can be
transported away . Several authors, however, have
calculated that estrogen's effect on blood lipids probably
onl y accounts for 25-50 % of its apparent
cardioprotectiveness. 5.6
In 1993, two papers in the Lancet focused on
vasodilator effects of estrogen. Rosano et al showed that
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estrogen acutely improved exercise-induced myocardial
ischemia, implicating a vasodilator effect of estrogen. 7 In a
sub equent Hypothesis, they suggested that estrogen acts
a a calcium channel antagonist, and marshaled
arguments that the effect is not mediated by nitric oxide
( 0 ). 8 However, Williams et a! showed in surgically
postmenopausal monkeys that both long-term estrogen
administration 9 and acute estrogen administra tion
prevented paradoxical constriction to acetylcholine,
suggesting that the protective effect of estrogen with
respect to vasodilation may indeed be mediated by NO.
They subsequently showed using N-methyl-L-arginine,
that the effects of psychosocial stress on endotheliummediated vasodilation was mediated by N0.10
itric oxide is released in areas of high shear, and is
not only a vasodilator, but has antiplatelet and other
effects which reduce proliferation in the intima . 11 Its
counterpart, endothelin, is a hormone released by the
endothelium in conditions of low shear, which is not only
a vasoconstrictor, but which interacts with other factors to
enhance coagulation and vascular proliferation. 12 Spence
has hypothesized that nitric oxide and endothelin may be
important in remodelling of arteries to conform to flow
patterns, with filling in of low shear regions, analogous to
meanders in a river.
Recently, Polderman et al reported that women have
low endothelin levels, men have high endothelin levels,
and that when they undergo sex change surgery and
hormonal therapy, their endothelin levels cross over to
levels characteristic of their new sex. Juxtaposition of the
findings of Polderman et al with those of Rosano et al
suggests the possibility that the vasodilator effects of
estrogen may be related to antagonism to endothelin.
If estrogen reduces and testosterone increases the proatherosclerotic effects of endothelin, then it may be
possible not only to confer protection from atherosclerosis
on postmenopausal women by estrogen replacement, but
also to protect men with androgen antagonists. The
challenge, for men at least, will be to find a way of
antagonizing testosterone without causing impotence and
gynecomastia . It may not be so undesirable to reduce
aggression and hostility, which along with atherosclerosis
are undesirable accompaniments of masculinization. It i
po sible that drugs such as finasteride or its analogues,
which interfere with 5-alpha red uctase, might lead to
solutions to this problem.

CLINICAL EVIDENCE
Many observational studies have found a lower risk of
CHD in women taking post-menopausal estrogen
compared to non-users. Three meta-analyses done early in
this decade summarized these findings and reported a 3550% lower risk of CHD in estrogen users compared to
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nonusers. 13-15 Sarrett-Connor and Grady published a more
recent meta-analysis based on all studies published
through mid-1997. 16 Their summary estimate of the
relative risk for CHD among women who ever used
estrogen compared to never users was 0.70 (CI, 0.65 to
0.75). By far the predominant HRT regimen in these 25
studies was unopposed equine estrogen.
Does the addition of a progestin, taken to protect
women with intact uteruses against endometrial cancer,
attenuate the preventive effects of estrogen on
cardiovascular mortality? A number of studies have
reported the effect of treatment with estrogen plus a
progestin, usually medroxyprogesterone acetate, on CHD
risk. Using the same statistical methods as above, SarrettConnor and Grady found a summary relative risk for
CHD, based on these studies, of 0.66 (CI, 0.53 to 0.84),
highly similar to the estimate for unopposed estrogen
therapy. These results, in conjunction with favourable
experimental data on the effects of estrogen-progestin
treatment, suggest that cardiovascular protection can be
maintained with combination therapy.
WHAT ABOUT BREAST CANCER?
The fear of breast cancer is a highly emotional issue,
and may be largely responsible for the political stance that
can be summarized as follows: "Doctors are medicalizing
a normal part of aging and putting all kinds of women on
hormones they don't need so that multinational drug
companies will make all kinds of money". It is easy for
physicians to fall into the trap of dismissing this fear as
irrational innumeracy; such attitudes only exacerbate the
problem of communication and adversely affect the
perceptions of women who are faced with the decision
whether to initiate HRT.
It appears that there are three sources of
misunderstanding that contribute to a very substantial
under-utilization of HRT among women who stand to
benefit greatly from it: 1) misperceptions about th.e age of
onset of breast cancer in relation to HRT; 2) a significant
overestimate of the incremental risk of breast cancer
attributable to HRT; and 3) a significant underestimate of
the benefit in proportion to the risk.
Since progesterone replacement markedly reduces,
and hysterectomy eliminates the risk of uterine cancer, for
most women the main risk of taking HRT is breast cancer.
For women age 50 to 70, the cumulative risk of breast
cancer is about 4.5% without HRT. The incremental risk
attributable to HRT is 0.2% after 5 years of treatment, .6%
after 10 years, and 1.2% after 15 years. This means that if a
woman starts on HRT at age 60, the risk of breast cancer
attributable to HRT, extended out to age 75, would be
about 1.5%. The belief that HRT will bring on breas t
cancer at a young age, similar to that of their young
friends, and on which their fear is based, is unfounded.
That risk must be compared with the benefit, for
women with vascular disease. It is important therefore to
understand how high the risk is, for women that have
developed angina, myocardial infarction, or carotid
stenosis. As shown above, patients with vascular disease
have a very high risk. The benefits of HRT appear to be
even greater than those of cholesterol-lowering agents:
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Fig•re 1. Six-year risk for women age 50-70 with and without hormone

replacement the;apy (HRTJ. The bars show the 6-yeor risk of breast ca11<er versus

the risk of death, stroke or myocardial infarction in patients with various vascular
conditions: coronary artery disease with asymptomoti< carotid stenosis (CAD/ACS)

asymptomatic carotid stenosis alone (ACS)h. Coronary artery disease (CAD) an~
symptomatic carotid stenosis (TIA/CS), wit and without hormone replacement
therapy. The tap end of the bars for cardiovascular risk is without HRT, the banorn
end With HRT; for breast cancer the top of the bar represents risk with HRT, the
banom without HRT. As shown the incr8ased risk of breast ca11<er with HRT is very
small compared with the r~uction of risk with HRT in patients with vascular
disease. Reprinted with permission.
HRT reduces vascular disease by approximately 44%,
compared to a 40% reduction in coronary events, a 37%
reduction in bypass surgery and a 30% reduction in
mortalitl: with simvastatin in patients wit~ coronary
disease. 1 •18 Thus the number needed to treat will be lower
than for lipid lowering drugs, and the benefit greater, with
HRT. Women with symp tomatic carotid stenosis, or a
combination of carotid stenosis and coronary disease, have
such a high risk that not taking HRT is probably a grave
error.
Figure 1 shows the balance of risks and benefits for
HRT in relation to various stages of severity of
cardiovascular disease, and for breast cancer. The 6-year
risk was calculated by extrapolating time in a linear
fashion from the published risk of vascular disease as
discussed above, and from the risk of breast cancer with
and without HRT in the collaborative analysis referred to
above. It was assumed that the benefit of HRT was 44%;
this is likely a conservative estimate, as women with
vascular disease stand to benefit more than the averaie of
the group in which such benefits were observed. 17' 1 As
shown, the potential benefit of HRT in patients with
vascular disease far outweighs the risk.
CONCLUSION
A number of ongoing clinical trials will further clarify
the efficacy of HRT in the prevention of cardiovascular
disease, as well as shed more light on the risk of breast
cancer in HRT users. In the meantime, it seems likely that
most post-menopausal women can safely benefit from the
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cardioprotective effects of an estrogen-progestin regimen,
and those women with risk fa ctors for cardiovascular
d isease (eg, a strong family his tory, diabetes mellitus,
hypertension, homocyst(e)inemia and so forth) should be
strongly encouraged to do so.
ACKNOWLEDGEMENTS:
This paper quotes extensively from a position paper
prepared for the Heart & Stroke Foundation of Ontario,
a nd from JDS ' s chapter in Current Rev iew of
Cerebrovascular Disease (in press, 1998).

REFERENCES
1. U.S. Department of Health and Human Services, Public Health Service,
Centers for Disease Control and Prevention, National Center for Health
Statistics. Monthly vital statistics report. 1995; 43 ed.
2. Maynard C, Weaver WD. Treatment of women witlr acute Ml: new findings
from tire MIT/ registry. journal of Myocardia/Ischemia 1992; 4:27-37.
3. O'Connor G, Morton J, Diehl M, et a/. Differences between men and women
in hospital mortality associated with coronary artery bypass graft surgery.
Circulation 1995; 188:2104-2110.
4. Anonymous editor. Proceedings of NHLBI Conference: Cardiovascular
Health and Disease in Women . 1993.
5. Bush TL, Barrett -Connor E, Cowan LD, Criqui MH, Wallace RB ,
Suchindran, et a/. Cardiovascular mortality and noncontraceptive use of
estrogen in women: results from the Lipid Research Clinics Program Followup Study. Circulation 1987; 75:1102-1109.
6. Gruchow HW, Anderson Hf, Barboriak J/, Sobocinski KA. Postmenopausal
u.se of estrogen and occlusion of coronary arteries. American Heart journal
1988; 115:954-963.
7. Rosano GM, Sarrel PM, Poole-Wil.son PA, Callins P. Beneficial effect of
oestrogen on exercise-induced myocardial ischaemia in women with coronary
artery disease. Lancet 1993; 342:133-136.
8. Callins P, Ro.sano GM, Jiang C, Lindsay D, Sarre/ PM, Poole-Wil.son PA.
Cardiova.scular protection by oestrogen-a calcium antagonist effect? Lancet
1993; 341:1264-1265.
9. Williams JK, Adam.s MR, Klopfenstein HS. Estrogen modulates responses of
atherosclerotic coronary arteries. Circulation 1990; 81:1680-1687.
10. Williams JK, Kaplan JR, Manuck SB . Effects of psychosocial stress on
endothelium-mediated dilation of atherosclerotic arteries in cynomolgus
monkeys. journal of Clinical Investigation 1993; 92:1819-1823.
11 . Lowenstein CJ, Dinerman JL , Snyder SH. Nitric oxide: a physiologic
messenger. Annals of Internal Medicine 1994; 120:227-237.
12. Luscher TF, Boulanger CM, Dohi Y, Yang ZH. Endothelium-derived
contracting factors . Hypertension 1992; 19:117-130.
13. Bush T. The epidemiology of cardiovascular disease in postmenopausal
women. Annals of the New York Academy of Sciences 1990; 592:271
14. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, eta/. Homzone therapy
to prevent disease and prolong life in postmenopausal women . Annals of
Internal Medicine 1992; 117:1016-1037.
15. Stampfer Mf, Calditz GA. Estrogen replacement therapy and coronary heart
disease: a quantitative assessment of the epidemiologic evidence. Preventive
Medicine 1991; 20:47-63.
16. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease,
and other considerations. Annual Review of Public Health 1998; 19:55-72.
17. Stampfer MJ, Colditz GA, Willett WC, Man.son JE, Rosner B, Speizer FE, et
a/. Postmenopausal estrogen therapy and cardiovascular di.sea.se. Ten-year
follow-up from the nurses' health study. New England journal of Medicine
1991; 325:756-762.
18. Man.son JE, Toste.son H, Ridker PM, Satterfield S, Hebert, O'Connor GT, et
a/. The primary prevention of myocardial infarction. New England journal
of Medicine 1992; 326:1406-1416.
Q

PARKE DAVIS

SrnlviNG To MAKE MIRACLES HAPPEN
A LITn.E Scx:>NER
Miracles can happen.
But behind every miracle is hard work and determination.
The determination to make our lives a little better,
the hard work necessary to get closer to a cure.
It doesn't happen overnight; it often takes years of
dedicated research. But when that research culminates in
a breakthrough or a new pharmaceutical,
miracles become possible.
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HORMONE REPLACEMENT THERAPY:
Issues f or Discussion between
Physic 1• an s and their Patients
By Lynda Newkirk, MEDS 2000
JP is a 55 year old woman who has jus t undergone
menopause. She is generally healthy and presents to her
fami ly physician today for a general physical exam and
PAP test. Her physician suggests that JP consider hormone
replacement therapy. JP is unsure. She states "I have no
family history of heart problems so I'm not sure that I need
hormone replacement therapy. Besides, I've heard that it
increases your chances of breast cancer. Is there something
else I could do instead?"

he subject of hormone replacement therapy (HRT) is
one of the great debates in medicine today. Who
should get HRT? What should they get? When
should they start? How long should it be continued? Some
physicians think that all post-menopausal women who do
not have any absolute contraindications should be given
HRT. Is such a blanket statement appropriate? o two
women are the same, physiologically or contextually. The
pros and cons of HRT must be evaluated for each
individual. Physicians must be knowledgeable about the
risks and benefits of HRT in order to be able to assist their
patient in making an informed personal decision. The
purpose of this paper is to highlight some of the key issues
that physicians should discuss with their patients who are
considering HRT.

T

THE PR O S AND C O NS O F H O RMONE
REPLACEMENT THERAPY
Cardiovascular
The lesser incidence of cardiovascular disease (CVD)
in pre-menopausal women in comparison to m en of
similar age, and the significant increase in CVD in postmenopausal women suggests that estrogen m ay be
cardioprotective. In fact, studies have shown up to a 50%
decrease in the risk of cardiovascular mortality in women
who take HRT.1.2.J.4.S Cardioprotection is potentially the
most beneficial effect of HRT, as CVD is the leading killer
of post-menopausal women.5
It is the estrogen component of combined HRT w hich
is cardioprotective. In fact, it has been suggested that
progesterone may oppose the beneficial effec ts of
estrogen. Consequently, in women without a uterus,
unopposed estrogen is ideal. 1•3 Women with a uterus
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require the addition of progesterone to prevent
endometrial cancer. One study showed that a hormone
regime involving micronized progesterone maintained
more of the cardioprotective effects than did a regime
involving medroxyprogesterone acetate.1 Although the
cardioprotection may be slightly less than that provided
by unopposed estrogen, studies continue to confirm that
combined HRT provides significant cardioprotective
benefits.1.J
Despite the large number of studies which report
cardio ascular benefits from HRT, some researchers
dispute the beneficial effects of short term therap y .6
Furthermore, there has been some concern that almost all
the studies reported to date have been partially funded by
drug companies? Finally, it seems that the cardiovascular
benefits of HRT may not be as great for women who have
no significant risk factors for cardiovascular disease (i.e.
have never smoked cigarettes; do not have high
cholesterol levels, high blood pressure, or diabetes; have
no parental history of early myocardial infarction; and
have a body-mass-index of less than 25). 4 In thi s
population the relative ri s k of mortality is 0.89, in
comparison to the relative risk of 0.51 in the group with at
least one cardiovascular risk factor. 4 However, it is likely
that the majority of women have at least one of the above
listed risk factors. It is important to remember that CVD is
the number one killer of postmenopausal women,
resulting in six times as many deaths as breast cancer;
therefore any degree of cardioprotection is certainly
beneficial.5
Prevention of CVD is one of the primary benefits of
HRT. Therefore HRT should be seriously considered in all
women with cardiovascular risk factors.
Bone Health
It is generally accepted that post-menopausal women
undergo a period of rapid, estrogen-dependent bone loss.
Decreasing bone density predisposes women to
osteoporosis and fractures . Osteoporotic fractures are a
major cause of morbidity and mortality in Canada today.
Studies have shown that HRT inhibits bone resorption and
maintains bone density.2.s·9•10 This significantly reduces the
risk of osteoporotic fractures (up to 50% reductions in
fracture rates have been reported).2.s The favorable effect
on bone health is an important benefit of HRT and should
be considered in all women, especially those with risk
factors for osteoporosis.
Some individuals wonder if calcium supplementation
and other conservative treatment strategies such as
weight-bearing exercise and vitamin D supplementation
are sufficient to prevent accelerated bone loss. It seems
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that while calcium and vitamin D supplementation are
beneficial compared to a placebo, they are not as effective
as HRT in preventing accelerated bone loss .8 •9 •10
Individuals who have decreased bone density or
significant risk factors for osteoporosis require more than
just exercise and vitamin and mineral supplementation to
maintain their bone density. They should seriously
consider HRT, or a second line treatment such as
bisphosphonates. 9
Breast Cancer
A major issue of debate has been whether or not HRT
increases the risk of developing breast cancer. There have
been a number of contradictory findings. The National
Cancer Institute of the United States recently carried out a
meta-analysis and determined that the use of HRT does
increase a woman's risk of developing breast cancer after
five yea rs of u se. 11 A strong piece of evidence to this
regard comes from the Nurses' Health Study,4•12 a study of
121 700 registered nurses followed between 1976 and 1992.
The results of this study find the multivariate adjusted
relative risk of breast cancer in individuals taking estrogen
supple mentation (wi th or without progestin) to be
between 1.28 and 1.41 depend ing on the hormone
regimen. 12 Although this is a relatively small increase in
ri k, it is significant as the baseline risk that a woman will
develop breast cancer at some point in her lifetime is one
in eight. 13 It is important to note that the risk of breast
cancer seems to increase with duration of treatment. The
urses' Health Study show that, for indi vi dual s
currently using HRT, the relative risk of mortality from all
cau es in comparison to people who had never used HRT
is 0.63, but that it increases to 0.80 after 10 or more years of
u e. 4 They attribute this to an increase in deaths due to
breast cancer. An increased ri k of developing breast
cancer is the primary drawback of HRT and must be
weighed against the cardiovascular, bone health, and
other benefits.
Colorectal Cancer Risk
Studies have shown that the use of HRT significantly
reduces the risk of colorectal cancers (relative risk
reported are 0.54 and 0.71 for colon cancer, and 0.91 for
rectal cancer). 14 Since colon cancer is the second most
common cancer in women, and the third most common
cause of cancer death in the population, 13 this is an
importa nt consideration for those evaluating HRT,
especially if they have a family history of colon cancer.
Endometrial Cancer
Combined estrogen and progesterone HRT does not
increase the risk of developing endometrial cancer. 1.2·15
Studies have shown th at un opposed estrogen does
increase the risk of endometrial hyperplasia and
endometrial cancer in women with an intact uterus, so a
combi ned estrogen plus proges terone approach is
mandatory for these individuals who choose HRT. 1•2 • 15
Physicians should note that when a progesterone cream is
used instead of oral/systemic progesterone, blood levels
of progesterone may be insufficient to provide a protective
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effect on the endometrium.16 These women may effectively
be taking unopposed estrogen and must be followed
accordingly.
Vaginal Dryness and Urinary Incontinence
Some post-menopausal women report vaginal dryness
and urinary incontinence. Studies have shown that oral
and / or topical estrogen therapy reduces vaginal dryness
and can improve urinary continence.2.5·16
Menopausal Symptoms
It has been reported that HRT reduces menopausal
symp toms such as hot flushes, insomnia, and night
sweats.5•16

Neurologic
It has been suggested that estrogen may delay the
onset of Alzheimer's disease and ma y "s low the
progression or prevent the cognitive impairment and
neuronal degeneration associated with senile dementia
and Alzheimer's disease." 14 Further research is necessary
before definite conclusions can be drawn.

Weight Gain
Women have expressed concerns regarding weight
gain as a possible side effec t of HRT. The PEPI Trial
demonstrated that women in all treatment groups
(including the placebo group) gained weight, and that the
only significant difference in a comparison of weight
changes was that the women in the placebo group gained
more than the women in the unopposed estrogen group
(2.1 and 0.7 kg respectively, at 36 months).1 The reality is
that weight gain is a result of consuming more calories
than one burns on a daily basis . Women who are
concerned about weight gain should be educated about
this relationship and counseled on strategies to prevent
weight gain, such as regular exercise and a healthy diet.
Bleeding
Sometimes HRT results in bleeding. This is more
likely to be a problem if HRT is initiated before the
woman s tops menstruating. The risk of breakthrough
bleeding may be reduced if a withdrawal bleed is brought
on by the administration of a progesterone challenge
before beginning HRT. 17 Breakthrough bleeding persisting
for more than 6 months after the start of treatment or of
new onset in someone taking HRT must be investigated
by endometrial biopsy.17 If endometrial biopsy confirms
no pathologic cause for the bleeding, the physician may
consider changing the hormone regimen. One option is to
use a cyclic regimen, whereby the bleeds s hould be
regulated. Otherwise, it may just be a matter of time
before the woman stops bleeding.
Other Side Effects
Some other side effects of HRT have been
documented, including breast tenderness, headache, and
depression. 17 Physicians ma y need to adjust hormone
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doses, types of hormones (i.e. micronized progesterone
instead of medroxyprogesterone acetate) , or even
terminate treatment if a woman is experiencing adverse
effects. Women who are considering HRT and are
concerned about this issue should be reassured that the
treatment regime can be adjusted or terminated if she
experiences unacceptable side effects.

will likely not achieve the same systemic effect as oral
medications.16 These women may also benefit from foods
which are rich in phytoestrogens.5•18•19 For those who are
looking for a natural approach, many of the available
estrogens as well as micronized progesterone are all nonsynthetic options.16
Alternative Therapies

In General

The Nurses' Health Study determined that women
who are taking HRT have a lower risk of death from all
causes than do women who have never taken hormone
supplementation (relative risk 0.63, increasing to 0.80 after
10 or more years of use). 4

COMPLEMENTARY APPROACHES
Women can reduce their risk of devel o ping
cardiovascular disease and osteoporosis by adopting a
healthy lifestyle . This may be most beneficial when
combined with HRT, but is perhaps even more important
in women who are unwilling or unable to take HRT. Some
elements of a heart and bone-healthy lifestyle are:
• healthy diet (low fat, high fibre, well balanced with
food containing sufficient vitamins and minerals)5•16
• regular aerobic and weight-bearing exercise5•16
• abstinence from smokinir·16
• limiting caffeine and alcohol intake5
• consider supplements: antioxidant vitamins C and E,
calcium and vitamin D (beneficial for bone mineral
density) s.7,16
The consumption of foods high in phytoestrogens
(natural estro~ens occurring in plants) may also be
beneficial. 5•18 • 1 •20 The best known sources of
phytoestrogens are soy products, although they are also
found in legumes, wheat, berries, and seeds .5 •18•19
Phytoestrogens are considered to have a mild estrogenic
effect, and consequently may reduce menopausal
symptoms and be mildly bone and cardio-protectiveY ·19
A study by Lovati et al. demonstrated that substituting
soy protein for animal protein in otherwise identical low
lipid diets (20% calories from protein, 26% calories from
fat, and a total of 1400 - 2100 kcal daily) significantly
reduced total and low density lipoprotein cholesterol in
hypercholesterolemic women and men.20 The effects of
phytoestrogens in the diet merit further investigation, but
meanwhile, individuals may wish to consider the addition
of soy products, or other foods high in phytoestrogens, to
their diet. A healthy lifestyle including proper nutrition
and exercise is the first step to a healthy body, and
consequently physicians should discuss lifestyle issues
with all of their patients.
A Natural Approach
Some women are uncomfortable with the idea of
taking systemic HRT, and / or only willing to consume
natural products. There are strategies for both of these
patients. There are topical hormone preparations available
for those unwilling to take oral medications, although they
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In recent years society has increasingly turned
towards the use of alternative therapies such as
naturopathy and homeopathy. A number of alternative
remedies have been proposed for the treatment of
menopausal symptoms and the prevention of heart
disease, osteoporosis, and cancer. There is little scientific
evidence to support most of these therapies, 16 and further
discussion of these issues is beyond the scope of this
paper.

CO NCLUSIO N
HRT is a complex issue. The risks and benefits must
be weighed and a decision must be made for each woman
individually. A summary of ideas for patient counseling is
included as Appendix 1. Currently there is a problem with
non-compliance in women who have been prescribed
HRT.16 It is important for women to be involved in the
decision making process, to have their question s
answered, and to be in agreement with the treatment
decisions. An involved, informed patient is more likely to
feel positive about and be compliant with HRT. Physicians
should discuss HRT and lifestyle issues with all of their
perimenopausal patients, helping those women to make
educated personal decisions.
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Appendix 1: COUNSELING THE PATIENT
Facts to discuss with your patients:
•
•

•
•
•
•
•

HRT relieves many menopausal symptoms.
HRT is cardioprotective, especially for women who
have any cardiovascular risk factors. Cardiovascular
disease is the leading killer of postmenopausal
women.
HRT helps maintain bone density, decreasing the risk
of developing osteoporosis.
HRT decreases the risk of developing colorectal
cancer.
HRT does not increase the risk of developing
endometrial cancer.
HRT may cause an increase in the risk of developing
breast cancer.
Some women experience mild side effects while on
HRT; some of these may pass with time, but if not
modification or termination of treatment is always an
option. Consider a three month trial period.

Qu estions for the woman to ask herself:
•

•
•

•
•

•
•

•
•

Do I have any cardiovascular risk factors? (smoking,
high cholesterol levels, high blood pressure, diabetes,
family history of heart disease before age 65,
overweight)
Do I feel that I would benefit from cardiovascular
protection provided by HRT?
Do I have risk factors for osteoporosis? (family
history, low bone density, smoker, history of excessive
alcohol intake, menopause before age 40, history of
menstrual irregularity due to hormone deficiency,
long-term use of glucocorticoids, high-dose thyroid
replacement therapy, chemotherapy, heparin, primary
hyperparathyroidism)5•17
Do I feel that I would benefit from bone density
protection provided by HRT?
Do I have or am I willing to take on a heart and bonehealthy lifestyle? (healthy diet; regular aerobic and
weight-bearing exercise; abstinence from smoking;
limiting caffeine and alcohol intake)
Am I experiencing menopausal symptoms? (hot
flushes, urinary incontinence, etc.)
Do I have risk factors for breast cancer? (personal or
family history of breast cancer; premalignant breast
les ions;
earl y
menstruation
( <12);
late
menopause(>52); nulliparity; radiation treatment to
the chest; family history of ovarian, uterine, or colon
cancer; obesity}16
How concerned am I about the increase in the risk of
breast cancer with HRT?
Do I have any other questions or concerns regarding
HRT and its side effects which I would like to discuss
with my physician?

P h ysi cian s:
For recommendations regarding
contraindications, baseline investigations, starting d oses,
surveillance and trouble-shooting, see "Recommendations
for prescribing ovarian hormone therapy" CMAJ 1997;
155(8)1130-1133.
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OBSTETRIC FISTULA AND
MATERNAL MORBIDITY IN THE
DEVELOPING WORLD
By Jennifer Hankins
bstetric fistula, the ve icovaginal fistula resulting
from prolonged obstructed labour, is a condition
rarely seen in the developed world today . In
contrast, prior to the advent of surgical obstetrical care a
hundred years ago, obstetric fistula was ery common in
women throughout the world. Indeed, it is a condition
known to have occurred historically, as demonstrated by
the ancient Egyptian mummy of Queen Henhenit of the
Xlth Dynasty (c. 2050 BC), who a~pears to have lived with
a very large vesicovaginal fistula .
Although obstetric fistula is virtually unheard of in
most women in the western world today, for women in
the developing world it is as if time has stood still. In
Ethiopia alone a hospital has been built for the exclusive
care of women with obstetrical fistulas, with 1000 new
surgical repairs done each year. 2 The obstetrical fis tula
rate for women in the de ve loping world is largely
unknown, but it is estimated to be high based on high
reports of prolonged obstructed labour and maternal
mortality. In Africa in particular, death in childbirth is
common: the World Health Organization (W HO)
estimates the maternal mortality rate in Africa to be at
least 640 deaths per 100,000 live births (compared to 8
maternal deaths per 100,000 live births in the USA). 3
Similarly, in Scandinavia, the lifetime risk of a woman
dying in childbirth is 1 in 25,000, but in rural Africa the
rate may be as high as 1 in 15.3 The extent of ma ternal
morbidity in the developing world has been difficult to
fully appreciate as much of it goes unreported. In general,
overall ma ternal morbidity (including pregnancy-induced
hypertension, ectopic pregnancy, postpartum infection,
obstructed labour, uterine rupture, uterine prolap e and
fistula) in developing countries has traditionally been
estimated to be 16 episodes of illness for every maternal
death.4 Given that approximately 500,000 women die
every yea r from complications of pregnanc y and
childbirth, the extent of maternal morbidity is likely
enormous (roughly 8 million women / year) . What is
significant is that m uch of this is largely preventable.
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The obstetrical fistula differs from the post-surgical
vesicovaginal fistula (which results from focal trauma to
healthy tissues) in that it is the result of extensive vascular
injury and necrosis of pelvic tissues due to prolonged
pressure from the fetal presenting part 2. Clearly,
additional pathology can also occur during this process. In
some parts of Africa, obstructed labour may last for over a
week, leading to extensive tissue damage and numerous
injuries to multiple organ systems. 2 Thus, as Arrowsmith
et al note, "caring for these patients requires much more
than simply 'repairing' a vesicovaginal fistula". 2
In addition to the vesicovaginal fistula, other
documented injuries resulting from this "obstructed
labour injury complex" include total urethral loss, stress
incontinence, hydrouteronephrosis, renal failure,
rectovaginal fistula, rectal atresia, anal s phincter
incontinence, cervical destruction, amenorrhea, pel vic
inflammatory di sease, secondary infertility, vagi nal
stenosis, osteitis pubis, and foot drop .2 Because of the
odor, possible childlessness and inability to carry out daily
tasks, the social consequences of these injuries are often as
severe: divorce, abandonment by family, worsening
poverty, malnutrition, exclusion from religious activities
and even suicide may ensue.z.s As Harrison observes, "an
important feature of obstetric fistula is that it cannot be
fully discussed without raising a wide range of social,
economic and political issues". 5
Several environmental factors contributing to the
development of obstetric fistula and other associated
injuries have been postulated. Firstly, vesicovaginal fistula
occur more frequently in young teenage women who
marry and become pregnant at an early age.6 In these
women, the pelvis is often not fully developed leading to
cephalopelvic disproportion which results in obstructed
labour, severe obstetric fistula, rectovaginal fistula and
vaginal fibrosis . Poor nutritional states may worsen this
phenomenon, as malnourished women are more likely to
be of shorter stature and have smaller pelves. 6 In one
report from Nigeria, of 174 women with fistulas, 65% were
acquired in the first pregnancy, none of the women had
had any education (and only 15% of their husbands did),
and over 90% married before menarche. 7 Secondly, a lack
of utilization of medica l resources (i.e., labouring and
delivering outside of a hospital setting) also plays a role.5
Hospitals may be too far away or a woman may not have
the resources available to access prenatal care or hospital
care at the time of labour and delivery.5 Additionally, a
woman in the developing world may only be able to seek
medical care if her husband gives her permission to do o.
If he is absent for some reason, she may be forced to
labour and deliver at home, even if there is a hospital
nearby.6 Thirdly, traditional practices may also play a role.
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In parts of igeria, for example, the "gishiri" cut is often
practiced in order to trea t obstructed labour, infertility,
dysparunia, amenorrhea, goitre, backache or dysuria. This
involves c u tting the anterior and occasionally the
posterior aspect of the vagina with a razor blade, and can
contribute to obstructed labour and the development of a
fistula directly.2.s·6 Other traditional practices leading to
fistula include the insertion of traditional medicines and
caustic materials into the vagina to treat such things such
a infertility and dyspar unia .6 Las tly, traditional beliefs
that evil spirits or wrongd oing cause the manifestations of
obstetric fistula impede understanding and knowledge of
how to prevent this. 7
Indeed, understanding and prevention are the keys.
Obstetric fistula is more than just a complication of
childbirth; in many women it is a chronic, social and
physical death sentence that need not exist. If it can be
virtually eliminated in the western world, the developing
world should be no different. Perhaps most challenging of
all is the need for a change in attitude towards women and
their health care needs. It has been argued that traditional
practices and customs such as early marria~e and the use
of the "gishiri" cut should be eliminated. ·6 At the very
leas t, women in the developing world need access to
appropriate health care services including prenatal,
intrapartum and postpartum care. Universal education
about the use and availability of medical services cannot
be overemphasized enough. Interdisciplinary cooperation
between health care workers and specialists is needed in
order that the numerous social and physical complications
of obstructed labour are addressed. More information is
n ee ded on the exten t of maternal morbidity in the
developing world. Maternal morbidity and mortality will
not decline in the developing world until such action is
taken, and until that time, women will continue to suffer
needless!y.
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NORVASC
(omlodipino bosytate)
Tablets 2.5, 5 ond 10 mg
Antihypertensivo-Antianginal Agent
ACTlOII AND CI.JIIICAI. PKAIIIACOlOGY
NORVASC (amlodipino bosytatol is a calcium ion influx inhibitor (calcium entry blocker or calcium ion antagonist).
Amlodipine is a member of the dihydropyridine class of e~lcium antagonists.
IIIIIICATICNIS AND CI.JIIICAI. USE
~
NORVASC (amlodipine bosytate) is indicated in the trutment of mild-to-moderate ossantial hypertension.
NORVASC should normally be used in those patients in whom traotment with diuretics or bote-blockers was found
ineffective or hu been associated with unacceptable adverse effects. NORVASC can be tried as an initial agent tn
those patients whom the use of diuretics and/or beta-blockers is contraindicated or in petients with mad·cal
conditions in which thesa drugs frequently cause serious adverse effects. Combination of NORVASC with a
diuretic. a beta-blocking agent. or an angiotensin converting enzyme inhibitor has been found to be compatible and
showed additive antihypertensive effect.
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NORVASC is indicated for the management of ctvonic mble angina (effort-associeted angina) in patients who
remaKt symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those
agents. ORVASC may be tried in combination with beu -blocbrs in chronic stable angina in patients with niJf'lMI
ventricular function.. When such concomitant therapy is introduced. care must be taken to monitor blood pressure
=~n:.snsion Cln occur from the combined effects of the drugs.
NORVASC (amlodipine besytato) is contraindicated in patients with hyperunsitMty to tho drug or other
:tz::.=ines and in patients with severe hypotension (less than 90 mmHg-systolic).
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Rarely, patients. particularly those with severe obstructive coronary artery disease, have developed documented
increasad frequency, duration and/or severity of angina or acute myocardial infarction on sterting celcium channel
blocker therapy or at the time of donga increase. The machtnism of this effect has not been elucidated.
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NORVASC shodd be used with caution in 1 presence of fixed left ventricular outflow obstruction
taortic stenosis).
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There art no adequate studies in patients with liver dysfunction and dosage recommendations have not bean
em~~ed. In a _
smaU number of patients with mild-to-moderate hepatic impairment given single dose of 5 mg,
amlodopono hoH·Iife has boon prolonged. NORVASC should, therefore, be administered with caution in thosa
~;.;:,.~ monitoring should be perlt>nnld. A lower starting dose may be required (stt DOSAGE AIIO
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be done by tho gradual reduction of tho dose of beta-blocker.
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Although generally calcium chaMel blockers should only be used with caution in pttients with heart foilura, it has
bttn obStMid that NORVASC had no overaU deleterious affect on survival and cardiovascular morbidity in both
short-term and long-term clinical trials in these patients. While a significant proportion of tho patients in those
studies had a history of ischamic hurt disease, angina or hypertension, the studios wort not designed to
evaluate the treatment of angina or hypenension in patients with concomitant heart failure.
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NORVASC (amlodipine bosytate) may occasionally procipiteto symptomatic hypotension. Careful monitoring of
blood pressure is reconvnanded. especially in patients with a histofy of cerebrovascular insufficiency, and those
til ·ng medications known to lower blood pressure.
l'eri......I E MikHo-modtrate peripheral edema was the most common adverse event in the dinical trials tsae ADYEJISE
I£ACT10NS). The incidence of peripheral edema was dose-dependent and ranged in frequency from 3.0 to 10.~
in 5 to 10 mg dose range. Care should be tlken to differentiate this peripheral edema from the effects of increasing
taft ventricular dysfunction.
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Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found
to be terotogtnic in animals. In rots, omlodipino has boon shown to prolong both the gtstation period and the
duration of label. There is no clinical experience with NORVASC in pregnont women. NORVASC should be usad
during pregnancy only~ the potentiol benefit outweighs tho potential risk to the mother and fews.
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tt is not known whether amlodipine is excreted in human milk. Since amlodipine safety in newborns has not been
established, NORVASC should not be given to nursing mothers.
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Tho use of NORVASC is not roconmondod in dildran 8nca sahlty and eflic:acy have not been - - i n that popu1non.
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In tlderty patients ~ years) clearance of amlodipine is decreased with a resulting increase in AUC. In clinical
trials the incidence of adverse reactions in elderly patients was approximately 6~ highar than that of younger
poputabon (<65year3). Adverso reat110nS o>clude edema, muscle tromps ond diuintss. NORVASC should be used
cautiously in elderly patients. Oosago adjustment is advisable (see DOSAGE AIIO - T I O I I I).
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through inhibition of the cytochrome P450 system, grapefruit juice can increase plasma
levels and augment pharm~codynamic onocts of some dihydropyridine calcium chaMtl blocker>. Following orol
odministration of 10 mg emlodipine to 20 male voluntttrs. pharmacokinetics of amlodipina were sim~ar when
amlodipine was administered with and without grapefruit juice.
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al drugs, care should be exorcisod when trilling pe1ionts wid> multiple medications. Dihydropyridine calcium
channal blockers undergo biotransformation by the cytochrome P450 system. mainly via CYP3M isoenzyme.
Coadministration of amlodipine with other drugs which foQow tho some route of biotransformation may resuh in
altered bioavdability of amlod'pino or these drugs. Dosages of sim~arly metabolized drugs. particularly those of
~therapeutic ratio, and especially K1 patients with renal and/or hepatic impairment may require adjustment
when starting or stopping concomitandy administered amlodipina to maintlin optimum thertpeutic blood levels.
Drugs known to be inhibitors of the cytochrome P450 system include: azole antifungals, cimttidine, cyclosporine,
erythromycin, quinidine, terfenadine. warfarin.
Drugs known to be inducers of tho cytochrome P450 system include: phenoborbiteL phenytoin. rifampin.
Drugs known to be biotransformod via P450 include: bonzodiazopinos. ftecainide. inipraminl, propofenone, ~
Amlodopono has a low (rate of first-pass) hapabc cleoronct and consaquent high bioava~abiity, and thus. may be
expected to have 1 kJw potenbal for clinicelty r-'evant effects associated with elevation of amlodipine plasma
levels when used concomitantly with drugs that compete for or inhibit the cytochrome P450 system.
~. w.rt.n.. Cyc.._._IJituioo: Pharmacokinttic interaction studies with amlodipino in healthy
volunteers have indictted:
• c - . . did not alter tho pharmacokinetics of amlodipino.
• amtodipine did not change w.rt.n.·induced prothrombin response time.
• amlodipine does not significantly alter the pharmacokinetics of cycleoperiL
• amlodipine did not change serum tlitexill levels or lliflm. renal cleartnce.
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Concornitont administration of Mnlox" (magnesium hydroxide and oluminum hydroxide) had no affect on tho dis·
position of a sing e 5 mg dose of amlodipine in 24 subjects.
- - = When beta-adrenergic receptor blocking drugs are administered concomitantly with NORVASC.
patients should be carefuly monitored since blood pressure towering effect of beta ~btockers may be augmented by
omlodipina's reduction in peripharll vascular resistance.
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NORVASC has been evaluated for safaty in about 11.000 patients with hypertension and angina.
The following events occurred in <1~ but>0.1" of patients in comparotive cfinical trials (double-blind
comparative vs Pacebo or active agents; n =2.615} or under conditions of open trials or marteting experience
where a causal relationship is uncertain.
_ _ , arrhythmia (including ventricular tachycardia and atrial fibrilation), bradycardio, hypotension.
poripharll ischemia, syncope_. tachycardio. posturol dizziness, postural hypotension. c..o1 111111 ........I
hypoesthoae, tremor, vertigo. •
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postmarteting experience, jaundice end hepatic tnzyma tltvations (mostly consistent with cholestasis) in some
cases severe enough to require hospitllization have bean reported in association with use of amkH:Iipine.
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SYIIPTOIIS AIIO TIIEATIIIEIIT OF OYBIIIOSAGE
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Ovtrdosago can causa excessive peripheral vasod~ation with marltod and probably prolonged hypotonsion and
possibly a roftox tachycardia. In humons, oxperionct with owrdosago of NORVASC (amlodipine bosyltto) is limited.

When amlodoprne was ongested at doses of 11J!i.250 mg some patients remained normotensive with or without
gastric lavage while another patient experienced hypotension (9MO mmHg) which normalized folowing plasma
expansion. A patient who took 10 mg of amlodipine with bonzodiuapino developed shock which was refractory
to trutrnont and died. In a 19 month-old child who ingested 30 mg of amlodipino (about 2 rng/kg) there was no
evidence of hypotension but tachycardia (110 bpm) was obstrvtd. lpecac was administered 3.5 hrs alter ingestion
and on subsequent observation (overnight) no sequelae were noted.

T-

Ciini~a~ sigrifica~t hypotensi~n due to overdosage requires active cardiovascular support including frequent
monrtonng of cardiac and resporatory function, olovotion of extremities, and attention to circulating fluid volume
and urine output. A vasoconstrictor (such as norepinephrine) may be helpful in restoring voscular tone and
blood i><•ssuro, provided that there is no contraindication to its use. As NORVASC is highly protein bound.
htmod1atysis ~ not likely to be of benefit. Intravenous calcium gluconata may be beneficial in reversing the
effects ofcalcnrm channel blockade. Clearance of •mlodipino is prolonged in elderly patients and in patients
~~= amlodoprne absorption IS slow, gastric lovage may be worthwhile in some casas.

=-=

Dosage should be individuelized depending on patient's ~erance and responsiveness. For both hypertension
ond angina. tho racornmended initial dosa of NORVASC (amlodipino bosytatol is 5 mg once daily. If necessary,
dose can be increased after 1·2 weeks to 1 maximum dose of 10 mg once daily.

U.. iotloe EWorlyorioo , _ _ ......... _ , - - . .
The recommended initial dose in patients over 65 years of age or patients with impaired renaJ function is 5 mg
once daily. If required, increasing in tho dose should be dono gradually and with caution (stt i'IIECAIITlOIIII.
u.. ioo , _ -loopeitM llopolicOosage requirements hoV1t not been osteblishad in patients with impaired hepatic function. When NORVASC is
used in these patients, the dosage should be care
and grodualy adjusted depending on patient's toltronce
and response. A lower starting dose of 2.5 mg once daily should be considered (sao W~ l.
DOSAGE fOIIMS
AniiMilily
NORVA5C is ava~able as white octagonal tablets containing amlodipino bosytata equivalent to 2.5, 5 and 10 mg
amlodopono per tablet The respective teblet strengths ora dobossad on one tablet face as "NRV 2.5", "NRV 5"
end "NRV 10" with "Pfizer" on the opposite face. The 5 mg tablet is scored. Supplied in whitt plastic (high density
=
: n•) bottles of tOO tablets for 11th strangth Also tho 5 mg and 10 mg are supplied in bottles of 250 tablets.
Store at t !>-JOI>C. Protect from ~ght.
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MARVELON* 21 and MARYELON* 28
(desogestrel and ethinyt estradiol tablets)

Prescribing lnfonnatlon
f'lla,.anllllcal Claulllcatlu: Synthetic steroidal combination oral
contraceptive.
IIMIIAiill: Conception Control.
Cutraldlcat1111: 1. History of/or actual thrombophlebitis or
thromboembolic disolders. 2. History of/or actual c:mbfovascu1ar lisolders.
3. History of/or actual myocardial infan:lion or coronary arterial disuse.
4. Active livtr disuse or history of/or actual benign or malignant livtr
tumours. 5. Known or suspected carcinoma of the breast. 6. Known or
suspected estrogen-depend neoplasia. 7. lMlcfoagnosed abnonnal vagilal
bleeding. 8. AJry ocular lesion arisino from ophthalmic vascular disease,
such as partial or complete loss of vision or defect in visual fields. 9. Wilen
pregnancy is suspected Of diagnosed.
Wlnrillp: 1. I'IHilplli.. Faclln fir c..-y Arflry llileal: Cigarette
smcD1g increases the risli: of serious cardiovasaJiar side etfeds and mortaity.
lli1l1 cmtrof pis imase !lis risli:, especialy wilh ilcreasi1g age. ConvilCi1g
data are available to support an upper age limit of 35 years tor oral
contracepliYe use in women who srnob. Other women who are iOOependently
at high risk lor cardiovascular disease include those with diabetes,
hypertension, abnormal li!lil prolie, or a lamiy lislory of these. Whether oral
contraceplivts accentuate !his risli: is unclear. In low risk, non-smotino
women ol any age, the benefits of oral contraceplivt use outwtigh the
possible cardiovascular risks associated with low dose lormulations.
Consequenlly, oral contraceptives may be presailed for these women up to
the age of meriOjlaUse.
Cigarette srnoldng incruses the risli: of seriotJs adverse effects on the

heart and blood vessels. This risk increases with age and becomes
significant in oral contraceplivt-users over 35 years of age. Women
should be counselled not to smote.
2. Oisalll- IIMicalill at 1111 urflnl -ilnDIIII Ill:
A. nre•h1•~111c nf Carflnasular Dlnrhrs such as:
Thrombophlebitis, pulmonary embolism, cerebrovascular disorders,
myocardial Ischemia, mesenteric thrombosis, and retinal thrombosis.
B. Cuflll111 lill i e~ '""l'tlt ta tlllll 111111 aaf t1 n1nlar
........_ e.g. immobii22tion alt!r aa:idents or confinement to bed during
tono-tenn ilness. Other non-hom1onal methods of contraceplion should be
used
regular aclivilies are resumed. For use of oral contraceptives .men

is ~. see PRECAUTIOit$. c. Vilul Dlllcls, Partial "
C.,lell. D. l'a!IIIIMitla, If o,IIIUI•Ic Yaalar llll-. E. Snen
IIIHaclll of Ulbtn ElliiiiY If WII'HIIII of l'rHiistlll 11111'1111
lluUctll. l'rlcalliHI: 1. l'llyslcal ED•Iutill llf ~lln·1': Before
oral contraceptives are used, a thorough history and physical examination
should be performed, includino a blood PBSSUre determilalion. Breasts,
liver, extremities and pelvic organs should be examined. A Papanicolaou
smear should be taken ~ the patient has been sexually active. The first
foflow-up visit should be done three months after oral contraceptives are
presaiJed. Therealler, examina!i1ns should be performed at least once a year
or more lrequenlly ~ indicated. AI uch annual visit, examination should
inc:b:le those proadures !hat were done at the initial visit as outlined above or
per recommendations of the Canadian Task Force on the Periodic Heafth
Examination. 2. Prq111cy: Oral contraceptives should not be taken by
pregnant women. HowMr, I conception accidently 0CCU1S while 13ldng the
surge~y

pill, there is no conclusive evidence that the estrogen and progestin
contained In the oral contraceptive will damage the developing child.
3. ilnllllllfl11: In breastleeding women, the use of oral contraceptives
results in the hormonal componenls being exa!led in breast mile and may
reduce its quantity and quality. Hthe use of oral contraceptives is initiated
alt!r the establishmenl of lactation, there does nof appear to be any effect on
the quantity and quDty of the milk. There is no evidence !hat low dose oral
contraceptives are harmful to the nursing inlant. 4. Hl,atlc Fuctl11:
Patients who have had jaundice including a history of choleslalic jaundice
during pregnancy should be givtn oral contracepliYes with great care and
under dose observation. The devmpment of sever! generaired pruritus Of
icterus requires that the medication be withdrawn until the problem is
resoMd. Hthe jaundice should PltM to be choleslalic in type, the use of
oral contraceptives should not be resumed. In patients taking oral
contraceptives, changes in the composition of the bile may occur and an
increased incidence of gallstones has been reported. Hepatic nodules
(adenoma and local nodular hyperplasia) have been reported, particularly in
tono-tenn users of oral contracepliYes. Afthough these lesions are extremely
rare, they have caused lalil intra-abdominal hemorrllaoe and should be
considered in women presenting with an abdominal mass, acute abdominal
pain, or evidence of intra·abdominal bleeding. 5. ~: Patients with
essential hypertension whose blood pressure is welk:onlrolled may be given
oral contraceptives but only under close supervision. II a significant

ele¥31ion of blood pressure in previously normotensive or hypertensive
subjects occurs at any lime during the administration ol the drug, cessation
ol medication is necessary. 6. 111raltt alf Hufac~t: The onset or
exacerbation of ~ or the dMiopmenl of headache of a new pattern
which is recurrent, persistent or severe, requires discontinuation of oral
conlnleeptives and evaluation of the cause. 7. Oldoln: Current low dose
oral contraceptives exert minimal · pact on glucose metabolism. Diabetic
patients, or those with a lamily history of diabetes, should be observed
closely to detect any worsening of carbohydrate metaboUsm. Patients
predisposed to diabetes who can be kept under dose supervision may be
givtn oral contracepliYes. Young diabetic patients whose disease is of recent
origin, wekonlroled, and nof associated wilh hypertension Of olhef signs
of vasadar disease such as oc:dar loodal changes, shWd be monitored more
freQuently while using oral contraceplives. 8. Ocola llileal: Patients who
aa pregnant or are 13ldng oral contraceptives, may experience oomeal edema
!hat may cause visual dislw1lances and changes in tolerance to contact lenses.

especially of the rigid type. Soft contact lenses usually do not cause
disturtJanczs. Hvisual changes or alterations in tolerance to contact lenses
occur, lernj)oraly or permanent cessation of- may be advised. 9. ..._
Increasing age and a strong lanjy lislory are the most significant risli: faclors
for the deYelopment of breast cancer. Other established risli: lactOfs inc:b:le
obesity, nuliparity and late age at first ful.lerm pregnancy. The identified
groups of women thai may be at imased risli: of deYeloping breast cancer
beloo menopause are kJno-!enn users of oral conlraceplives (more than 8
Y!OfS) and slart!rs a1 early age. In a lew women, the use of oral contracepliYes
may ac:ce1erate the growth of an existing but undiagnosed breast cancer. Since
any poferllial incrased risli: related to oral contraceptive use is smal, lhere is
no reason to chanoe prescribing habits at present Women reaiving oral
contracepliYes shWd be instructed in sell-examination of their breasls. Their
physicians should be notified whenMr any masses are detected. Ayearly
clinical breast examination is also retofM1ended because, I a bRas! cancer
should develop, estrogen·cocrtaining drugs may cause a rapid progression.

10. Ya11111 llnfl11: Persistent irregular vaginal bleeding requires
assessment to exClude under1yino pathology. 11. Flllrthls: Patients with
libroids (leiomyomata) should be careluly observed. Sudden enlargement
pain, or tenderness require discootinuation of the use of oral contraceptives.
12. ~ DiiiNin: Patients with a history of ernoliol1al disturbu:es,
especialy the depfessM! type, may be more prone to have a recurrtnee of
depfession while 13ldng oral conlraceplives. In cases of aserious recurrence, a
trial of an alternate method of contraception should be made which may help
to ~ lite possible relationship. Women with premenstrual syndrome
(PMS) may have a varied response to oral contraceptives, ranoing from
symptomatic impnJYtment to worsening of the condition. 13. Lalllfatery
Tills: Results of laboratory les1s should be interpreted in the light !hat the
palienl is oo oral oontral:eplives The lolowing laboratory 1es1s are modified.
A. l.lftr tuctltl Inti: Aspartate serum transaninase (ASD · variously
reported elevations. Mah pl1osphatase and gamma gManWle transanWlase
(GGD · sightly elevalld. B. Ca11a1at111 InS: M"ma elevation of test values
reported I« such paramelefS as protlvornbin and Fadors VII, VIII, IX and X. C.
n,nlll fllcllll InS: Prot!in bidng of thyroxine is incrased as iAdicated
by increased total serum thyroxine concentrations and decreased T3 reskl
uptal<e. D. ~ Smal changes of unproyen clinical significance may
occur in 1ipopro1ei1 dlolesterollractions. E. GI I I 'J9llld: lH and FSH levels
are suppressed by lite use of oral contraceptives. Wait two weeks after
discontirlling the use of oral conlraceplives before measurements are made.
14. n- s,a..: Pathologists shWd be advised of oral contracepliYe
therapy when specinn obtained ITorn surgical procedures and Pap smears
are subnilted I« examination. 15. 11111n II flrlllly: After discontinling oral
contraceptive lhelllpy, the patient shoukl delay pregnai1Cf
at least one
normal spontaneous cycle has occurred in order to date the p<egnancy. An
alternate contraceptive method should be used during this time.
16. Mllllnllu: W n having a history of oligomenorrhea, secondary
amenorrhea, or irregular cycles may remain anovulatory or become
amenorrlleic following discontinuation ol ~ogestin combination
therapy. Amenorrhea, especially ~ associated with breast secretion, that
continues for six months or more after withdrawal, warrants a carelul
assessment of hypothalamic-pituitary function . 17. nre.~ll•hllc
C.,llalltls - 1'111--...y: There is an increased risli: of post-surge~y
ltoOCiiboelilbolic ~ in oral contraceptive users, alt!r major surgely.
If teasible, oral contraceptives should be discontinued and an alternalivt
method substiluted alleast one moath prior to IWOR elective SliQSY. Oral
contrac:epliYes should nof be resumed
the first menstrual period after
hospital discllarge lolowing SUrgefy. 18. Dnlllllrlclltll: The concurrent
administration of oral conlraceplives wilh olhef drugs may !!SUI in an al!f1Jd
response to either agent Reduced effectivtness of the oral contraceptive,
shWd 1 occur, is more lbly wilh the low dose lorrrUations. n is ~to
ascertain all drugs that a patient is taking, both prescription and non·
~

before oral contraceptives are presailed.

Birth control pills do not protect against sexualy transmitted disuses
(STDs) including HIV/AIDS. For protection against STDs ft is advisable to
use latex condoms in combilation wilh bi1h control pils.

Drip Wlllcli lly lllcrNMIIII Elllcacy II Oral c.nc.,titn:
. . . . _ . _: Carbamazepile, ethosuximide, p/lenollarl)ita phenytoin,
pRnidone. Induction of hepatic microsomal enzymes: Rapid metabolism of
estrogen and increased binding of progestin and edlinyt estradiof to SHBG.
Use higher dose OCs (50 meg elhinyt estradiol), another drug or another

method. Aatl"1tlcs: Ampicinin, cotrimoxazote, penicinin. Enterohepalic
circulation disturbance, · estinal hurry. For short course, use additional
method or use another drug. For long course, use another method.
Rifampicin. lncrused metabolism ol progestins. Suspected acceleration
ol estrogen metabolism. Use another method. Chloramphenicol,
metronidazole, neomycin, nitrolurantoin, suHonamides, tetracyclines.
llldudion of hepatic microsomal enzymes. Also disturbance of enterohepatic
cirtulation. For short course, use additional method or use another drug. For
long course, use another method. Troleandomycin. May retard melabolism
of DCs increasing
risk ol cholestatic jaundice. For short course, use
additional method or use another drug. For long course, use another
method. Altlflllpl: Griseofulvin. Stimulation ol hepatic metabolism of
contraceptive steroids may occur. Use another method. Stfatinl 11f
""11tlcs: Benzodiazepines, barbiturates, chloralhydrate. glutethimide,
meprobamate. Induction of hepatic microsomal enzymes. For short course,
use additional method or another drug. For long cwse use another method
or ligher dose OCs. Altlcia: Deaeased intestinal absorption of progeslins.
Otlllr 011p: Phenylbutazone, antihistamines, analgesics, antimigraine
preparations, V"ilanWI E. Reduced oc efficacy has been reported. Remains to
be confirmed.
llllllftatlol " llllllr Dill Acllll ~ Oral c.tract,tinl:
Alcellll: Possible increased levels of ethanol or acelaldehyde. Use with
caution. Al, ~a - 11 AfllllriCI,tlf Altlb: Clonidine. Sedation effect
increased. Use with caution. Alli-cN~~INb: All. DCs incruse clotting
!actors, decrease efficacy. However DCs may potentiate action in some
pa · nts. Use anollter method. Alti.._lsuts: AD. Auid retention may
increase risk of seizures. Use another method. Alti-flHttic flip: Oral
hypoglycemics and insulin. DCs may impair gklcose tolerance and increase
blood glucose. Use low dose estrogen and progestin DC or another method.
Monitor blood glucose. Alll-~y,.rttllln 1111t1: Guanethidine and

methyldopa. Estrogen component cause sodium retention, progestin has no
effect. Use low estrogen DC or use another method. Beta blockers.
Increased drug effect (decreased metaboHsm). Adjust dose of drug ij
necessary. Monitor cardiovascular status. Alltl.,mtcs: Atetaminophen.
Increased renal clearance. Dose of drug may have to be increased .
.wipyri!ine. Impaired metabolism. Decrease dose of drug. ASA. Etfecls of
ASA may be decreased by the short term use of OCs. Patients on chronic
ASA therapy may require an increase in ASA dosage. Ml_,.elc Aclll:
Theoretically, a hypercoagulable state may occur because DCs augument
clotting lactors. Avoid concomitant use. .._iMIIc All* Isoproterenol
Estrogen causes decreased response to these drugs. ~ dose of drug as
~- Discontinuing OCs can result in eii:eSSivt drug activity. Caflli11:
The actions of caffeine may be enhanced as DCs may impair lite hepatic
metabolism of caffeine. Use with caution. CHinllrol l-'11 111111:
Clofibrate. DCs may increase the clearance of clofibrate leading to decreased
IMI of clofibrale. Use wilh caution. Clrllcllllflla: Prednisone. lolaltedly
increased serum levels. Possl>le need for decrease in dose. Cyclnjllri1ot:
May lead to an increase in cydosporine levels and hepatotoxicity. Monitor
hepatic function. The cydospoline dose may have to be decreased. fllic
Aclll: OCs have been reported to inpair folate metabolism. ..,.,..111:
Possible increased analgesia and CNS de pression due to decreased
metabolism of meperidine. Use combination with caution. f'll1loflllazill
TIIINIIIIIztft: All phenothiazines, reserpine and similar drugs. Estrogen
potentiates the hyperprolacline effect of these drugs. Use other drugs or
lower dose DCs. If galactorrliea or hyperprotactinemia occurs use other
method . Slfallnl 11f H"111ics: Chlordiazepoxide, lorazepam .
Oxazepam, Diazepam. Increased effect (increased metabolism). Use with
caution. n.,llrtllll: M. Deaeased oxidation, leading to possiJie mxicity.
Use with caution. Monitor lheophytline levels. Tricyclic Altilll,.mlll:
Ckrnipramine (possibly others). Increased side effects; i.e. depression. Use
wilh caution. YlllMI 112: OCs have been reported to reduce serum levels of
Vitamin BIZ.
Mn111 Ructlta: An increased risk of lite following serious adverse

reactions has been associated with the use of oral contraceptives:
• Thrornbopl*liit • f'l*nonary ernboism • Mesenteric tllrcrnbosis • Netm-

ocular lesions, e.g, retinal thrombosis • Myocardial infarction • Cerebral
tllrcrnbosis • Cer!bral hemorrflage • Hypertension • Beriign hepatic tumours
• Galbladder disease • Congenital anomalies. The lollowing adverse reactions
also have been reported in patients receiving oral contraceptives: Nausea and
vomitilg, usually the most common adverse reaction, occurs in apj1IOXimately
10% or less of patients during the first cycle. Other reactions, as a general
rule, are seen less lrequently or only occasionaly, as lolows: • gastrolestinal
symptoms (such as abdominal cramps and bloating) • brealdhrougli bleeding
• spotting • change in menstrual flow • dysrnenorrtlea • amenorrllea during
and after lrealmenl • lernj)oraly infertiity alt!r clisconlillance of treatment

• edema • chloasma or melasma which may persist • breast changes:
tenderness, enlargement, and secretion • change In weight (increase or
decrease) • endocervical hyperplasias • possible diniootion in lactation when
given irnrnediat!ly posl"jlartUm • ciQestalic jaundice • migraine • imase in
size of uteme leiomyomata • rash (alelgic) • mental depression • reduced
tolerance to carl>oliydrates • vaginal candiliasis • premenstruaHikt syndrome
• · olerance to contact lenses • chanoe in comeal curvature (steepenino)
• cataracts • optic neurtis • retinal tlvombosis • changes in ibldo • chorea

• changes In appetite • cystitis·like syndrome • rhinitis • headache
• nervousness • dizziness • hirsutism • loss ol scalp hair • erythema
multiforme • erythema nodosum • hemonflagic eruption • vaginitis • porphyria
• impaired renal function • Raynaud's phenomenon • auof ory disturbances
• hemolytic uremic syndrome • pancreatitis.
Trllllllllll C1Nr1111at1 If Al:dlllltll i1111t111: Serious I etfeds have nof
been reported lolowing acute ingestion of large doses of oral contraceptives
by youno children. Overdosage may cause liiusea, and withdrawal bleeding
may occur in lernales.
ilnlllllf Mlillllrltltl: • 21-Pill PACK: 21 active pis (wilh hormones)
takerl daly I« three wee1<s. and then tab no pills I« one week. • 2&-Pill
PACK: 21 active pills (with hormones) takerl daly I« three weeks, and then
SI!Yell "reminder' pis (no hormones) l3bn daly for one week.
Anlla~lllty

11 011111 ~-: MARVELON. 21 : Each sachet contains a
blister dispenser with 21 round white tablets. Each tablet for oral

administration con1ains 0.15 mg desogestrel and 0.03 mg etflinyl estradiol
MARVELON .2B: Each sachet contains a bfister dispenser with 21 round

while tablets and 7 round green tablets. Each white tablet lor oral
administration con1ains 0.15 mg desogestrel and 0.03 mg ell*lyl estradiol
Each gl!ell tablet!« oral administration contains inert ingredients. Marvelon
is a Schedule Fdrug.
S!Millty llf Sflrlll "-IIIIIUtilll: Stoo beiWten 1~J00c.
Producl monograph Mlable on request
~:

1. Marvelon Product Monog raph. 2. Rabe T. et al. The effects of
monop/Jisic illd l!iphasic ofif contraceptives on ovarian function iJJd
endometril f thickness. The European Journal of Contraception and
Reproductive Health Care. 2 (1997) :5-51. 3. IMS Heafth.
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Impressive tolerability after 4 years

Long-acting BP control for mild-tomoderate hypertensives
• effective! control BP at target le el for a full
24 hours and be ond' 2 '

• compared with antihypertensi es from four
different cia ses, more orva c* patients
remained on therap after 4 ears 30

• intrinsical! long half-life maintain pia ma le els
to reduce BP up to 24 hour after a mi eel dose~ ••

• onl 3% withdrawal rate among 12,831
patients in 16 clinical tudies9

• significant! greater BP reduction during the
critical morning hour than nifedipine XL;§

" orvasc" should always be prescribed as once-<laily therapy.
Both treatments reduced daytime, nighttime and 24-hour mean
an-bulatory blood pressures. orvasc" 5-1 0 mg o.d. ~ nifedipine
XL 30-60 mg o.d. - 12 week open-aossover in 40 patients, critical
morning hoUrs = (0500 to 11 00), (p<0.02).
l'.orvasc" 5-10 mg o.d (n= 103) ~ felodipine ER 5-10 mg o.d.
'n= 103 after 8 weeks (p=0.036) 82% of 'orvasc" patients reached
t11get DBP of S90 nvnHg '~ 69% for felodipine.
; orvasc- In= 114 1, 83'- Oi orvasc- patien remained on therapy
after 48 monchs.
orvasc" IS indicated in the treatmen1 of mild-to-modera e essential
hypertensM:Jn \\--hen diuretics or beta-blod:ers are unsuitable. The most
convnon acM!rse reactions include edema (8.9%) and headache 18.3%).'

• more effecti e than felodipine at the ame
dose6 -

•
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Consult ~escribir:'& information for important safety information
and drug mteracbons.
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